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Coronary artery disease and aortic stenosis represent two important manifestations of 
cardiovascular disease, a dominant cause of morbidity and mortality in the UK and 
worldwide. In recent years, advances in modern imaging techniques have transformed 
our understanding of the pathophysiology of these underlying disease states, enabling 
the detailed characterisation of disease processes and the identification of a large 
number of potential therapeutic targets.  To address the increasing burden of 
cardiovascular disease, improved identification of patients at risk of disease 
progression and future events is crucial. Application of advanced non-invasive 
imaging will be instrumental in achieving this goal and could enable improved 
targeting of existing or novel therapies directed against these disease processes.  
The objective of this thesis was to investigate the ability of novel advanced non-
invasive imaging to quantify disease burden, to measure disease activity and to assess 
disease progression in both coronary artery disease and aortic valve disease.  
  
 xviii 
Methods and Results 
THE ASSOCIATION BETWEEN NON-INVASIVE FRACTIONAL FLOW RESERVE AND 
PLAQUE BURDEN IN NON-OBSTRUCTIVE ATHEROSCLEROSIS  
The association between nonobstructive atherosclerosis and non-invasive fractional 
flow reserve derived from computed tomography (FFRCT) measured in distal 
coronary vessels was investigated in 155 patients undergoing computed tomography 
coronary angiography with greater than 25% coronary stenosis in at least one 
epicardial vessel. Plaque analysis was performed on all vessels with between 25-70% 
stenosis using dedicated software (Autoplaque, Cedars Sinai Medical Center, Los 
Angeles, USA). Multiple plaque components including calcified plaque (CP) volume, 
non-calcified plaque (NCP) volume, low density plaque (LD-NCP) volume, 
remodelling index (RI) and contrast density difference (CDD) were quantified. An 
abnormal distal vessel FFRCT (V-FFRCT) was defined as ≤0.75. Total plaque volume, 
calcified plaque volume, noncalcified plaque volume and low-density plaque volume 
were higher in vessels with an abnormal V-FFRCT compared to those with a normal 
V-FFRCT (p<0.05 for all). After adjusting for percent diameter stenosis and contrast 
density difference, all measures of plaque volume were independent predictors of an 
abnormal V-FFRCT (OR 2.09, 1.36, 1.95, 1.95 for TP, CP, NCP and LD-NCP volume, 




18F-FLUORIDE POSITRON EMISSION TOMOGRAPHY AND PROGRESSION OF CORONARY 
CALCIFICATION 
In a pre-specified sub-study of a randomised controlled trial, the relationship between 
18F-fluoride PET activity and the progression of coronary calcification was 
investigated in patients with clinically stable, multivessel coronary artery disease. In 
183 participants, increased 18F-fluoride activity (defined as a TBRmax >1.25) 
correlated with change in calcium score at one year (Spearman’s Rho 0.37, p<0.0001). 
Participants with evidence of increased 18F-fluoride uptake at baseline demonstrated 
more rapid progression of coronary calcification at one year (change in calcium score, 
97 [39-166] versus 35 [7-93] AU; p<0.0001). When individual coronary segments with 
increased 18F-fluoride activity were compared to negative reference plaques in the 
same participant, segments with increased 18F-fluoride uptake demonstrated 
progressive calcification at one year (from 95 [30-209] AU to 148 [61-289] AU; 
p<0.001) whereas there was no change in calcium score for reference segments (from 
46 [16-113] to 49 [20-115] AU; p=0.329).  
IMAGE OPTIMISATION AND MOTION CORRECTION OF CORONARY PET-CT 
The effect of different PET reconstruction algorithms and application of cardiac 
motion correction upon coronary 18F-fluoride PET activity was assessed in a cohort of 
patients with a recent diagnosis of Acute Coronary Syndrome (n=22).  Image quality 
was assessed using Signal-to-Noise Ratio (SNR). An optimal balance between signal 
intensity and noise was achieved using 24 subsets, 4 iterations, point-spread-function 
modelling, time of flight and 5-mm post-filtering which provided the highest median 
SNR. A novel cardiac motion correction method led to improved SNR of culprit 
 xx 
plaques (24.5[19.9-31.5]) when compared to the standard method of using PET data 
from the diastolic cardiac phase only (15.7[12.4-18.1]; p<0.001). Further, motion-
correction led to a greater SNR difference between culprit and reference lesions (10.9 
[6.3-12.6]) compared to diastolic (6.2 [3.6-10.3] p=0.001) and summed data (7.1 [4.8-
11.6] p=0.001). 
CT-AVC AND ECHOCARDIOGRAPHY IN THE PROGRESSION OF AORTIC STENOSIS 
In a study of participants with aortic stenosis, the reproducibility of CT calcium scoring 
of the aortic valve as well as its ability to detect changes in disease severity over time 
was assessed and compared with echocardiography, the current gold standard imaging 
technique in aortic stenosis. In a group of 15 participants who underwent repeat CT 
scanning within four weeks, quantification of aortic valve calcification by CT (CT-
AVC) was reproducible (limits of agreement -12 to 10%, ICC 0.99). Peak aortic jet 
velocity was the most reproducible measure of aortic stenosis severity on 
echocardiography (limits of agreement -7 to 17%; ICC 0.96). In a second cohort of 
patients, progression of calcification on CT and haemodynamic progression by 
echocardiography was assessed and a ratio of annualised disease progression and 
measurement variability was generated and used to estimate numbers of patients 
required to detect annualised changes in disease severity on both modalities. CT-AVC 
demonstrated a favourable progression-to-variability ratio (Cohen’s d statistic 3.12) 
versus echocardiography (Cohen’s d statistic for peak velocity 0.71), suggesting fewer 
patients would be required to detect changes in disease progression. 
 
 xxi 
CARDIAC MOTION CORRECTION APPLIED TO PET-CT AND PET-MR OF THE AORTIC 
VALVE 
The application of cardiac motion correction was investigated in a group of 
participants with aortic stenosis undergoing 18F-fluoride PET-CT (n=5) and PET-MR 
(n=1). When compared to the standard method of utilising PET data acquired during 
the diastolic phase only, the application of cardiac motion correction improved signal 
to noise ratio (48.8 vs 21.2; p<0.05) and tissue to background ratio (3.1 vs 2.5 p<0.05).  
Conclusions 
The application of advanced non-invasive imaging techniques can provide novel 
measures of disease burden, activity and progression in both coronary atherosclerosis 




Within this thesis, I investigate new techniques to use scanning technology to help 
improve the identification of the burden, activity and progression of two leading causes 
of cardiovascular disease: coronary artery disease and aortic stenosis.  
In this thesis, I firstly investigated the role of advanced imaging methods which can 
be applied to computed tomography of the heart. Computed tomography coronary 
angiography can provide detailed images of the blood vessels supplying blood to the 
heart. This enables visualisation of the artery walls and identification of different 
components of atherosclerosis including calcium and lipid deposits. Specialised 
imaging software can allow detailed measurements of the volume and composition of 
atherosclerotic plaques.  Fractional flow reserve is used as a measure of how blocked 
an artery has become and provides a guide as to whether areas of narrowing in blood 
vessels cause reduced blood flow to the heart muscle. This is traditionally measured 
during an invasive angiogram, but recent technology has enabled this to be measured 
directly from computed tomography scans. In this thesis, I investigated whether non-
invasive fractional flow reserve from Computed Tomography (FFRCT) was related to 
the volume and composition of atherosclerosis in blood vessels without a clear or 
significant narrowing.  I found that diffuse atherosclerosis in blood vessels could cause 
an abnormal FFRCT, suggesting this may provide a measure of plaque burden and 
composition.   
 
 xxiii 
Positron Emission Tomography (PET) is a scanning technique which can measure the 
activity of specific disease processes following injection of targeted radioactive 
molecules into the body. In a study of patients with heart disease, I investigated the 
use of a radioactive molecule (18F-sodium fluoride) which binds to areas of developing 
calcium within the body. In this thesis, I have found that this molecule can identify 
areas of activity within the walls of blood vessels in the heart which predict progression 
of calcium formation within one year. This may enable us to detect patients who are 
more at risk of disease progression and may benefit from more aggressive treatment. 
This may also be of value in studies investigating the role of new treatments for heart 
disease.  
As a scanning technique, PET has a number of challenges when imaging the heart. 
One major challenge is motion caused by the beating of the heart during the duration 
of the scan, as well as movement of the lungs during each breathing cycle. This makes 
it difficult to localise precisely areas of activity and can lead to areas of interest 
becoming blurred or noisy. In this thesis, I investigated how different methods of post-
processing PET images leads to variations in signal intensity and image noise and how 
to optimise this for imaging the heart. I also applied a motion correction technique to 
PET images which aimed to counteract the effects of motion caused by movement of 
the heart during the scan. This led to an improvement in signal intensity and reduction 
in image noise in both the coronary arteries and the aortic valve. These results will be 
useful for future studies using this scanning technology to image the heart.  
Finally, I investigated the role of computed tomography in aortic stenosis. Computed 
tomography scanning provides the ability to quantify calcium in the aortic valve, 
 xxiv 
providing a measure of the severity of aortic stenosis. I found that this scanning 
technique is reproducible and is able to detect small changes in calcium load over time. 
The repeatability of CT calcium scoring combined with its ability to detect small 
increases in disease severity over time means that this imaging technique could 
potentially identify patients in whom aortic stenosis is progressing rapidly and, by 
detecting early markers of change, may also be useful in research studies  investigating 
the role of new treatments for this condition.   
In summary, the advanced imaging techniques studied in this thesis provide a means 
of exploring different features of coronary artery disease and aortic stenosis.  This will 
not only help to improve our understanding of these important disease processes but 
has the potential to change the way in which we assess an individual patient’s risk of 
disease progression in the future. Further studies are now needed to investigate the 
direct impact of these findings on patient outcomes and the role of novel treatments 
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Chapter 1 Introduction 
1.1 OVERVIEW 
Recent years have witnessed innovative advances in the diagnosis and management of 
cardiovascular disease. Despite this, predicting and anticipating events at an individual 
patient level remains challenging and this precludes individualised tailoring of 
treatment. As a consequence, cardiovascular disease remains a leading cause of death 
in the United Kingdom and worldwide.  Technological advances in non-invasive 
imaging modalities have precipitated an increasing drive to utilise technology to 
provide a safe and efficient means of exploring the underlying disease mechanisms 
responsible for progression of cardiovascular disease and ultimately adverse clinical 
outcomes. Interest has also focused on how we may utilise technology to assess the 
effect of novel therapies on the progression of cardiovascular disease.  
This thesis aims to investigate the role of advanced non-invasive imaging strategies in 
providing measures of and improving our understanding of disease burden, activity 
and progression in coronary atherosclerosis and aortic stenosis, two distinct leading 
manifestations of cardiovascular disease.  
1.2 CORONARY ATHEROSCLEROSIS 
1.2.1 THE VULNERABLE PLAQUE 
The majority of acute ischaemic vascular events are precipitated by rupture of a 
vulnerable atherosclerotic plaque. In this population, events are often unheralded and 
occur without preceding symptoms.  Our understanding of specific characteristics of 
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the vulnerable atherosclerotic plaque has been enhanced by retrospective pathological 
studies which have identified common phenotypic features of the atherosclerotic 
plaque most prone to rupture and trigger thrombotic events. These characteristics 
comprise the ‘thin-cap fibroatheroma’ and include a thin fibrous cap, large plaque 
volume, necrotic core, positive remodelling, intraplaque haemorrhage and spotty 
calcification. (1-4) Pathological and imaging studies have highlighted that such 
vulnerable lesions often do not cause significant luminal obstruction. (2) The degree 
of calcification of vulnerable lesions is variable, with over half exhibiting spotty or no 
visible calcification, and only a minority demonstrating diffuse calcification.  (2) Such 
high-risk plaques often do not occur in isolation, and patients at greatest risk of future 
events often exhibit multiple high-risk lesions. (5) 
Longitudinal imaging studies have demonstrated that plaque morphology may evolve 
over time and that high-risk plaques may heal to form more stable thick cap 
fibroatheroma or fibrotic plaques, possibly after periods of subclinical rupture and 
plaque expansion. (6, 7) Patients with chronic stable disease often exhibit symptoms 
as a consequence of luminal obstruction and more extensive calcification is often a 
feature of advanced, stable atherosclerosis.  (8) 
1.2.2 CALCIFICATION  
Whilst historically considered a passive and degenerative pathology, vascular 
calcification is now recognised as a complex, dynamic and tightly regulated process 
that bears many similarities to skeletal bone formation. The incidence of vascular 
calcification rises with age, observed in up to 50% of individuals aged 40-49 (9) and 
over 80% of individuals over the age of 70, its presence often reflecting advanced 
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atherosclerosis. (10) In  two-thirds of asymptomatic men and women over the age of 
70, extensive calcification is found throughout multiple vascular beds. (10) However, 
its progression may also be accelerated in metabolic disorders including diabetes 
mellitus, hypercholesterolaemia and chronic renal disease. (11, 12) 
Within the coronary arteries, intimal calcification is pathognomonic of atherosclerosis. 
The extent of coronary calcification correlates closely with atherosclerotic plaque 
burden and can be used as a reliable surrogate marker of coronary heart disease. (13) 
In patients aged 30-39 with symptomatic coronary artery disease, coronary 
calcification is observed in 70%. (1) Whilst the absence of visible calcification does 
not exclude the presence of atherosclerosis (13), individuals without coronary 
calcification have a low cardiovascular mortality. Conversely, the extent and severity 
of calcification are associated with an increased risk of adverse cardiovascular events. 
(14, 15)  
In atherosclerosis, the initiation of vascular mineralisation is closely associated with 
progressive inflammation, cell death and necrosis. We hypothesise that this process 
may be initiated in an attempt to wall off the necrotic core, subdue inflammation, and 
shield the hypoxic inflamed plaque from circulating pro-inflammatory and 
thrombogenic mediators. A similar healing response can be observed in other 
conditions associated with focal, necrotic inflammation. For example, in response to 
the caseating granuloma in primary pulmonary tuberculosis, the body acts to contain 
this inflammation within the calcified Ghon focus. Similarly, in certain parasitic 
infections and foreign body inclusions, calcification is initiated to encapsulate these 
focal areas of intense inflammation.  
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The earliest form of mineralisation that may be identified within the vasculature exists 
in the form of calcified microvesicles containing hydroxyapatite: the most abundant 
mineralised form of calcium phosphate found in both bone and the vasculature. 
Hydroxyapatite initially forms as nanoparticles that exist as long crystalline structures. 
As these nucleate and propagate, microvesicles coalesce to form organised 
macrocalcific deposits. As mineralisation progresses further, large granules and 
organised plates of calcium form, and calcification within the vasculature adopts a 
form akin to lamellar bone. (16) Once initiated, vascular calcification can progress 
quickly, aided by the downregulation of inhibitors of mineralisation. (17, 18) 
When this advanced stage is reached, the barrier between the thrombogenic plaque 
core and circulating blood has successfully formed. In atherosclerosis, this translates 
into an increase in stability of the plaque and is reflected by a lower risk of rupture and 
thrombosis.  (2) 
1.2.2.1 Microcalcification 
In contrast to the stability possibly imparted by extensive calcification, the earliest 
stages of microcalcification are associated with intense inflammation and plaque 
vulnerability. The majority of ruptured plaques exhibit evidence of spotty 
microcalcific deposits, leading to the appreciation of microcalcification as a key 
pathological feature of the vulnerable plaque. (2, 4) 
The association between the early stages of calcification and plaque vulnerability may 
be a consequence of the ongoing intense inflammation and necrosis within the plaque, 
before the process of calcification has succeeded in its role of shielding the necrotic 
core from the vascular lumen. During its initial stages, microcalcification has been 
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postulated to play an active role in inflammation by inducing further vascular smooth 
muscle cell death and release of pro-inflammatory mediators.  (19) 
Additionally, it has been hypothesized that early calcification may be directly 
implicated in plaque rupture due to its influence on mechanical stress within the intima. 
An abundance of high-density microvesicles containing hydroxyapatite scattered 
amongst the low-density lipid contents of the necrotic core may precipitate plaque 
rupture by increasing shear stress. (20) If calcified vesicles migrate to the thinned 
fibrous cap, increased mechanical stress within this vulnerable region may predispose 
to acute microfractures, rupture and subsequent thrombosis. (21)  A recent study by 
Hutcheson, et al, documented an inverse relationship between collagen content and 
size of microcalcifications in atherosclerotic plaques, suggesting a relationship 
between fibrous cap degradation and microcalcification. (22) 
Irrespective of the mechanism, it is evident that early microcalcification coincides with 
active, inflamed, vulnerable atherosclerosis.  Histologically, early calcific deposits 
colocalize with macrophage burden, and matrix vesicles responsible for initiating 
mineralisation or generating microcalcification may be derived from macrophages. 
(17, 18, 23-25) In contrast, extensive calcification may reflect advanced, less inflamed 
and stable disease in which dense, organised calcium has effectively formed a barrier 
between the thrombogenic plaque core and circulating blood. (2, 4, 17, 26) 
Histological evidence has elucidated that advanced calcification is remote from areas 
of inflammation and macrophage accumulation (17), supporting the hypothesis that 
this process may indeed subdue inflammation.  
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1.3 IMAGING CORONARY ATHEROSCLEROSIS 
Traditional diagnostic approaches have focused on identifying the presence and degree 
of coronary artery stenosis and downstream ischaemia. However, evidence has 
continued to emerge that the overall burden of disease and plaque characteristics in 
coronary atherosclerosis have prognostic significance. Indeed, the majority of acute 
coronary events are caused at arterial sites with nonobstructive disease on antecedent 
coronary angiography. (27) Further, it is increasingly understood that patients with 
evidence of high-risk plaque features or plaque progression are at risk of future events 
irrespective of the degree of coronary stenosis. (28, 29) For these reasons, 
multimodality imaging has recently focused on identifying features of the vulnerable 
plaque which provide targets for the researcher and clinician to develop a greater 
understanding of disease burden, characteristics and biological disease activity to 
improve risk stratification in patients with coronary artery disease. (Figure 1.1) 
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Figure 1.1 Possible approach using multi-modality imaging to stratify risk in patients with 
atherosclerosis. 
Advances in imaging technology now allow multiple different atherosclerotic features 
to be assessed using both invasive and non-invasive technology. The challenge is to 
use these advances to improve patient risk stratification, to guide clinical management 
and ultimately to reduce adverse cardiovascular events. A possible future approach to 
patient assessment and risk stratification is presented. Initial screening with risk factor 
assessment and simple strategies to measure plaque burden may be used in large 
populations, guide lifestyle interventions and the prescription of aspirin and statins.  In 
those with advanced plaque burden more advanced imaging using assessments of 
luminal stenosis, myocardial ischemia and plaque characteristics can then be used to 
identify those at the highest risk of future events. Combined information is likely to 
provide complementary results. These vulnerable patients could then be targeted with 
powerful yet expensive systemic therapies that are emerging (e.g. PCS-K9 inhibitors) 
or dual antiplatelet therapy where the potential for bleeding may be outweighed by the 
high cardiovascular risk.  As further data emerges, the use of hybrid imaging (e.g. 
PET/CT) may further refine advanced non-invasive risk stratification, differentiating 
patients with active disease versus those with burnt out stable atheroma. Finally, in 
those patients being considered for revascularisation, advanced invasive imaging 
including FFR and other emerging approaches can be used to optimise decisions 
regarding percutaneous intervention (PCI) or coronary artery bypass grafting (CABG).   
(Adapted from Dweck MR and Doris MK et al, Nat Rev Cardiol 2016;13(9):533-48) 
(30)  
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1.3.1 CORONARY ARTERY CALCIUM SCORING 
The quantification of coronary artery calcification on non-contrast CT provides a 
surrogate marker of total plaque burden. This is routinely performed using the 
Agatston method which applies a factor relating to maximum plaque attenuation and 
multiples this by the calcium area to generate a weighted sum of lesions with 
attenuation greater than 130 Hounsfield Units (HU). (31) The coronary calcium score, 
expressed in Agatston Units (AU) has demonstrated prognostic significance, with a 
greater burden of coronary calcification associated with adverse prognosis beyond 
conventional risk factors. (32, 33) Beyond the total plaque burden, additional measures 
including the distribution of coronary calcium, number of plaques and plaque density 
have been shown to add to total Agatston score in the assessment of prognosis. (34) 
Further, progression of calcium score on CT predicts adverse prognosis independent 
of the baseline calcium score. (14) The relatively low cost, availability and ease of 
imaging protocols without need for contrast make coronary artery calcium scanning 
an attractive non-invasive imaging modality for imaging coronary atherosclerosis. 
Modern imaging protocols now enable CT calcium scoring to be performed with a low 
radiation exposure (1-3 mSv). (35) 
1.3.2 COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY 
Computed Tomography Coronary Angiography (CTCA) has demonstrated accuracy 
in identifying the presence, extent and severity of coronary artery disease compared 
with invasive angiography.  (36, 37) The SCOTHEART study investigated the benefit 
of CTCA in clarifying the diagnosis of angina secondary to coronary heart disease and 
demonstrated that, in patients with recent onset stable chest pain, CTCA clarified the 
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diagnosis of angina secondary to coronary heart disease, improving diagnostic 
certainty in one in four patients. (38) This in turn led to positive treatment decisions 
whereby the identification of obstructive and nonobstructive disease guided changes 
to management and the initiation or cessation of preventative therapies where 
indicated. Subsequent follow-up analyses have demonstrated that the use of CTCA in 
addition to standard care reduced the risk of death from coronary heart disease or non-
fatal MI at 5 years, with no difference in overall rate of invasive angiography or 
revascularisation. (39)  
In addition to identifying the presence of obstructive or nonobstructive atherosclerosis, 
CTCA also provides the opportunity to directly visualise the arterial wall, highlighting 
plaque composition and identifying adverse features such as necrotic core, positive 
remodelling and spotty calcification. The presence of high-risk plaque features on 
CTCA, particularly if identified in combination, is associated with an increased risk of 
future adverse cardiac events. (28, 40, 41) 
1.3.2.1 Automatic plaque quantification 
While the identification of adverse plaque features on CTCA has demonstrated 
prognostic significance, this process is subjective, may be time-consuming and has 
demonstrated only fair agreement between observers. (42) The development of semi-
automated software capable of identifying and quantifying the burden of high-risk 
plaque features on CTCA both reduces the time taken for analysis and improves 
reproducibility. (43, 44) Semi-automated software has demonstrated accurate 
quantification of noncalcified plaque when compared with intravascular ultrasound. 
(45)  In a post-hoc analysis of the SCOTHEART study, low attenuation plaque burden 
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was the strongest predictor of future fatal or nonfatal myocardial infarction  
irrespective of cardiovascular risk score, coronary calcium score and area stenosis. 
(29) Patients with a low attenuation plaque burden greater than 4% were 5 times more 
likely to suffer a fatal or nonfatal myocardial infarction at five years. (29) 
1.3.3 FRACTIONAL FLOW RESERVE DERIVED FROM CT ANGIOGRAPHY 
(FFRCT) 
In addition to the detection of high-risk plaque features on CTCA, the evolution of 
approaches to combine this anatomical information with physiological measures of 
coronary blood flow and perfusion hold promise for the future of CTCA. Recent 
developments in the calculation of fractional flow reserve noninvasively (FFRCT) 
have been highlighted in three large multicentre studies (NXT, DISCOVER-FLOW 
and DeFACTO) which have compared the accuracy of FFRCT with invasive FFR 
measurements. (46-48) A meta-analysis of the DeFACTO, NXT and DISCOVER-
FLOW trials concluded that FFRCT has a pooled sensitivity similar to CTCA (0.89 
versus 0.89 at per-patient analysis; 0.83 versus 0.86 at per-vessel analysis) but 
improves specificity in both a per-vessel and per-patient analysis (0.71 versus 0.35 at 
per-patient analysis; 0.78 versus 0.56 at per-vessel analysis). (49) The high negative 
predictive value of FFRCT has raised promise for its potential to exclude ischaemia 
caused by intermediate grade lesions, potentially avoiding unnecessary invasive 
angiography. (50) Recently, the Prospective LongitudinAl Trial of FFRCT: Outcome 
and Resource Impacts (PLATFORM) study has investigated the clinical use of FFRCT 
and the results revealed that CTCA with FFRCT did in fact lead to a marked reduction 
in the frequency of invasive angiography showing no obstructive coronary artery 
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disease. (51) This was a non-randomised study and there was no comparison with 
CTCA alone, and further study is therefore warranted. 
1.3.4 POSITRON EMISSION TOMOGRAPHY 
Positron emission tomography (PET) utilises radiolabelled tracers targeting specific 
molecular processes within tissues and the vasculature. Combined with anatomical 
information gained from computed tomography, hybrid PET-CT imaging provides a 
unique opportunity to identify active biological processes non-invasively. Tracers 
targeting many key pathological processes in cardiovascular disease have been 
developed, some already well established. (Table 1.1) Currently the most widely 
available and utilised tracer is 18F-fluorodeoxyglucose (18F-FDG), a glucose analogue 
which becomes trapped within metabolically active cells. The increased metabolic 
activity of macrophages compared to surrounding tissues has enabled its use as a 
marker of inflammation.  Given its close association with inflammation, early 
microcalcification also serves as a suitable imaging target for the identification of high-
risk vascular disease. The detection of microcalcification within the vasculature may 
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Table 1.1 Applications of 18F-fluorodeoxyglucose and 18F-sodium fluoride in 
cardiovascular disease. 
 18F-Fluorodeoxyglucose 18F-Sodium Fluoride 




Specificity Poor High 
Clinical Application 
1. Atherosclerosis 
of Large Vessels 
Increased uptake in large 
arteries (TBR ³1.7) is a strong 
predictor of subsequent 
vascular events. (52) 
At least one site of increased 
uptake observed in all patients 
with prior CV events. (53) 
2. Coronary 
Artery Disease 
Increased uptake in culprit 
plaque in 33% of patients 
following MI. One half of 
vessel territories unable to be 
interpreted due to myocardial 
uptake. TBRmax of culprit 
plaques 1.71 and non-culprit 
plaques 1.58 (p=0.34). (54, 55) 
Increased uptake in culprit vessel 
in 93% of patients following MI.  
Focal uptake in 45% of patients 
with stable CAD. TBRmax of 
culprit plaques 1·66 and non-
culprit plaques 1·24 (p<0·0001). 
(55) 
3. Carotid Disease Uptake 27% higher in 
symptomatic vs asymptomatic 
plaques. (56) 
Uptake correlated with CV risk 
factors. (57) Increased uptake in 
culprit vs contralateral plaques. 
(58)  
4. Aortic Stenosis Increased TBR in 35% of 
patients with aortic stenosis 
(TBR>1.63). Modest rise in 
max TBR with severity 
(r=0.47, P<0.001). (59, 60) 
Increased uptake in 91% of 
patients with aortic stenosis 
(TBR>1.97). Progressive rise in 
max TBR with severity (r=0.73, 
P<0.001). Uptake predicts disease 
progression. (60, 61) 
Histology 
1. Excised Aortic 
Valves 
Signal did not correlate with 
macrophage burden (CD 68 
staining) [r=0.43; p=0.22], 
suggesting non-specific 
binding. (61) 
Signal co-localized with regions of 
calcification and could also be 
observed in regions of evolving 




Accumulation in macrophage 
rich areas of plaque. (56) 
Focal uptake at site of plaque 
rupture. (55) Uptake associated 
with active calcification and 
necrosis. (55, 62) 
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1.3.4.1 18F-sodium fluoride 
18F-Sodium Fluoride was first developed in 1962 when it was introduced as a suitable 
radioactive tracer for the study of bone disease. (63) In the following years, its use was 
largely superseded by technetium-99m-diphosphonate compounds. However, the 
highly favourable pharmacokinetics of this tracer and increased sensitivity in the 
detection of skeletal metastases led to its re-emergence as a favourable scanning agent 
in both focal and generalised bone disease. It is currently used widely in the diagnosis 
of both malignant and metabolic bone disease and in the evaluation of skeletal trauma.  
(64-68) 
In skeletal imaging, 18F-sodium fluoride binds to hydroxyapatite, the major inorganic 
component of skeletal bone. The level of uptake and corresponding signal intensity 
largely depend on both blood flow (the rate limiting step) and surface area of exposed 
hydroxyapatite. In metabolic bone disease or malignancy, increases in regional blood 
flow as well as increased bone turnover lead to a greater surface area of exposed 
hydroxyapatite and result in increased uptake of the tracer. (65) 
Following intravenous administration, 18F-sodium fluoride is rapidly cleared from the 
plasma by diffusion through capillary beds into the extracellular compartment. When 
it reaches the bone surface, the exchange of the fluoride ion with the hydroxyl group 
in hydroxyapatite leads to the formation of fluoroapatite (Ca10(PO4)6F2). Following 
rapid initial chemisorption, the slower incorporation of fluoroapatite with the bone 
matrix occurs, a process which can take days or weeks. (69) 
As a result of minimal plasma protein binding, high first-pass extraction and avid 
irreversible association with hydroxyapatite, almost all of the injected dose is retained 
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by bone after a single pass of blood. This facilitates high contrast skeletal imaging just 
one hour following injection. (69, 70) The biological half-life of 18F-sodium fluoride 
is 90 min. (70) 
Within the vasculature, 18F-sodium fluoride uptake occurs by similar mechanisms, 
providing a marker of calcification activity. Phosphor-imaging autoradiography has 
demonstrated that 18F-sodium fluoride associates with regions of calcification with a 
high affinity and exhibits negligible non-specific binding. (62) In 
immunohistochemical analysis, 18F-sodium fluoride co-localizes specifically to 
vascular calcification as opposed to upstream markers of the calcific response. (62) 
Within the vasculature, 18F-sodium fluoride detects regions of dynamic 
microcalcification (<50 µm), with a proportionately smaller radioactivity signal 
observed in large calcific deposits and many regions of heavily calcified 
atherosclerotic plaque displaying no tracer uptake. (54, 62, 71) Indeed, the intensity of 
18F-sodium fluoride uptake has been found to be inversely correlated with calcified 
plaque density. (72) This feature may be explained by the finding that arterial 18F-
sodium fluoride is unable to penetrate through organised mineral layers in advanced 
macrocalcific deposits, with uptake dependent on the surface area of exposed 
hydroxyapatite. This hypothesis has been supported by micro-PET/micro-CT analysis 
of carotid endarterectomy specimens. When intact specimens were imaged following 
incubation with 18F-sodium fluoride, increased activity was demonstrated only on the 
surface of macroscopic calcium deposits, with no uptake within their core. However, 
if specimens were sectioned prior to incubation with 18F-sodium fluoride, increased 
tracer uptake was subsequently observed within the newly exposed regions of 
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macrocalcification. (62) This offers an explanation for the apparent discordance 
between advanced calcification and 18F-sodium fluoride uptake. In large volume and 
flat calcified deposits, most of the hydroxyapatite is internalised and the radioactive 
tracer cannot penetrate through the organised mineral layers. Conversely, dispersed 
convex vesicles in the early stages of microcalcification provide a much larger surface 
area of available hydroxyapatite. (62) A clear value of this radiotracer lies in its ability 
to identify microcalcification as opposed to macrocalcification visible on computed 
tomography. Therefore, by selectively detecting regions of biologically active 
developing microcalcification within the vasculature and doing so with both a high 
affinity and sensitivity, PET imaging with 18F-sodium fluoride identifies key features 
of plaque vulnerability and an active disease state thereby providing distinct 
information to computed tomography and potentially leading to a number of important 
cardiovascular applications. Whilst not present in all vulnerable atherosclerotic 
plaques, the presence of microcalcified deposits has been demonstrated in the majority 
of acute plaque ruptures. (2) 
1.3.5 TECHNICAL CHALLENGES OF POSITRON EMISSION TOMOGRAPHY 
Whilst emerging as a promising technique, many technical challenges relate to cardiac 
PET imaging, and overcoming these will be crucial to assist in the adoption of this 
technique in the research and clinical setting.  
Imaging of the coronary arteries is particularly challenging due to the impact of 
respiratory and cardiac motion on coronary artery territories, often leading to blurring 
of the PET signal. Discarding the PET data obtained during systole and only using the 
data from end diastole effectively reduces motion but does so at the expense of 
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increasing noise. This can pose difficulty in distinguishing true positive lesions from 
background noise and leads to an average difference of only 34% in tissue-to-
background ratios between positive and negative coronary plaques. (55) However, the 
application of innovative motion correction techniques has shown promise in reducing 
background noise and improving tissue-to-background ratios. (73) (Figure 1.2) 
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Figure 1.2 Noise reduction and TBR improvement in 18F-fluoride PET images of 65-y-old 
man.  
(A) On linear grayscale transverse slices, 18F-fluoride plaque uptake is seen in left 
anterior descending (LAD) (red arrows) and left circumflex (LCX) (green arrows) 
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coronary arteries. The images show blurred lesion signal in ungated images, significant 
noise in 1-bin images, and high lesion signal with reduced noise in motion-corrected 
images. (B) On PET (top), PET-CTCA (middle), and multiplanar-reformatted PET-
CTCA (bottom) images with exponential colour table and same window and level 
settings, vulnerable plaque is seen in right coronary artery (RCA) (yellow arrows). 
Low lesion signal is seen in ungated images, significant noise in 1-bin images (blue 
arrows), and high signal with less noise in motion-corrected images. (C) 3-dimensional 
rendering of 1-bin image (25% of PET counts) as in study of Joshi et al. (55) (left) and 
motion-corrected image (right) superimposed on rendered CTCA volume. Increased 
uptake is seen in RCA, LAD, and LCX coronary arteries in high-noise 1-bin image 
and remains clear in motion-corrected image. (Rubeaux M et al, J Nucl Med 
2016;57:54-59). (74) 
 
Another challenge exists as a consequence of the finite spatial resolution of PET 
imaging systems, meaning that quantitative measurements of tracer concentrations in 
small areas can pose difficulty. Partial volume effects may lead to blurring of the 
radiotracer signal, especially from small tissue structures such as the coronary arteries. 
(75) As measurements of tracer uptake in small volume structures become increasingly 
important, the potential for enhanced correction techniques may develop.  
The advent of combined PET and magnetic resonance imaging, with the combination 
of excellent soft tissue contrast and functional imaging capabilities, holds promise in 
imaging of the vasculature. With the evolution of innovative motion correction 
techniques, this technology has the potential to enhance our understanding of the 
natural history of vascular calcification and its clinical consequences, thereby 
influencing and improving management of cardiovascular disease. 
Even with such technological advances, the question will remain as to whether the 
identification of 18F-sodium fluoride positive coronary plaques will complement 
existing investigative strategies and allow improved prospective identification of 
vulnerable patients with high-risk disease. Given the expensive cost of PET-CT 
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imaging and use of additional radiation, use of this technique must be found to have 
an incremental clinical impact above existing risk prediction models and imaging 
strategies prior to clinical implementation.  This will require results from large 
prospective studies demonstrating the clinical utility and cost effectiveness of imaging 
the coronary arteries and vasculature.   
1.4 AORTIC STENOSIS  
1.4.1 BACKGROUND 
Aortic stenosis (AS) affects over 7 million people aged over 75 years in Europe and 
North America and its prevalence is expected to triple in the next forty years. (76-78) 
The development of effective medical therapy is a major unmet clinical need that will 
require both a greater understanding of the underlying pathophysiology and the 
adoption of novel imaging methods to establish safety and efficacy of candidate drugs. 
AS is a fibrocalcific disease in which progressive deposition of lipid, collagen and 
calcification leads to thickening and immobility of the aortic valve leaflets, resulting 
in progressive valve narrowing and obstruction to left ventricular outflow. Over time, 
the left ventricle responds to the consequent increase in afterload by myocyte 
hypertrophy, extracellular expansion and ultimately myocardial fibrosis and 
decompensation. (79, 80)  
1.4.2 THE PATHOPHYSIOLOGY OF AORTIC STENOSIS  
The Valve: The initiation phase of AS shares many pathophysiological similarities 
with atherosclerosis and is dominated by inflammation, lipid infiltration and 
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extracellular matrix remodelling under the control of inflammatory signalling 
pathways. (81-85) Like atherosclerosis, the initiating insult appears to be a 
combination of increased mechanical and oxidative stress or reduced shear stress 
leading to endothelial damage and a powerful inflammatory response.  As this process 
continues, inflammatory signalling pathways are superseded by a powerful and 
relentless cycle of progressive calcification, coordinated by osteoblast-like cells and 
governed by pro-osteogenic signalling pathways. (79, 86, 87) The accumulation of 
calcium within the valve during the later propagation phase induces further injury, 
thereby establishing a vicious cycle of accelerating calcification and progressive 
valvular obstruction.  
The Myocardium: In addition to progressive valvular obstruction, AS has direct effects 
on the left ventricle. Progressive valve obstruction results in an increased afterload, 
triggering myocyte hypertrophy and compensatory wall thickening that initially 
preserves wall stress and maintains cardiac output. Over time, however, cellular 
hypertrophy progresses to myocyte death, expansion of the extracellular space and 
replacement fibrosis. (80, 88-91) Indeed these two processes drive left ventricular 
decompensation and the transition from hypertrophy to heart failure.  
1.4.3 WHAT DO WE REQUIRE OF IMAGING IN AORTIC STENOSIS? 
Cardiac imaging is pivotal to the management of aortic stenosis and relied upon to 
confirm the diagnosis and to grade stenosis severity and assess myocardial health both 
at baseline and over time.  AS is a slowly progressive condition that advances at a 
variable and inconsistent rate.  In order to accurately measure or predict disease 
progression over time, imaging tests must have sufficient reproducibility and 
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robustness to detect small changes in disease severity with high accuracy.  In the 
clinical setting, this is of utmost importance when selecting the appropriate 
management strategy and optimal timing of intervention for the individual patient. In 
the research setting, these attributes are crucial in clinical trials seeking to investigate 
efficacy of novel therapies. Indeed, imaging biomarkers with improved repeatability 
and sensitivity to change will minimise sample sizes, follow-up duration and the 
expense of trials. Drug trials using imaging endpoints therefore desire biomarkers that 
maximise signal-to-noise or the progression-to-noise ratio: the ratio between the 
magnitude of average progression in a particular parameter compared to its scan-
rescan repeatability (the error in measuring that parameter on two different scans). 
While transthoracic echocardiography has remained the gold standard method for 
assessing the aortic valve and myocardium and the tool of choice in the clinical setting, 
novel imaging techniques demonstrate potential advantages and are therefore being 
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Figure 1.3.  The role of imaging in aortic stenosis progression.  
Non-invasive imaging provides the ability to directly image the aortic valve and 
consequent pathophysiological effects on the myocardium. Imaging the valve may be 
performed by CT to quantify aortic valve calcium load (CT-AVC), PET to measure 
calcification activity and/or echocardiography to assess haemodynamic severity. The 
response of the left ventricle may be assessed by echocardiographic measures of mass, 
EF and/or strain, while CMR offers additional quantification of fibrosis. The ability of 
these techniques to detect therapeutic efficacy depends on the scan-rescan repeatability 
of the test and the rate of change of the parameter being measured. These attributes are 
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1.4.4 ECHOCARDIOGRAPHY 
While there may not be a true reference standard for AS severity, echocardiography is 
considered the “gold-standard” for clinical assessment. Early work in the 1970s found 
that Doppler ultrasound could be used to examine the jets of stenotic and regurgitant 
lesions. (92) This laid the groundwork for Hatle (93, 94)  to demonstrate that Doppler 
ultrasound was highly feasible in AS and the peak jet velocity, converted into a 
gradient using the simplified Bernoulli equation, (95) had good agreement with 
invasive measurements. Otto, (96) along with many others, have since demonstrated 
that echocardiographic biomarkers strongly predict the need for intervention. Finally, 
the use of echocardiographic markers of severity as enrolment criteria in the 
PARTNER B trial (97) demonstrates the ability of echocardiography to select patients 
for beneficial therapy. Combined with the absence of radiation, widespread 
availability and low imaging costs, these characteristics place echocardiography as the 
first-line modality for screening and serial follow-up in aortic stenosis. 
Although multiple echocardiographic parameters exist to assess disease severity, 
current guidelines recommend the assessment of severity and progression based upon 
peak velocity, mean gradient and aortic valve area (AVA). (98) Each of these central 
parameters have been found to predict outcome across multiple studies. (99-101) 
Aortic peak velocity remains the first line biomarker in recent guidelines 
[ESC/EACTS 2017], providing powerful prognostic information and superior 
reproducibility than other parameters. (102, 103) However, peak velocity is dependent 
on flow status and accurate alignment of the echocardiography probe with the jet of 
blood through the valve. While mean gradient is subject to the same limitations as peak 
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velocity, aortic valve area (AVA) is in principle less flow dependent.  However, 
measurements of aortic valve area can represent an important source of discrepancy, 
particularly as a result of variations in direct measurements of the left ventricular 
outflow tract (LVOT). As LVOT diameter is squared to provide AVA by the continuity 
equation, small differences in measurement can lead to significant variation, and often 
an underestimation of AVA. Echocardiographic measurements therefore display 
considerable variability leading to inaccuracies when estimating disease progression.  
Moreover, echocardiographic measurements demonstrate relatively slow progression 
with time. As a consequence, the progression to noise ratio for most echocardiographic 
assessments is not favourable. (104, 105)  While this is often not a major issue in 
clinical practice, in the research setting it means that clinical trials require relatively 
large numbers of patients and prolonged follow-up to detect true treatment effects. 
(104) 
An additional limitation worth considering is that echocardiographic measures of AS 
often provide conflicting assessments of disease severity. Indeed, discordant 
echocardiographic results are seen in one quarter of patients, most often arising from 
a valve area <1 cm2 suggesting severe disease, and a peak velocity <4.0 m/s or mean 
gradient <40 mmHg indicating moderate stenosis.   (106, 107)  In cases of low flow, 
low gradient aortic stenosis, flow can be temporarily increased to assess the true 
haemodynamic severity of aortic valve disease. Low dose dobutamine stress 
echocardiography (DSE) is often useful in this regard - with an increase in velocity 
with increased flow rates used to diagnose true severe AS (108) and to discriminate 
patients with and without contractile reserve. (109) However, a significant proportion 
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of patients with discordant findings are in fact found to have normal flow status, 
making echocardiographic results difficult to interpret.  
For these reasons, interest in developing novel assessments of disease severity and 
progression in aortic stenosis is growing, and novel imaging techniques may 
complement echocardiography in adjudicating disease severity and monitoring disease 
progression. 
1.4.5 COMPUTED TOMOGRAPHY CALCIUM SCORING 
Calcification is the predominant process causing valve obstruction in AS. 
Quantification of the calcium burden has therefore been suggested as an alternative 
flow-independent method of determining disease severity. (110) This was first 
demonstrated using a semi-quantitative assessment on echocardiography, (110, 111) 
although the clinical utility of this approach has been limited by subjectivity and 
suboptimal reproducibility. (112)  Interest has instead turned to computed tomography 
(CT) calcium scoring, an established clinical technique already widely used to quantify 
coronary arterial calcification. Using a non-contrast, ECG-gated CT acquisition and 
similar protocols as for coronary calcium scoring, the burden of valvular calcium can 
be quantified using the Agatston method, which encompasses both the area and 
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Figure 1.4. CT calcium scoring of the aortic valve.  
An example of mild aortic valve calcification (Patient A, top panel) and severe 
calcification by CT (Patient B, bottom panel) in transverse (left) and short-axis (right) 
views of the valve. 
 
Early studies of aortic valve CT calcium scoring (CT-AVC) highlighted that this could 
provide a complementary measure of stenosis severity, correlating moderately with 
haemodynamic severity on echocardiography. (112, 113) A major advance was the 
realisation that men and women require different calcium scores to develop severe 
stenosis, even when adjusted for body size or LV outflow dimensions, and therefore 
that sex-specific thresholds were needed to grade severity. (114) In 646 patients with 
normal LV systolic function, the application of calcium score thresholds of 2065 (AU) 
for men and 1274 (AU) for women correctly classified severe AS with a sensitivity of 
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³86% and specificity of ³79%. (106) These thresholds have been validated in a further 
multicentre cohort of over 900 patients, holding particular potential in adjudicating 
disease severity in patients with discordant echocardiography results. (115, 116)  
In addition to defining severity, CT-AVC offers powerful prediction of future clinical 
events. (115, 116) Indeed, in recent multicentre studies, severe calcification was 
associated with a 3 to 4-fold increase in death or AVR, (107, 117) emerging as an 
independent predictor of these events after adjustment for clinical and  
echocardiographic parameters.  CT-AVC may also provide value in measuring disease 
progression, improving the progression-to-noise ratio previously discussed.  
Quantification of calcium by CT has been shown to demonstrate excellent 
interobserver reproducibility and scan-rescan repeatability; with limits of agreement 
approximately ±70 AU and variation of approximately 4-8%, respectively. (112, 114, 
118) Moreover, mean annual progression in calcium score is relatively large, ranging 
from approximately 141 AU/year in mild AS to 361 AU/year in severe AS. (115)   
Whether CT calcium scoring will be modifiable with medical therapies is yet to be 
determined, however its attributes have led to its adoption in the research setting as the 
primary efficacy end point in multiple ongoing studies investigating novel treatments 
for aortic stenosis. CT calcium scoring is not currently recommended for routinely 
tracking disease progression in the clinical arena, although recent ESC guidelines 
support its use in adjudicating disease severity in patients with discordant 
echocardiographic assessments and normal flow. (98)  
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1.4.6 POSITRON EMISSION TOMOGRAPHY 
Positron Emission Tomography (PET) is another novel technique, the use of which is 
being explored in aortic stenosis. By monitoring biological processes within the body, 
this modality has the potential to offer important mechanistic insights into 
pathophysiology. Further, as a marker of disease activity and very early calcium 
formation, there is growing interest in using PET to detect early therapeutic effects in 
aortic stenosis at a stage in the process when calcium is more likely to be reversible. 
(Figure 1.5) 
 
Figure 1.5. 18F-fluoride PET-CT of the aortic valve. 
Contrast-enhanced CT of the aortic valve (top panel) with fused 18F-fluoride PET-CTA 
images in the same patient (bottom panel). Strong PET uptake can be localized to the 
aortic valve in short-axis (left), coronal (middle) and sagittal (right) views. 
 
Radiolabelled sodium fluoride (18F-fluoride) is a widely available PET tracer that can 
be used to measure calcification activity in the vasculature, with an affinity for 
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developing microcalcification. (53, 55, 61, 62)  18F-fluoride activity is increased in 
patients with aortic valve disease compared to the healthy population, with a 
progressive rise in PET uptake with increasing severity of aortic stenosis (jet velocity 
and calcium score). (60) Furthermore, early studies have suggested that 18F-fluoride 
activity predicts the rate of future disease progression as measured by CT-AVC and 
echocardiography. (61, 119) Indeed, new areas of macrocalcification appear to 
subsequently develop at sites of increased baseline 18F-fluoride uptake, consistent with 
this tracer identifying developing calcification before it is visible on CT. (Figure 1.6) 
As a marker of disease activity, 18F-fluoride therefore holds potential in detecting 
therapeutic effects more rapidly than conventional anatomical imaging approaches. 
(120) Encouragingly, excellent reproducibility of this technique has been 
demonstrated (ICC >0.8) and scan-rescan reproducibility has also shown good 
agreement with a percentage error of ±10%. (120) However, the incremental value of 
this modality beyond anatomical imaging modalities has yet to be shown and given 
the cost, availability of scanners and radiation exposure, it is unlikely to be used 
clinically in the near future. However, 18F-fluoride PET does hold major promise in 
the research arena and as an end point in clinical trials of novel therapy, potentially 
being more sensitive to treatments effects than other imaging markers. While it 
remains to be determined whether the aortic valve 18F-fluoride PET signal is 
modifiable with medical therapy, the same is true for all imaging biomarkers in the 
absence of an effective medical therapy for this condition.  Interestingly, skeletal 18F-
fluoride uptake in metabolic bone disease does appear to be modifiable, demonstrating 
clear changes after only one month of bisphosphonate therapy. (121) 
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Figure 1.6 18F-Fluoride PET-CT predicts disease progression in aortic stenosis. 
Baseline CT calcium score scans (left) for patients 1 (top panel, A) and 2 (bottom 
panel, B). Fused 18F-fluoride PET-CT scans (middle) show fluoride uptake 
in red and yellow.  Follow-up CT at 1 year (right) suggests that the baseline PET 
signal predicts where new macroscopic calcium, visible on the CT, is going to develop. 
(Dweck M et al, Circ Cardiovasc Imaging 2014;7:371-378) (61)  
 
Another widely used PET tracer that has been explored in imaging of the aortic valve 
is 18F-FDG. This glucose analogue becomes trapped in metabolically active cells and 
serves as a surrogate marker for macrophage burden and inflammation. In aortic 
stenosis, 18F-FDG activity is increased in patients with aortic stenosis although in 
practice image interpretation is frequently challenging due to overspill of activity from 
the adjacent myocardium. (60, 61) Finally, the development of PET-MRI scanning 
platforms provides new opportunities to perform PET imaging studies at low radiation 
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dose and potentially allowing multiple time points to be studied in individual patients. 
(122) 
1.4.7 THE USE OF IMAGING TO TEST DRUG EFFICACY 
As yet, no medical therapy has proven effective in reducing progression of AS or 
improving clinical outcomes in patients with this condition. However, as our 
understanding of the complex pathophysiological processes underlying AS improves, 
novel therapeutic strategies have been developed and are under active investigation.  
(Table 1.2) A challenge is to identify patients in whom the progressive cycle of 
calcification may be reversible with effective therapy, and this may be more likely to 
occur early in stages of calcium formation. Most randomised trials to date have 
targeted patients with mild or moderate aortic stenosis and it has been suggested that 
patients would be more effectively treated at an earlier stage. However, as the majority 
of patients with aortic sclerosis do not develop aortic stenosis, identifying patients with 
mild aortic valve calcification who are likely to derive benefit from treatment would 
be challenging. Furthermore, many patients do not present until they have developed 
advanced disease and so developing therapies which halt disease progression in this 
patient group is also of great importance. Regardless of the stage of disease, it appears 
probable that calcification is more likely to be reversible in its earlier stages of 
development meaning that imaging techniques that can identify early developing 
microcalcification are likely to be of value.  
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Table 1.2. Current trials investigating the effects of novel therapies on progression of aortic stenosis.  
Trial name Trial Identifier Therapy Population Imaging End Points Primary Outcome 
Early Aortic Valve 
Lipoprotein(s) Lowering 
(EaVall) 
NCT02109614 Niacin vs Placebo 238 participants with 
aortic sclerosis or mild 
aortic stenosis 
CT calcium score 
Echo 
Change in CT calcium 
score at 2 years 
Study Investigating the Effect of 
Drugs Used to Treat 
Osteoporosis on the Progression 
(SALTIRE2) 
NCT02132026 Alendronate or 
Denosumab vs Placebo 
150 patients with AV 
Vmax >2.5 m/s and grade 
2-4 calcification on echo 
CT calcium score 
Echo 
18F-fluoride PET-CT 
Change in CT calcium 
score at 2 years 
PCSK9 Inhibitors in the 
Progression of Aortic Stenosis 
NCT03051360 PCSK9 inhibitor vs 
placebo 
140 patients with mild to 
moderate AS 
CT calcium score 
Echo 
18F-fluoride PET-CT 
Change in calcium score 
and 18F-NaF PET activity 
at 2 years 
Bicuspid Aortic Valve Stenosis 
and the Effect of Vitamin K2 on 
Calcium Metabolism on 18F-
NaF PET/MRI (BASIK2) 
NCT02917525 Vitamin K2 vs Placebo 44 patients with a 
bicuspid aortic valve and 
mild-moderate 
calcification on echo 
CT calcium score 
Echo 
18F-fluoride PET-MRI 
Change in 18F-NaF PET 
activity at 6 months 
Value of oral phytate in the 
prevention of progression of 
cardiovascular calcifications 
(CALCIFICA) 
NCT01000233 Phytine vs Placebo 250 patients with grade 2 
or 3 aortic valve 
calcification on echo 
CT calcium score CT calcium score at 2 
years 
Aortic Stenosis and 
Phosphodiesterase Type 5 
inhibition (ASPEN) 




Change in LV mass at 6 
months 
Change in diastolic 
function on Echo 
Change in LV longitudinal 
strain on echo 
A Study Evaluating the Effects 
of Ataciguat (HMR 1766) on 
Aortic Valve Calcification 
NCT02481258 Ataciguat (HMR1766) vs 
Placebo 
35 patients with AVA 
between 1-2 cm2 and 
calcium score greater 
than 300AU + EF>50%. 
CT calcium score 
Echo 
Change in CT calcium 
score at 6 and 12 months 
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1.4.7.1 Lipid-lowering strategies  
While statin therapy has failed to slow disease progression in three randomized trials 
(123-125), the question remains as to whether alternative lipid-lowering approaches 
could be successful, potentially at earlier stages of the disease. One promising 
therapeutic target is lipoprotein(a), a cholesterol-rich plasma lipoprotein containing an 
LDL particle with apolipoprotein B100 bound to apolipoprotein(a). (126) 
Lipoprotein(a) has been recognized as a powerful cardiovascular risk factor (126), and 
a recent genome-wide association study has implicated a single-nucleotide 
polymorphism in the Lp(a) locus to the development of the disease. (127)   
The growing evidence that Lp(a) plays a causal role in the development and also 
perhaps the progression of AS  (128, 129) has led to great enthusiasm in exploring this 
as a therapeutic target.  One potential therapeutic agent is Niacin, which has been 
shown to lower Lp(a) in a dose-dependent manner. Whether extended-release Niacin 
can reduce the progression of aortic valve disease is currently under investigation as 
part of the Early Aortic Valve Lipoprotein(s) Lowering (EaVall) study (NCT 
02109614). This pilot study will randomise over 200 patients with elevated Lp(a) and 
mild aortic valve disease to extended-release Niacin or placebo with a primary 
outcome of change in CT-AVC at two years. (129)   
1.4.7.2 Anti-calcific therapies 
Calcification is a key target for novel therapies in AS given its central role in driving 
progressive valvular obstruction. An important concern, however, is how best to 
reduce calcification activity in the valve while maintaining bone health in elderly 
patients with AS who are at risk of osteoporosis and fractures. One potential option is 
to use treatments licensed for osteoporosis, such as bisphosphonates or RANKL-
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inhibitors, which not only improve bone health but have demonstrated the ability to 
reduce vascular calcification. (130) In addition to reducing bone resorption and thereby 
reducing circulating calcium and phosphate, bisphosphonates have been shown to 
reduce local production of inflammatory cytokines, inhibit release of matrix 
metalloproteinases and stimulate macrophage apoptosis. (131, 132) Pre-clinical 
studies have demonstrated that bisphosphonate therapy reduces valvular calcification 
in animal models. (133, 134) The monoclonal antibody to RANKL, denosumab, acts 
by preventing the interaction between RANKL and RANK, a cytokine which plays an 
important role in up-regulating pro-osteogenic mediators and inducing osteoblastic 
transformation of valve interstitial cells (VICs). Whether these therapies reduce the 
progression of valvular calcification has yet to be determined and is currently being 
investigated in a randomized placebo-controlled trial (SALTIRE II NCT02132026). 
This blinded study is using change in CT calcium score at two years as the primary 
efficacy end point. However, measures of calcification activity by PET-CT will also 
be performed at baseline and one year, in addition to serial echocardiography every 
six months. (135)   
Another potential anti-calcific therapy under investigation is Vitamin K. Vitamin K is 
required for activation of Matrix Gla Protein (MGP), a potent inhibitor of vascular 
calcification synthesised by vascular smooth muscle cells. In the aortic valve, MGP 
acts by blocking the binding of BMP-2 to its receptor, thereby preventing BMP-
mediated differentiation of VICs to pro-osteogenic cells. MGP also inhibits growth of 
microcalcification crystals by binding directly to hydroxyapatite and stabilising 
circulating calcifying protein particles. (136) Reduced expression of MGP has been 
                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 36 
demonstrated in calcific aortic valves. (137) The BASIK2 randomized trial will 
investigate the effect of vitamin K2 in 44 patients with bicuspid aortic valve disease 
(NCT02917525). The primary outcome of the study is the change in 18F-fluoride PET 
signal on PET-MRI at six months. (136)  
1.4.7.3 Anti-fibrotic strategies 
Therapies targeting the remodelling response of the left ventricle have also gained 
interest. While the RIAS trial of ACE-inhibitor therapy showed a small positive effect 
on LV mass, a small and underpowered study did not demonstrate an effect of 
eplerenone on LV mass progression. (138) Further work in this field is required 
particularly to investigate the effects of novel therapies on myocardial fibrosis (139), 
with hope that more aggressive inhibition of the RAAS system and or novel anti-
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1.5 THESIS AIMS AND HYPOTHESES 
The overall aim of this thesis is to explore advanced imaging approaches to detect the 
burden, activity and progression of disease in coronary artery disease and aortic 
stenosis. This objective can be divided into four component parts. The first is to 
explore the role of advanced imaging technology with novel quantitative plaque 
measures on fractional flow reserve derived from computed tomography angiography 
to investigate the relationship between plaque burden, plaque characteristics and non-
invasive fractional flow reserve. The second is to investigate whether uptake of the 
radiotracer 18F-fluoride may predict progression of coronary calcification. The third 
objective is to investigate technical improvements to PET imaging of disease activity 
including a novel motion correction method to assess whether application of these may 
improve the utility of this novel imaging method in both coronary atherosclerosis and 
aortic valve disease. Lastly, this thesis aims to investigate the role of CT quantification 
of the burden of aortic valve calcification in the assessment of aortic stenosis and 
disease progression.   
The following hypotheses will be tested; 
i. Quantitative measures of atherosclerosis burden in coronary epicardial vessels 
with non-obstructive stenosis may predict abnormal CT-derived fractional 
flow reserve across the whole coronary vessel (Chapter 3). 
ii. Uptake of the radiotracer 18F-fluoride in coronary vessels may predict 
progression of coronary calcification in patients with clinically stable coronary 
artery disease (Chapter 4).  
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iii. Application of a novel motion-correction method to coronary PET-CT will 
improve quantification of 18F-fluoride uptake and disease activity (Chapter 5). 
iv. Measurement of aortic valve calcification burden by computed tomography is 
a reproducible technique and may provide value in the assessment of disease 
progression in aortic stenosis (Chapter 6).  
v. Application of a novel cardiac motion correction method to both PET-CT and 
PET-MRI of the aortic valve is feasible and will improve signal quantification 
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Chapter 2 Methodology 
2.1 SUMMARY 
Data for chapter 3 were produced from a prospective observational cohort of patients 
who underwent computed tomography coronary angiography at Cedars Sinai Medical 
Center, Los Angeles, USA. Data for chapter 4 were produced as a pre-specified sub-
study of the Dual antiplatelet therapy to Inhibit coronary Atherosclerosis and 
MyOcardial injury in patients with Necrotic high-risk coronary plaque Disease 
(DIAMOND) prospective randomised controlled trial (ClinicalTrials.gov identifier: 
NCT02110303).  Data for chapter 5 were derived from a prospective observational 
cohort of patients with acute coronary syndrome recruited from Cedars-Sinai Medical 
Center in Los Angeles, USA. Data for chapter 6 were derived from sub-studies of the 
Role of Active Valvular Calcification and Inflammation in patients with Aortic 
Stenosis (‘Ring of Fire’) study (ClinicalTrials.gov identifier: NCT01358513) and the 
ongoing Study Investigating the effect of Drugs Used to Treat Osteoporosis on the 
Progression of Calcific Aortic Stenosis (SALTIRE 2) randomised controlled trial 
(ClinicalTrials.gov identifier: NCT02132026) for which I was the Principal 
Investigator between October 2017-August 2019.  Data for chapter 7 were produced 
from the SALTIRE 2 study and a patient recruited as part of an ongoing research study 
at Cedars Sinai Medical Center in Los Angeles, USA. Specific study designs and 
methodology are described in detail in each relevant chapter.  
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2.2 PATIENT COHORTS 
2.2.1 FFRCT AND PLAQUE BURDEN POPULATION 
The study population for chapter 3 included patients who underwent Computed 
Tomography Coronary Angiography (CTCA) at Cedars Sinai Medical Center for 
clinical reasons and provided written informed consent at the time of scanning for data 
to be used for research purposes. Participants were recruited between February-
October 2016. Patients were included if there was evidence of at least 25% stenosis in 
one major epicardial vessel. Patients with prior coronary stent implantation, coronary 
artery bypass surgery or inadequate CTCA image quality were excluded. The Chief 
Investigator for this study was Dr Daniel Berman.  
2.2.2 DIAMOND TRIAL POPULATION 
The Dual antiplatelet therapy to Inhibit coronary Atherosclerosis and MyOcardial 
injury in patients with Necrotic high-risk coronary plaque Disease (DIAMOND) study 
(NCT02110303) was a double-blind randomised controlled trial of an investigational 
medicinal product (CTIMP) which aimed to investigate whether ticagrelor therapy 
reduces high-sensitivity troponin I in patients with established coronary disease and 
high-risk plaque. The primary results of this study have recently been reported. (143) 
The study population comprised patients aged ³40 years with clinically stable 
established multivessel coronary artery disease. Multivessel disease was defined as at 
least two major epicardial vessels with any combination of either (a) >50% luminal 
stenosis, or (b) previous revascularisation by percutaneous coronary intervention or 
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coronary artery bypass graft surgery. Patients were excluded if they had been 
diagnosed with an acute coronary syndrome within the preceding 12 months or had 
undergone revascularisation within the preceding 3 months. Full eligibility criteria are 
provided in Table 2.1. Participants were recruited from the Royal Infirmary of 
Edinburgh, UK and underwent combined Positron Emission Tomography and 
Computed Tomography Coronary Angiography (PET-CTCA) and non-contrast CT 
imaging at the Clinical Research Imaging Centre at the Royal Infirmary of Edinburgh. 
For the pre-specified sub-study, participants without follow-up imaging and those in 
whom interval revascularisation was performed in a new vessel were excluded, leaving 
183 participants included in the analysis of a total of 220 recruited. The Chief 
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Table 2.1. Inclusion and exclusion criteria for the DIAMOND study 
Inclusion Criteria 
For inclusion in the study subjects should fulfil the following criteria: 
1. Patients aged ≥40 years with angiographically proven multivessel coronary 
artery disease defined as at least two major epicardial vessels with any 
combination of either (a) >50% luminal stenosis, or (b) previous 
revascularization (percutaneous coronary intervention or coronary artery 
bypass graft surgery). 
2. Provision of informed consent prior to any study specific procedures 
3. Receiving aspirin 
Exclusion Criteria 
Subjects should not enter the study if any of the following exclusion criteria are 
fulfilled: 
1. An acute coronary syndrome within the last 12 months 
2. An indication for dual anti-platelet therapy, such as drug eluting stent 
3. Receiving thienopyridine therapy such as clopidogrel or prasugrel 
4. Percutaneous coronary intervention or coronary artery bypass graft surgery 
within the last 3 months 
5. Inability or unwilling to give informed consent 
6. Women who are pregnant, breastfeeding or of child-bearing potential 
(women who have experienced menarche, are pre-menopausal and have 
not been sterilised) will not be enrolled into the trial 
7. Known hypersensitivity to ticagrelor or one of its excipients 
8. Active pathological bleeding or bleeding diathesis 
9. Significant thrombocytopenia: platelets <100 x 109 /L 
10. History of intracranial haemorrhage 
11. Moderate to severe liver impairments (Child’s Grade B or C) 
12. Maintenance therapy with strong CYP3A4 inhibitors, such as 
ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or 
clarithromycin 
13. Major intercurrent illness of life expectancy <1 year 
14. Renal dysfunction (eGFR ≤30 mL/min/1.73m2) 
15. Contraindication to iodinated contrast agents 
16. Planned coronary revascularization or major non-cardiac surgery in the 
next 12 months 
17. Maintenance therapy with simvastatin or lovastatin at doses greater than 
40mg daily 
18. Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran 
or apixaban 
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2.2.3 CEDARS-SINAI ACS POPULATION  
This study population comprised patients who were recruited from Cedars Sinai 
Medical Center, Los Angeles, USA, following presentation with an acute coronary 
syndrome and with angiographic evidence of >50% luminal stenosis in one or more 
coronary arteries. Participants were recruited between December 2015 and June 2016. 
All participants underwent a comprehensive baseline clinical assessment followed by 
combined PET-CTA at the Mark Taper Cardiac Imaging Center, Cedars Sinai Medical 
Center. The Chief Investigator for this study was Dr Daniel Berman.  
2.2.4 SALTIRE 2 TRIAL POPULATION  
SALTIRE 2 is a prospective, double-blinded randomised controlled clinical trial 
investigating the effects of alendronic acid and denosumab on the progression of aortic 
stenosis. (NCT01358513). The study has recruited 150 individuals aged over the age 
of 50 years with aortic stenosis (defined as peak aortic jet velocity >2.5 m/s and grade 
2-4 calcification on echocardiography). Exclusion criteria included hypocalcaemia, 
known allergy or intolerance to alendronate of denosumab, life expectancy <2 years 
or planned aortic valve surgery in the next six months. Full eligibility criteria are 
shown in Table 2.2.  Participants from this population were included in the 
echocardiography cohort in chapter 6 and in the PET-CT cohort of chapter 7. Prior to 
commencement of the main study, a sub-study was performed to investigate 
reproducibility of 18F-Fluoride PET-CT imaging methodologies and, for this purpose, 
a subgroup of participants was invited to attend for two 18F-Fluoride PET-CTCA and 
CT calcium scans within 4 weeks. The calcium scoring data from this population are 
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analysed in chapter 6. The Chief Investigator for this study was Professor David 
Newby. 
Table 2.2. Inclusion and exclusion criteria for the SALTIRE2 study.  
Inclusion Criteria 
For inclusion in the study subjects should fulfil the following criteria: 
1. Age >50years 
2. Peak aortic jet velocity >2.5m/s on Doppler echocardiography 
3. Grade 2-4 calcification of the aortic valve on echocardiography 
Exclusion Criteria 
Subjects should not enter the study if any of the following exclusion criteria are 
fulfilled: 
1. Anticipated or planned aortic valve surgery in the next 6 months 
2. Life expectancy <2years 
3. Inability to undergo scanning 
4. Treatment for osteoporosis with bisphosphonates or denosumab 
5. Long-term corticosteroid use 
6. Abnormalities of the oesophagus or conditions which delay 
oesophageal/gastric emptying 
7. Inability to sit or stand for at least 30 minutes 
8. Known allergy or intolerance to alendronate or denosumab, or any of their 
excipients 
9. Hypocalcaemia 
10. Regular calcium supplementation 
11. Dental extraction within 6 months 
12. History of osteonecrosis of the jaw 
13. Major or untreated cancers 
14. Poor dental hygiene 
15. Women of childbearing potential who have experienced menarche, are pre-
menopausal, have not been sterilised or who are currently pregnant 
16. Women who are breastfeeding 
17. Renal failure (estimated glomerular filtration rate <30ml/min) 
18. Allergy or contraindication to iodinated contrast 
19. Inability or unwilling to give informed consent 
20. Likelihood of noncompliance to treatment allocation or study protocol 
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2.2.5 RING OF FIRE TRIAL POPULATION 
The Ring of Fire study was a prospective clinical study which recruited patients aged 
over 50 years with mild, moderate and severe aortic stenosis. Participants underwent 
echocardiography, 18F-Fluoride PET-CT and 18F-FDG PET-CT at baseline with 
follow-up echocardiography and/or non-contrast Computed Tomography performed 
at one and two years. The primary results of this study have already been reported. 
(60) For the purposes of this sub-study, the echocardiography and calcium scoring data 
from the PET-CT scans were analysed. The Chief Investigator for this study was 
Professor David Newby. 
2.2.6 AORTIC VALVE MOTION CORRECTION POPULATION 
This study population consisted of five patients recruited as part of the SALTIRE 2 
study as previously described and one patient recruited from Cedars Sinai Medical 
Center who underwent a single PET-MRI scan as part of an ongoing observational 
study investigating the role of hybrid imaging in cardiovascular disease. The Chief 
Investigator for this study was Dr Daniel Berman.  
2.3 ECHOCARDIOGRAPHY 
Echocardiography utilises ultrasound to gain detailed information about cardiac 
structure and function and is the gold standard clinical tool for the diagnosis and 
monitoring of aortic stenosis.  
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2.3.1 IMAGE ACQUISITION AND ANALYSIS 
Transthoracic echocardiography was performed by an experienced and accredited 
echocardiographer (Audrey White) using a pre-specified standardised protocol 
aligning with European Society of Echocardiography guidelines. (144) All scans were 
performed in the same room on a single dedicated echocardiography machine (Phillips 
Affinity 70 Ultrasound System) with participants in the supine and left lateral 
positions.  
Images were acquired in the parasternal long and short axis views, apical 4 and 5-
chamber views, subcostal and suprasternal views. Structural dimensions of the right 
and left ventricles, atria, left ventricular outflow tract and aortic root were measured. 
Left ventricular systolic function was estimated by visual assessment and confirmed 
using Simpson’s biplane measurement where possible. Left ventricular diastolic 
function was also assessed using mitral valve pulsed wave and tissue Doppler.  All 
valves were analysed by using visual assessment, colour flow, continuous wave and 
pulsed wave Doppler.  
The severity of aortic valve disease was graded according to the European Society of 
Echocardiography Guidelines. (98) Peak aortic jet velocity was obtained from multiple 
acoustic windows using continuous wave Doppler ensuring careful patient positioning 
and a pencil probe to assess the right parasternal window.  
Pulsed wave and continuous wave Doppler were used to measure peak transvalvular 
velocity and mean gradient using multiple acoustic windows and ensuring careful 
patient positioning. Continuous wave Doppler measurements were repeated at the 
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suprasternal notch, apex and right parasternal edge using a pencil probe.  An average 
of three measurements was obtained in participants in sinus rhythm, and an average of 
five measurements from patients in atrial fibrillation.  Aortic valve area was calculated 
using the continuity equation. The degree of aortic valve calcification was also 
assessed using a semi-quantitative scale previously described. (110) This scale 
comprised scores of 1-4; 1, no calcification; 2, mildly calcified with small isolated 
spots; 3, moderately calcified with multiple larger spots and 4, heavily calcified with 
extensive thickening of all cusps. (110) All research echocardiograms were performed 
by the same echocardiographer to minimise measurement variability, particularly with 
measurement of aortic valve area which has been shown to be high, with the exception 
of reproducibility assessments performed in chapter 6. (145) 
2.4  CTCA, FFRCT AND PLAQUE QUANTIFICATION 
Computed tomography coronary angiography (CTCA) provides detailed 3-
dimensional images of cardiac anatomy. The use of iodinated contrast increases the 
difference in CT attenuation between target tissues and surrounding structures, 
improving image enhancement. With modern scanning protocols, detailed anatomical 
and morphological information can be gained and the development of automated 
software for plaque quantification as well as techniques to combine this with non-
invasive fractional flow reserve provides the opportunity to gain detailed anatomical 
and functional information from a single scan.  
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2.4.1 IMAGE ACQUISITION 
Computed Tomography Coronary Angiography was performed on a dual source CT 
scanner (Somatom, Siemens Medical Solutions, Forchheim, Germany). Unless contra-
indicated, oral and/or intravenous beta blockade was administered to achieve a resting 
heart rate ≤70bpm prior to scanning. Sublingual nitroglycerin (0.4 or 0.8mg) was 
administered immediately prior to image acquisition. Where possible, images were 
acquired using prospective ECG-gating following the administration of intravenous 
contrast (Omnipaque or Visipaque, GE Healthcare, New Jersey). Images were 
acquired using retrospective ECG- gating with dose modulation if heart rate control 
was suboptimal. Scanning parameters included: tube voltage of 120 or 100 kVp (the 
latter used in patients with weight <200 pounds or BMI < 30 kg/m²), 0.6-mm slice 
thickness, 0.3-mm slice increment, 250-mm field-of-view, and 512 × 512 matrix.  
CTCA images were transferred to an external core laboratory for calculation of 
FFRCT, which was performed as previously described (Heartflow, Inc; Redwood City, 
USA). (146) Briefly, computational fluid dynamics is applied to an anatomic model of 
the coronary arteries and using a mathematical model of coronary physiology to 
generate a non-invasive measure of fractional flow reserve. (146) 
2.4.2 IMAGE ANALYSIS 
Coronary artery plaque quantification was performed using semi-automated software 
(Autoplaque, Cedars Sinai Medical Center, Los Angeles, USA) by four trained 
observers who were blinded to the CTCA and FFRCT results.   Proximal and distal 
limits of coronary arteries were manually defined, and coronary artery centrelines were 
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extracted using a semiautomated method. A circular region of interest was delimited 
in the proximal ascending aorta to define reference blood pool attenuation. The 
coronary vessel lumen, wall and plaque components including calcified plaque, non-
calcified plaque and low-attenuation plaque were automatically identified using scan-
specific thresholds. Manual adjustments were made by the operator as required.  
Plaque quantification using this technique has previously demonstrated excellent intra-
observer, inter-observer and scan-rescan reproducibility (Spearman’s Rho 0.87-0.99). 
(43, 44) 
2.5 CT CALCIUM SCORING 
Computed tomography (CT) uses X-rays to generate cross-sectional images of the 
body due to the differences in photon attenuation of different tissue classes. 
Attenuation coefficients can be transformed to Hounsfield Units (HU) which provides 
a quantitative scale to measure radiodensity.  Calcification can be quantified on CT by 
the widely used Agatston method. (31) This applies a density threshold of 130 HU and 
an area threshold of ³1mm2 to create a score by applying an arbitrary weighted density 
score for each range of Hounsfield Units as follows; 1 for 130-199 HU; 2 for 200-299 
HU; 3 for 300-399 HU and 4 for ³400 HU.  The Agatston score is then generated by 
multiplying the calcium density score by the area to provide a total score in Agatston 
Units (AU). (31)  
2.5.1  CORONARY CALCIUM SCORING 
Coronary calcification was quantified using dedicated analysis software (Vitrea 
Advanced, Vital Images, Minnetonka, USA). All analyses were performed in the 
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transverse plane. Calcium was quantified from the origin of the right coronary artery 
and left main stem to include each of the three main epicardial arteries (right coronary 
artery, left coronary artery and left circumflex artery) and their main branches. 
Coronary stents were excluded from analysis. Reproducibility of this technique has 
previously been described. (147, 148) 
2.5.2 AORTIC VALVE CALCIUM SCORING 
Aortic valve calcification was quantified using dedicated analysis software (Vitrea 
Advanced, Vital Images, Minnetonka, USA) in the transverse plane. Calcium was 
quantified from the base of the valve to the superior border of the valve before the 
ascending aorta. In cases in which confluent calcium extended into the ascending aorta, 
the origin of the left coronary artery was set as the most rostral slice beyond which 
further calcium was excluded. Efforts were made to exclude calcium from nearby 
structures such as the mitral valve annulus and coronary arteries.  (Figure 2.1) 
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Figure 2.1. Computed Tomography calcium scoring of the aortic valve. 
Computed Tomography calcium scoring performed on contiguous slices of the aortic 
valve in the transverse plane.  Examples from patients with mild (A) and severe (B) 
aortic stenosis are shown.  All calcium is highlighted in pink.  Contours are then drawn 
around calcium in the aortic valve which then turns yellow once selected.  An overall 
score in Agatston Units and a calcium volume are then generated. 
 
2.6  PET-CT  
Combined Positron Emission Tomography Computed Tomography (PET-CT) 
provides a unique insight into disease activity in cardiovascular disease. Following 
intravenous injection, radioactive ligands targeted against a specific disease process 
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accumulate and can provide a map of disease activity within the body which can be 
localised by anatomical information gained from computed tomography.  
2.6.1  IMAGE ACQUISITION AND RECONSTRUCTION 
The radiotracer 18F-fluoride was produced by the radiopharmaceutical department and 
Edinburgh Clinical Research Imaging Centre and underwent quality control checks 
prior to its use for scanning. Participants were administered a target dose of 250 MBq 
18F-fluoride (in those undergoing coronary PET-CT) or 125 MBq 18F-fluoride (in those 
undergoing PET-CT of the aortic valve) intravenously and rested in a lead-lined uptake 
room for sixty minutes. Dynamic imaging has demonstrated that sixty minutes 
circulating time provides peak radiotracer and target association and optimal contrast 
between plasma and vascular tissues. (62) Prior to the scan, participants were requested 
to empty their bladder in designated toilets. In the absence of any contraindications, 
patients were administered oral or intravenous beta-blockade to achieve a resting heart 
rate <65 bpm. For coronary imaging, participants were administered 400micrograms 
sublingual glyceryl trinitrate immediately prior to image acquisition unless 
contraindicated.  
All imaging was performed on a hybrid scanner (for participants in Edinburgh - 64-
multidetector Biograph mCT, Siemens Medical Systems, Erlangen, Germany and for 
participants in Los Angeles - GE Discovery 710) in a single bed position. An 
attenuation correction CT scan was performed prior to thirty minutes ECG-gated PET 
in list mode. This was immediately followed by ECG-gated non-contrast CT calcium 
scanning and contrast-enhanced CTCA at end expiration.  CTCA was acquired in the 
diastolic phase with prospective ECG gating where possible, but wider scanning 
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windows or retrospective gating were employed in cases where the resting heart rate 
remained suboptimal.  
PET data were reconstructed into four cardiac gates and the diastolic phase (gate 3, 
corresponding to 50-75% of the R-R interval) was used for primary analysis. For 
chapters 4 and 7, PET images were reconstructed using an Ordered Subsets 
Expectation Maximisation (OSEM) algorithm applying time of flight and point-spread 
function modelling (Siemens Ultra-HD) with the following parameters; 2 iterations, 
21 subsets, 256x256 matrix size and 5mm Gaussian smoothing). Corrections were 
applied for attenuation, dead time, scatter and random coincidences. For chapter 5, 
different methods of image reconstruction were employed, and these are described 
fully in the respective chapter.  
Cardiac motion correction was performed to compensate for coronary arterial motion 
during each phase of the cardiac cycle. Registration of all gates of PET data was 
performed using anatomical data from CTCA and aligning all PET gates with the end-
diastolic position. Coronary artery centrelines were first extracted using semi-
automated software (Autoplaque, Cedars Sinai Medical Centre) and the centreline co-
ordinates were transferred to the PET data to extract 3-dimensional volumes of interest 
defined by a 20mm radius around each centreline. A diffeomorphic mass-preserving 
image registration algorithm was applied to align all gates of PET data with the end-
diastolic phase, creating a new static image volume which utilised all PET counts. This 
technique has been shown to reduce image noise and improve discrimination of culprit 
coronary plaques. (149, 150) An overview of the motion-correction technique is shown 
in Figure 2.2. 




Figure 2.2. Overview of the motion correction method.  
(1) Coronary artery centrelines are extracted from CTCA in end-diastolic phase using 
CTCA analysis software. (2) Volumes of interest surrounding coronary arteries are 
extracted from 4- and 10-bin PET data using previously extracted CTCA centrelines. 
(3) All bins of data are registered to the common end-diastolic reference bin (bins 3 
and 7 for 4- and 10-bin data, respectively) by nonlinear level-set registration restricted 
to coronary regions. Then, registered VOIs are inserted back into their original PET 
volumes, and all registered PET images are summed into a single volume to obtain 
motion-corrected 4- and 10-bin data. MC = motion-corrected; VOI = volume of 
interest. (Rubeaux M et al, J Nucl Med 2016;57:54-59) (74) 
 
2.6.2 IMAGE ANALYSIS 
2.6.2.1 Coronary artery PET 
Careful co-registration of PET and CTCA was performed in three anatomical planes 
(transverse, sagittal and coronal) using anatomical structures on the contrast-enhanced 
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CT, including the ascending and descending aorta and myocardium to align the PET 
data with the cardiac chambers.  
Coronary artery plaques were deemed positive if there was focal radiotracer 
accumulation which co-localised to an atherosclerotic plaque on coronary CT 
angiography and followed the course of the coronary artery >5 mm in transverse, 
sagittal and orthogonal views. Where visual uptake was identified, semi-quantitative 
analysis was performed by drawing 2-dimensional regions of interest on the transverse 
images and quantifying the maximum standardised uptake value (SUVmax) for that 
lesion. In each participant, SUVmax was also quantified in a proximal coronary 
atherosclerotic plaque without visual evidence of radiotracer localisation as a 
reference. Background blood pool activity was quantified by measuring activity in the 
right atrium within 2-cm radius regions of interest on three consecutive slices.  Tissue-
to-background ratios (TBRs) were calculated by dividing plaque SUVmax values by 
mean average SUV values in the right atrium. Coronary plaques were considered PET-
positive in the presence of focal radiotracer uptake localised to a plaque with a tissue-
background ratio greater than 1.25, as described previously. (55) Image analysis was 
performed using an OsiriX workstation (OsiriX version 3.5.1 64-bit; OsiriX Imaging 
Software, Geneva, Switzerland) or FusionQuant software (Cedars Sinai Medical 
Center, Los Angeles, California). 
2.6.2.2 Aortic valve PET 
As described for coronary PET analysis, careful co-registration of PET and CTCA was 
performed in three anatomical planes (transverse, sagittal and coronal) using 
anatomical structures on the contrast-enhanced CT, including the ascending and 
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descending aorta and myocardium to align the PET data with the CT. The fused images 
were reoriented into the plane of the aortic valve to create an en-face image of the 
aortic valve. Three dimensional regions of interest were drawn around the aortic valve 
at the area of the most diseased segment by creating a three-dimensional polygon with 
a height of 6mm. A three-dimensional region of interest measuring 2mm3 was created 
in the right atrium at the level of the right coronary ostia to measure background blood 
pool activity. Tissue to background ratios (TBRs) were calculated by dividing the 
valve SUVmean by the SUVmean of the right atrium (TBRmean) and SUVmax of the 
aortic valve by the SUVmean of the right atrium (TBRmax). Image analysis was 
performed using FusionQuant software (Cedars Sinai Medical Center, Los Angeles, 
California).  
2.7 PET-MRI 
The combination of PET imaging with magnetic resonance (MR) imaging in hybrid 
PET-MR platforms provides some advantages over PET-CT. PET and MR data can 
be acquired simultaneously enabling accurate co-registration and with much lower 
radiation doses. Further, magnetic resonance imaging may provide detailed tissue 
characterisation and functional imaging.  
2.7.1 IMAGE ACQUISITION AND RECONSTRUCTION 
Combined PET-MR imaging was performed on a hybrid scanner (Biograph mMR 
scanner, Siemens, Erlangen, Germany). The participant was injected with 212 MBq 
18F-sodium fluoride and rested in a quiet environment. MR image acquisition began 
20 minutes later and included standard short axis cine views to evaluate left ventricular 
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function, contrast-enhanced MR angiography acquired in diastole and late gadolinium 
enhancement imaging for assessment of midwall fibrosis or myocardial scar. PET 
acquisition began sixty minutes following radiotracer injection and was acquired in 
list mode simultaneously with MR acquisition for sixty minutes. 
2.7.2 IMAGE ANALYSIS 
Image analysis of PET-MR was performed as described for PET-CT.  
2.8  ETHICAL CONSIDERATIONS  
All studies were approved by the local review board. For research conducted at Cedars 
Sinai Medical Center, the studies were approved by the Institutional Review Board 
(IRB). For studies conducted in Edinburgh, research was approved by the Research 
and Development Department within the University of Edinburgh and the South-East 
Scotland Ethics Committee. The SALTIRE 2 study and the DIAMOND study were 
each a Clinical Trial of an Investigational Medicinal Product (CTIMP) and were 
therefore approved by the Medicines and Healthcare products Regulatory Agency 
(MHRA). Studies performed in Edinburgh were also approved by the United Kingdom 
Administration of Radiation Substances Advisory Committee. 
All study participants provided written informed consent prior to taking part in any 
study procedures.  
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2.9  STATISTICAL ANALYSIS 
Details of specific statistical methods are described fully in each individual results 
chapter.  Statistical analyses were performed using SPSS statistics (IBM, versions 22 
and 23), Stata software version 13 (StataCorp, College Station, TX, USA) and R 
version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). Continuous 
variables were assessed for normality using Shapiro Wilks test and expressed as mean 
± standard deviation or median [interquartile range] as appropriate. Correlations 
between continuous variables were assessed with Pearson’s R or Spearman’s Rho 
subject to normality of the relevant variables.  Statistical significance was considered 
as a two-tailed p<0.05. 
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Chapter 3 Non-invasive Fractional Flow Reserve 




Non-invasive fractional flow reserve derived from coronary CT angiography (FFRCT) 
has been shown to be predictive of lesion-specific ischaemia as assessed by invasive 
fractional flow reserve (FFR). However, in practice, clinicians are often faced with an 
abnormal distal FFRCT in the absence of a discrete obstructive lesion. Using 
quantitative plaque analysis, we sought to determine the relationship between an 
abnormal whole vessel FFRCT (V-FFRCT) and quantitative measures of whole vessel 
atherosclerosis in coronary arteries without obstructive stenosis.  
Methods 
FFRCT was measured in 155 consecutive patients undergoing coronary CTA with 
≥25% but less than 70% stenosis in at least one major epicardial vessel. Semi-
automated software was used to quantify plaque volumes (total plaque [TP], calcified 
plaque [CP], non-calcified plaque [NCP], low-density non-calcified plaque [LD-
NCP]), remodelling index [RI], maximal contrast density difference [CDD] and 
percent diameter stenosis [%DS]. Abnormal V-FFRCT was defined as a minimum 
value of ≤0.75 across the vessel. 
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Results  
Vessels with abnormal V-FFRCT had higher per-vessel TP (554 vs 331 mm3), CP (59 
vs 25 mm3), NCP (429 vs 295 mm3), LD-NCP (65 vs 35 mm3) volume and maximum 
CDD (21 vs 14%) than those with normal V-FFRCT (median, p<0.05 for all). Using a 
multivariate analysis to adjust for CDD and %DS, all measures of plaque volume were 
predictive of abnormal V-FFRCT (OR 2.09, 1.36, 1.95, 1.95 for TP, CP, NCP and LD-
NCP volume, respectively; p<0.05 for all).  
Conclusions 
Abnormal V-FFRCT in vessels without obstructive stenosis is associated with multiple 
markers of diffuse non-obstructive atherosclerosis, independent of stenosis severity.  
Whole vessel FFRCT may represent a novel measure of diffuse coronary plaque 
burden.  
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3.2 INTRODUCTION 
The emergence of non-invasive FFR, derived from coronary computed tomography 
angiography (FFRCT), has been an important advance in combining detailed 
information regarding anatomy and physiology using coronary CT angiography (CTA) 
in a single standard examination, with no need for repeat contrast injection, additional 
radiation, or pharmacologic stress.  
FFRCT has been demonstrated to predict invasive FFR (46-48) and improve diagnostic 
specificity in the detection of hemodynamically significant coronary lesions compared 
to coronary computed tomography angiography (CTA) alone. (46) 
Quantitative plaque analysis from coronary CTA can allow the measurement of plaque 
volume and composition in specific lesions and whole vessels, providing detailed 
information about plaque burden and adverse plaque characteristics. Such methods 
have been used to investigate the impact of adverse plaque characteristics on FFRCT 
and myocardial ischaemia, demonstrating that the presence of large plaque volume and 
adverse plaque characteristics, such as positive remodelling and a lipid core, can allow 
the identification of ischaemia-inducing lesions, independent of the degree of stenosis. 
(151-153) In clinical practice, we have observed that FFRCT often becomes abnormal 
in only the distal portion of vessels. The significance of this finding and its relationship 
to diffuse epicardial disease is unknown. We hypothesized that whole vessel FFRCT 
(V-FFRCT) may reflect whole vessel plaque burden in vessels without severe stenosis.  
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3.3 METHODS 
3.3.1 STUDY POPULATION  
One hundred and fifty-five patients who underwent clinically indicated coronary CTA 
at Cedars Sinai Medical Centre between February and October 2016 with at least 25% 
stenosis in one major epicardial vessel were included. FFRCT was calculated as 
previously described (Heartflow, Inc; Redwood City, CA, USA). (146) Patients with 
prior coronary stent implantation, coronary artery bypass surgery or inadequate CTA 
image quality for FFRCT processing were excluded from the analysis. The study 
protocol was approved by the Cedars-Sinai Institutional Review Board and all patients 
provided written informed consent.  
3.3.2 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY 
ACQUISITION 
Coronary CTA was performed on a dual-source CT scanner (Somatom, Siemens 
Medical Solutions, Forchheim, Germany). When necessary, oral and/or intravenous 
metoprolol was administered to achieve a target heart rate of ≤70 beats/min (bpm). 
(154) Immediately prior to scanning, 0.4 or 0.8 mg of sublingual nitroglycerin 
(ScielePharma, Alpharetta, Georgia) was administered. Images were acquired with 
prospective ECG-gating following the administration of 85ml intravenous contrast 
(Omnipaque or Visipaque, GE Healthcare, Princeton, New Jersey). In the event of 
suboptimal heart rate control, images were acquired using helical scanning with dose 
modulation. Scanning parameters included: tube voltage of 120 or 100 kVp (the latter 
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used in patients with weight <200 pounds or BMI < 30 kg/m²), 0.6-mm slice thickness, 
0.3-mm slice increment, 250-mm field-of-view, and 512 × 512 matrix.  
3.3.3 QUANTITATIVE CORONARY PLAQUE ANALYSIS  
Coronary segments ≥2 mm with visible plaque were analysed along the entire length 
of the coronary arteries using semi-automated software (AutoPlaque version 9.7, 
Cedars-Sinai Medical Center, Los Angeles, CA, USA). Four experienced readers 
(Y.O, M.D, Y.A and B.K.T) who were blinded to the coronary CTA findings and 
FFRCT values analysed 365 vessels with visible coronary plaque using multiplanar 
coronary CTA images. Percent diameter stenosis (%DS) was calculated by dividing 
the narrowest lumen diameter by the mean of two non-diseased reference points. Scan-
specific thresholds for non-calcified plaque (NCP) and calcified plaque (CP) were 
automatically generated. Low-density non-CP (LD-NCP) was defined as plaque with 
attenuation <30 Hounsfield units. Plaque components were quantified within the 
manually designated areas using adaptive algorithms. (45) Remodelling index was 
determined as the ratio of maximum vessel area to that at the proximal normal 
reference point. (155) Plaque length (in mm) was the length of the diseased vessel as 
computed in AutoPlaque. Contrast density difference across the lesion was computed 
as follows: the luminal contrast density, defined as attenuation per unit area, similar to 
area gradient, (156) was computed over 1-mm cross sections of the arterial segment. 
The contrast density difference was defined as the maximum percent difference in 
contrast density compared to a proximal reference cross section without 
atherosclerotic disease. Manual adjustments of vessel contours were made if 
necessary. For each artery, whole vessel plaque volume measurements were obtained 
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by the sum of plaque volumes in each segment of the three major epicardial coronary 
vessels (left anterior descending, left circumflex and right coronary arteries). 
Plaque analysis was performed on a per-vessel basis after excluding vessels with 
severe obstructive stenosis (%DS ≥70), as the V-FFRCT values would be expected to 
be dominated by the presence of obstructive stenosis in these patients. The time 
required for whole vessel quantitative plaque analysis was approximately 10 minutes 
per vessel.  
3.3.4 COMPUTATION OF FRACTIONAL FLOW RESERVE DERIVED FROM 
CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY 
Computation of FFRCT was performed centrally by independent blinded analysts 
(software version 1.4). The FFRCT computation process has previously been 
described in detail.  (46, 146) Briefly, non-invasive fractional flow reserve (FFRCT) 
applies computational fluid dynamics to calculate the drop in coronary pressure across 
a stenosis as a ratio to pressure in a non-diseased artery, thereby acting as a surrogate 
measure of ischaemia.  
In each subject, FFRCT measurements were computed throughout the coronary tree. 
The distal minimum values for each entire coronary vessel (V-FFRCT) were included 
in the analysis. A whole vessel FFRCT ≤0.75 was considered abnormal. If the FFRCT 
could not be calculated due to small vessel calibre or poor image quality, the vessel 
was excluded from analysis. A case example illustrating quantitative plaque analysis 
and V-FFRCT measurements is shown in Figure 3.1. 
 




Figure 3.1 A case example of a 52 year old asymptomatic male with risk factors for coronary 
artery disease. 
CTCA demonstrates diffuse plaque in the proximal to distal portions of the left anterior 
descending coronary artery (LAD) (A). FFRCT was computed in the LAD and the 
results demonstrate an FFRCT value of 0.80 across the region of maximal stenosis and 
a distal V-FFRCT value (whole vessel FFRCT) of 0.73 (B). Quantitative plaque 
analysis was performed using AutoPlaque (C & D: proximal to mid LAD and E & F: 
mid to distal LAD) and demonstrated total non-calcified plaque (760 mm3, red), total 
calcified plaque (67mm3, yellow), total low-density non-calcified plaque (48 mm3), 
maximum remodelling index 1.6, maximum contrast density difference 30% and 
maximum diameter stenosis 47%. 
 
                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 68 
3.3.5 STATISTICAL ANALYSIS 
Continuous variables were presented as mean +/- standard deviation (SD) or median 
(interquartile range) as appropriate, after being assessed for normality using the 
Shapiro-Wilks test.  Categorical variables were expressed as numbers and percentages. 
Quantitative plaque parameters across >2 groups were compared using the Kruskal-
Wallis test; categorical variables were compared across groups using Pearson Chi-
square test or Fisher Exact test for cell counts < 6. The relationship between plaque 
volume (TP, CP, NCP and LD-NCP) and abnormal V-FFRCT was evaluated after 
adjusting for contrast density difference, and diameter stenosis, using logistic 
regression analysis. To account for collinearity in measurements of plaque volume, 
different multivariate models were used to assess the relationship between V-FFRCT 
and TP, CP, NCP and LD-NCP. Four different multivariable analyses were performed 
using logistic regression adjusted for CDD and diameter stenosis to investigate the 
association between abnormal V-FFRCT and TP, CP, NCP and LD-NCP volumes, 
respectively. Because up to three coronary arteries were examined per patient, 
intraclass coefficients were calculated to assess the within-patient correlations, as 
previously described. (157) For logistic regression analyses, the standard errors were 
then adjusted using the clustered sandwich estimator to take into account the within-
group correlations of up to 3 coronary arteries per patient. (158) Statistical analyses 
were performed with Stata software version 13 (StataCorp, College Station, TX, USA) 
and SPSS version 22 (IBM Corp, USA). Two-sided P-values <0.05 were considered 
statistically significant. 
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3.4 RESULTS 
3.4.1 PATIENT CHARACTERISTICS AND VESSELS ANALYSED  
Baseline characteristics of the study population are shown in Table 3.1. From a total 
of 465 vessels in 155 patients, 168 vessels were excluded from the analysis. This 
included 100 vessels with no visible plaque, 54 vessels with quantitative diameter 
stenosis >70%, and 25 vessels in which FFRCT could not be processed due to small 
vessel calibre. Of the remaining 297 vessels included in the analysis, 122 (41%) 
comprised the left anterior descending coronary artery, 80 (27%) the left circumflex 
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Table 3.1. Baseline characteristics. 
Baseline Characteristics 
Number of patients 155 
Age, years (mean ± SD) 66±10 
Male, n (%) 113 (73) 
Body mass index, kg/m2 (mean ± SD) 27±5 
Risk factors and history of coronary artery disease  
Diabetes, n (%) 27 (17) 
Hypertension, n (%) 81 (52) 
Hyperlipidaemia, n (%) 110 (71) 
Current smoker, n (%) 11 (7) 
Previous myocardial infarction, n (%) 2 (1) 
Symptoms 
Typical angina, n (%) 8 (5) 
Atypical angina, n (%) 12 (8) 
Nonanginal chest pain, n (%) 45 (29) 
Shortness of breath, n (%) 72 (46) 
Asymptomatic, n (%) 55 (35) 
SD= standard deviation 
3.4.2 RELATIONSHIP BETWEEN QUANTITATIVE DIAMETER STENOSIS 
AND V-FFRCT  
There were 32 vessels with abnormal V-FFRCT and 265 vessels with normal V-
FFRCT. The quantitative diameter stenosis was significantly higher in vessels with 
abnormal V-FFRCT than in vessels with normal V-FFRCT (diameter stenosis 
[median, IQR]: 40%, 26-47% in abnormal V-FFRCT vs. 26%, 14-37% in normal V-
FFRCT, p=0.003, Figure 3.2). There was no difference in the frequency of vessels with 
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50-69% stenosis between the groups with normal and abnormal V-FFRCT (16% in 
abnormal V-FFRCT vs. 12% in normal V-FFRCT, p=0.61).  
3.4.3 RELATIONSHIP BETWEEN PLAQUE CHARACTERISTICS AND V-
FFRCT 
Total plaque volume, CP volume, NCP volume, and LD-NCP volume were higher in 
vessels with abnormal V-FFRCT than in vessels with normal V-FFRCT (p<0.005 for 
all). Moreover, vessels with abnormal V-FFRCT had higher maximal CDD and plaque 
length compared to vessels with normal V-FFRCT (p<0.005 for both, Figure 3.2).  
There was no significant difference in remodelling index between vessels with normal 
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Figure 3.2. Differences in coronary plaque volume (A), contrast density difference, diameter 
stenosis and plaque length (B) and remodelling index (C) between vessels with normal and 
abnormal V-FFRCT.  
Distributions of plaque volume and plaque subcomponents boxes indicate quartiles, 
and whiskers display adjacent values. V-FFRCT: whole vessel FFRCT, NCP: non-
calcified plaque, LD-NCP: low-density non-calcified plaque, CP: calcified plaque, TP: 
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3.4.4 PLAQUE CHARACTERISTICS TO PREDICT ABNORMAL V-FFRCT  
In univariate analysis to predict abnormal V-FFRCT, all measures of plaque volume 
(TP, CP, NCP, and LD-NCP), CDD, plaque length and diameter stenosis were 
independent predictors of an impaired V-FFRCT (Table 3.2). In multivariate analysis 
adjusting for CDD and diameter stenosis, the results demonstrated a significant 
association between abnormal V-FFRCT and log-transformed TP, CP, NCP and LD-
NCP volumes (Odds ratio of TP volume: 2.09, 95% CI: 1.09 to 4.01, p=0.03, odds 
ratio for CP volume: 1.36, 95% CI: 1.01 to 1.84, p=0.04, odds ratio of NCP volume: 
1.95, 95% CI: 1.02 to 3.75, p=0.04, odds ratio of LD-NCP volume: 1.95, 95%CI: 1.06 
to 3.57, p=0.03, Table 3.3 Model 1-4). CDD was a significant predictor of an abnormal 
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Table 3.2 Univariate logistic regression analysis of quantitative plaque features for 
ischaemia based on impaired whole vessel FFRCT. 
 Odds ratio (95% CI) P value 
TP volume 2.03 (1.32-3.10) 0.001 
CP volume 1.36 (1.11-1.67) 0.004 
NCP volume 1.93 (1.26-2.94) 0.002 
LD-NCP volume 2.00 (1.35-2.96) 0.001 
Contrast density difference 3.35 (1.76-6.35) <0.001 
Diameter stenosis 1.03 (1.01-1.05) 0.006 
Remodelling index 7.16 (0.99-51.50) 0.05 
Plaque length 2.31 (1.40-3.79) 0.001 
TP=total plaque, CP=calcified plaque, NCP=non-calcified plaque, LD-NCP= low-density-
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Table 3.3. Multivariate logistic regression analysis of quantitative plaque features for 
ischaemia based on impaired whole vessel FFRCT (297 vessels with stenosis <70% and 259 
vessels with <50% stenosis). 
 
 Maximum Diameter Stenosis 
<70% (n=297) 

















0.002 4.44  
(1.46-13.44) 
0.008 
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Diameter Stenosis … 0.29 1.72 (0.77-3.82) 0.18 
Model 4 
Low Density Non-
Calcified Plaque Volume 
1.95  
(1.06-3.57) 









Diameter Stenosis … 0.33 … 0.21 
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3.4.5 ASSOCIATION BETWEEN PLAQUE CHARACTERISTICS AND 
ABNORMAL V-FFRCT IN VESSELS WITH <50% STENOSIS  
In vessels with a maximum diameter stenosis <50% (n=259), there were 27 vessels 
with abnormal V-FFRCT and 232 vessels with normal V-FFRCT. Multivariate 
analysis was performed using four models, as described above, to investigate the 
association between plaque volumes (TP, CP, NCP and LD-NCP) and abnormal V-
FFRCT adjusting for CDD and diameter stenosis.  
In vessels with a maximum diameter stenosis of less than 50%, the results also 
demonstrated a significant association between abnormal V-FFRCT and log-
transformed TP, CP, NCP and LD-NCP volumes (Odds ratio for TP volume: 2.89, 
95% CI:  1.26 to 6.63, p=0.01, odds ratio for CP volume: 1.67, 95% CI: 1.14 to 2.46, 
p=0.009, odds ratio of NCP volume: 2.40, 95% CI: 1.06 to 5.45, p=0.04, and odds ratio 
of LD-NCP volume: 2.72, 95%CI: 1.33 to 5.58, p=0.006, Table 3.3 Model 1-4). CDD 
remained a significant predictor for an abnormal V-FFRCT in all four multivariate 
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3.5 DISCUSSION 
Lesion-specific measures of non-invasive fractional flow reserve have been 
demonstrated to correlate well with invasive FFR and predict lesion-specific ischemia. 
In practice, however, an FFRCT value which drops only distally or exhibits a gradual 
decline across the length of a vessel is often observed, the relevance of which is 
unclear. Using semi-automated quantitative plaque analysis, we have shown that 
plaque volume and characteristics quantified on a per-vessel basis predict an abnormal 
FFRCT, suggesting that an abnormal V-FFRCT may reflect diffuse epicardial 
atherosclerosis.   
A previous study has investigated the influence of diffuse non-obstructive 
atherosclerosis on distal FFR measured invasively and demonstrated that vessels with 
diffuse but angiographically insignificant disease exhibit a gradual and progressive 
decline in FFR across the length of the vessel.  (159) This continuous drop in pressure 
on FFR was observed in half of the vessels with luminal irregularities but no visual 
stenosis on invasive angiography, while there was no distal decline in FFR in vessels 
without evidence of disease. Our results add further support to the finding that an 
impaired whole vessel fractional flow reserve may reflect diffuse atherosclerosis. 
Further, we have expanded these findings by evaluating plaque characteristics on CT 
and performing detailed plaque quantification. In our results, non-calcified plaque 
volume and low-density non-calcified plaque volume, a CT-identified surrogate 
measure of lipid core, were independent predictors of an impaired distal FFRCT. 
Indeed, both non-calcified plaque volume and low-density non-calcified plaque 
volume were stronger predictors of abnormal V-FFRCT than calcified plaque volume. 
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This relationship persisted even when all vessels with greater than 50% stenosis were 
excluded from analysis.  
Recent studies have highlighted that lesion-specific plaque characteristics can 
influence fractional flow reserve, and lipid density has consistently been identified as 
a strong predictor of flow in lesion-specific analyses. (152, 160, 161) This relationship 
was extended to entire vessels in our study as demonstrated in our results which 
revealed lipid density to be an independent predictor of an abnormal whole vessel 
FFRCT in vessels without obstructive stenosis. This suggests that distal FFRCT may 
be reflective of the presence of, not only diffuse disease, but also adverse plaque 
features.  
Previous studies have utilized intravascular ultrasound (IVUS) imaging to demonstrate 
that, in the early stages of atherosclerosis, endothelial dysfunction leads to abnormal 
endothelial reactivity and, even in minimal atherosclerosis, the presence of local 
endothelial dysfunction is closely associated with high-risk plaque characteristics 
including the presence of a lipid core. (162) The pathophysiological explanation for 
this finding is considered to be a consequence of the pro-inflammatory and oxidative 
effect exerted by the necrotic core which results in reduced nitric oxide bioavailability 
and an increase in local vasoconstriction by mediators such as isoprostane.  (163, 164) 
It may therefore be hypothesized that an abnormal V-FFRCT relates to impaired 
vascular reactivity across the length of the vessel, although further studies are required 
to confirm this.  
Our findings regarding the relationship between quantitative whole vessel plaque 
characteristics and whole vessel FFRCT are similar to relationships observed with 
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segmental plaque characteristics and lesion specific FFRCT. In patients with 
intermediate grade stenosis, we have previously shown that plaque burden on a per-
patient basis is predictive of an abnormal invasive FFR. (152) In a study of 56 patients 
undergoing invasive coronary angiography and invasive FFR, total plaque burden was 
a significant predictor of impaired invasive FFR (Odds Ratio [OR] 1.15, P=0.007). 
(152) Further, in a study examining the relationship between plaque features and FFR, 
percent aggregate plaque volume (defined as the aggregate plaque volume divided by 
the total vessel volume) provided incremental prediction of ischaemia by invasive FFR 
when added to adverse plaque characteristics and CTA-measured stenosis. (161) 
Another recent study examined the effects of diffuse atherosclerosis and, specifically, 
lesion length in all grades of stenosis and demonstrated that diffuse disease, as 
measured by lesion length, was an independent predictor of invasive FFR. (165) Our 
report, however, is the first to our knowledge to assess the impact of quantitative 
plaque volume, burden and composition in vessels with <70% stenosis on whole vessel 
FFRCT and suggests that distal whole vessel FFRCT is reflective of whole vessel 
plaque burden.  
We excluded severe stenosis in our analysis because we expected an individual 
stenosis to impact on the distal FFRCT value. Nonetheless, even with this exclusion, 
the maximum contrast density difference was predictive of abnormal V-FFRCT. Of 
importance, this relationship was observed even when vessels with 50-69% stenosis 
were excluded.  This highlights that the abnormal distal V-FFRCT values were not 
observed only as a direct consequence of a single proximal obstructive lesion.  
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Further, we adopted a threshold of less than or equal to 0.75 as indicative of an 
abnormal V-FFRCT. While this is lower than invasive FFR and FFRCT thresholds 
used in prior lesion-specific studies (160, 166), we wished to employ a value which 
would more reliably discriminate an abnormal distal pressure reserve. (167) 
3.5.1 LIMITATIONS 
While we have identified that diffuse non-obstructive disease and the presence of high- 
risk plaque characteristics predict an abnormal distal FFRCT, the relationship between 
abnormal V-FFRCT and tissue ischemia has not yet been documented. Future studies 
should consider the relationship between abnormal V-FFRCT and non-invasive 
measures of coronary flow or ischaemia, such as coronary flow reserve. Coronary flow 
reserve (CFR), measured by PET perfusion imaging, provides an integrated analysis 
of myocardial perfusion and the haemodynamic effects of both epicardial 
atherosclerosis and microvascular dysfunction in combination and could provide 
insight in this regard, particularly as a means of further understanding the relationship 
between microvascular dysfunction and non-obstructive coronary atherosclerosis in 
patients manifesting evidence of myocardial ischaemia without significant epicardial 
coronary stenosis. 
3.6 CONCLUSION 
Abnormal V-FFRCT in vessels without obstructive stenosis is associated with multiple 
markers of diffuse non-obstructive atherosclerosis, independent of stenosis severity.  
Whole vessel FFRCT may represent a novel measure of diffuse coronary plaque 
burden. 
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Chapter 4 Coronary 18F-Fluoride Uptake and 




Positron emission tomography (PET) using 18F-sodium fluoride (18F-fluoride) to detect 
microcalcification may provide insight into disease activity in coronary 
atherosclerosis.  This study aimed to investigate the relationship between 18F-fluoride 
uptake and progression of coronary calcification in patients with clinically stable 
coronary artery disease. 
Methods 
Patients with established multivessel coronary atherosclerosis underwent 18F-fluoride 
PET-computed tomography (CT) angiography and CT calcium scoring, with repeat 
CT angiography and calcium scoring at one year. Coronary PET uptake was analysed 
qualitatively and semi-quantitatively in diseased vessels by measuring maximum 
tissue-to-background ratio (TBRmax). Coronary calcification was quantified by 
measuring calcium score, mass and volume.  
Results 
In a total of 183 participants (median age 66 years, 80% male), 116 (63%) patients had 
increased 18F-fluoride uptake in at least one vessel. Individuals with increased 18F-
fluoride uptake demonstrated more rapid progression of calcification compared to 
those without uptake (change in calcium score, 97 [39-166] versus 35 [7-93] AU; 
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p<0.0001). Indeed, the calcium score only increased in coronary segments with 
increased 18F-fluoride uptake (from 95 [30-209] AU to 148 [61-289] AU; p<0.001) 
and remained unchanged in segments without 18F-fluoride uptake (from 46 [16-113] 
to 49 [20-115] AU; p=0.329). Baseline coronary 18F-fluoride TBRmax correlated with 
one-year change in calcium score, calcium volume and calcium mass (Spearman’s r 
= 0.37, 0.38 and 0.46 respectively; p<0.0001 for all).   At the segmental level, baseline 
18F-fluoride activity was an independent predictor of calcium score at 12 months 
(p<0.001). However, at the patient level, this was not independent of age, sex and 
baseline calcium score (p=0.50). 
Conclusions 
Coronary 18F-fluoride uptake identifies both patients and individual coronary segments 
with more rapid progression of coronary calcification, providing important insights 
into disease activity within the coronary circulation.  At the individual patient level, 
total calcium score remains an important marker of disease burden and progression. 
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4.2 INTRODUCTION 
Atherosclerotic calcification is a complex pathophysiological process central to the 
development of advanced coronary artery plaques. Macroscopic coronary artery 
calcification can be quantified using computed tomography, serving as an important 
surrogate measure of atherosclerotic plaque burden and providing powerful prognostic 
information beyond traditional risk factors. (41, 168, 169) Furthermore, progression 
of coronary macrocalcification is associated with an increased risk of adverse 
cardiovascular events and all-cause mortality. (14, 32, 170) 
The positron-emitting radiotracer 18F-sodium fluoride (18F-fluoride), commonly used 
to detect pathological metabolic activity in the skeletal system (66, 171), can provide 
important insights into calcification activity within the cardiovascular system. 18F-
Fluoride binds to hydroxyapatite in  proportion to the surface area of exposed crystal, 
such that it binds preferentially to areas of newly developing microcalcification where 
the surface area is many fold higher than large macroscopic deposits. (62) 
Microcalcification is a key healing response in atherosclerotic plaque (62), closely 
associated with necrotic inflammation and high-risk disease, but ultimately leading to 
downstream coronary macrocalcification and plaque stabilisation. 18F-Fluoride PET-
CT therefore has the potential to act as a marker of disease activity in the coronary 
vasculature by targeting a biologically important stage of the disease. (17) Indeed, ex 
vivo studies have confirmed the exquisite sensitivity of 18F-fluoride for early 
microcalcific deposits and its association with high-risk plaque features including 
macrophage infiltration and necrosis in atherosclerosis. (55, 172, 173) 
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Based on these principles, we hypothesised that coronary 18F-fluoride PET-CT should 
predict the future progression of coronary macrocalcification detected on CT. We 
therefore prospectively investigated the relationship between in vivo coronary 18F-
fluoride uptake and the progression of coronary arterial calcification in patients with 
clinically stable coronary artery disease.   
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4.3 METHODS 
4.3.1 STUDY DESIGN 
This study is a pre-specified analysis of an investigator-initiated double-blind 
randomized controlled trial conducted at a single centre in Edinburgh, UK. (55) The 
study was approved by the local institutional review board, the Scottish Research 
Ethics Committee (REC reference: 14/SS/0089), Medicines and Healthcare products 
Regulatory Agency, and the United Kingdom (UK) Administration of Radiation 
Substances Advisory Committee. The study was performed in accordance with the 
Declaration of Helsinki and all patients provided written informed consent prior to any 
study procedures. 
4.3.2 STUDY POPULATION 
Patients with clinically stable multivessel coronary artery disease were recruited 
prospectively from the Edinburgh Heart Centre, UK, between March 2015 and March 
2017. Patients were included if aged over forty years and with evidence of 
angiographically proven multivessel coronary artery disease, defined as at least two 
major epicardial vessels with any combination of either (a) >50% luminal stenosis, or 
(b) previous revascularization (percutaneous coronary intervention or coronary artery 
bypass graft surgery). Patients were excluded in the event of coronary 
revascularisation within the preceding 3 months or acute coronary syndrome within 
the previous 12 months. Patients were randomized (1:1) to receive ticagrelor or 
placebo in addition to aspirin therapy and the primary goal of the original study was 
to determine whether ticagrelor therapy, in addition to aspirin, reduces high-sensitivity 
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troponin I concentration in participants with high-risk coronary plaque. The primary 
study results have been previously reported.  (143) 
4.3.3 STUDY PROCEDURES 
All participants underwent a baseline clinical assessment and combined 18F-fluoride 
PET-CT scanning with the acquisition of a contrast-enhanced CT coronary angiogram 
and non-contrast CT for calcium scoring. Prior to scanning, participants with a resting 
heart rate >65 beats/min were administered oral beta-blockade (50-100 mg 
metoprolol) unless contraindicated. All participants were administered a target dose of 
250 MBq intravenous 18F-fluoride and rested in a quiet environment. Sixty minutes 
following injection, PET acquisition was performed on a hybrid PET-CT scanner (64-
multidetector Biograph mCT, Siemens Medical Systems, Erlangen, Germany). 
Attenuation correction CT scans were performed prior to the acquisition of ECG-gated 
list-mode PET data using a single 30-min bed position centred on the heart. Finally, 
an ECG-gated coronary CT angiogram was performed in mid-diastole during held 
expiration following sublingual glyceryl trinitrate. Repeat coronary CT angiography 
and calcium scoring was performed using the same imaging protocol and on the same 
scanner at one year.  
4.3.4 IMAGE ANALYSIS 
Calcium scoring 
Non-contrast CT images for calcium scoring were reconstructed in the transverse plane 
with 3-mm slice width and 1.5-mm increment. Coronary calcium was quantified on 
both a per-participant and per-segment level by an experienced observer using 
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dedicated software (Vitrea Advanced, Toshiba Systems). Calcification was quantified 
as calcium score (AU), calcium volume (mm3) and calcium mass (mg). Calcium score 
was derived using the Agatston method. (31) To calculate calcium mass, a calibration 
factor was derived using a phantom to calculate equivalent water diameter, adjusted 
for body-mass index and lateral diameter and applied at a specified X-ray tube voltage 
(Table 4.1). (174) Coronary stents were excluded from the per-patient analysis by only 
including calcium proximal or distal to the border of the stented segment. For the per-
segment analysis, only segments without stenting were selected as representative 
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Table 4.1. Calcium mass score calibration table.  
Minimum and maximum equivalent water diameter (Dw) values were calculated from 
CT images of a phantom with and without an obese expansion ring. Body mass index 
(BMI) and lateral diameter were calculated from Dw as previously described. (174) 
Linear interpolation of calibration factor and anthropomorphic measurements was 










Calibration factor at 
specified tube kilovoltage 
Dw (mm)  (mm) 
 
120 kV 
205 8.5 324  0.777 
210 9.8 332  0.780 
215 11.0 340  0.783 
220 12.2 349  0.786 
225 13.4 357  0.789 
230 14.6 365  0.792 
235 15.9 373  0.795 
240 17.1 381  0.798 
240 17.1 381  0.798 
245 18.3 390  0.801 
250 19.5 398  0.804 
255 20.7 406  0.807 
260 22.0 414  0.810 
265 23.2 422  0.813 
270 24.4 431  0.816 
275 25.6 439  0.819 
280 26.8 447  0.822 
285 28.0 455  0.825 
290 29.3 463  0.828 
295 30.5 472  0.831 
300 31.7 480  0.834 
305 32.9 488  0.837 
310 34.1 496  0.840 
315 35.4 504  0.843 
317 35.9 508  0.844 
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Coronary CT Angiography image analysis 
Visual assessment of CT-defined high-risk plaque characteristics was performed by 
trained observers. The presence or absence of five plaque characteristics (positive 
remodelling, low attenuation plaque, the napkin ring sign, spotty calcification and 
punctate calcification) was documented on a segmental basis using a 15-segment 
model. (175) Positive remodelling was defined as a vessel diameter of 10% greater 
than a reference segment proximal to the plaque. (40) Low attenuation plaque was 
defined as a focal area of plaque with an attenuation density of <30 Hounsfield units. 
(176) Spotty calcification was defined as focal areas of arterial calcification with a 
maximum diameter <3mm. The ‘napkin ring’ side was defined as a central area of low 
attenuation plaque surrounded by a rim of high attenuation, as described previously. 
(177) 
Coronary artery plaque quantification was performed on all non-stented segments with 
visible atherosclerotic plaque by a trained observer using semi-automated software 
(Autoplaque, Cedars Sinai Medical Center, Los Angeles, USA). Plaque components 
including remodelling index, calcified plaque, non-calcified plaque and low-
attenuation plaque volume were quantified using scan-specific thresholds referencing 
blood pool attenuation from a circular region of interest created in the proximal 
ascending aorta. Manual adjustments were made as required. This technique has 
previously demonstrated excellent intra-observer, inter-observer and scan-rescan 
reproducibility. (43, 44) 
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Positron Emission Tomography image analysis 
Positron emission tomography images were reconstructed in diastole (50-75% of the 
R-R interval, 2 iterations, 21 subsets, 5-mm Gaussian smoothing, Siemens Ultra-HD 
algorithm) and fused with contrast enhanced CT coronary angiography. Images were 
co-registered on three anatomical planes and qualitative and semi-quantitative analysis 
of coronary 18F-fluoride uptake was performed by experienced observers. Coronary 
18F-fluoride PET-CT analysis and reproducibility have been reported previously. (174) 
In brief, visual assessment for increased coronary 18F-fluoride uptake was performed 
on both a per-participant and per-segment level and deemed positive if there was focal 
radiotracer accumulation which co-localised to an atherosclerotic plaque on coronary 
CT angiography and followed the course of the coronary artery >5 mm in transverse, 
sagittal and orthogonal views. Where visual uptake was identified, semi-quantitative 
analysis was performed by drawing 2-dimensional regions of interest on the transverse 
images and quantifying the maximum standardised uptake value (SUVmax) for that 
lesion. In each participant, SUVmax was also quantified in a proximal coronary 
atherosclerotic plaque without visual evidence of radiotracer localisation as a 
reference. Background blood pool activity was quantified by measuring activity in the 
right atrium within 2-cm radius regions of interest on three consecutive slices.  Tissue-
to-background ratios were calculated by dividing plaque SUVmax values by mean 
average SUV values in the right atrium. Coronary plaques were considered PET-
positive in the presence of focal radiotracer uptake localised to a plaque with a tissue-
background ratio greater than 1.25, as described previously. (55) For the purpose of 
the per-segment analysis, participants were only included if there were both a PET-
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positive and PET-negative plaque which was not stented (Figure 4.1). Participants in 
which the only PET-positive or PET-negative plaque was stented were excluded from 
per-segment analysis.  Image analysis was performed using an OsiriX workstation 
(OsiriX version 3.5.1 64-bit; OsiriX Imaging Software, Geneva, Switzerland).  
 
Figure 4.1. An example of per-segment PET-CTA and CT calcium scoring image analysis. 
In this participant, the PET-positive segment was selected as the proximal right 
coronary artery which demonstrated increased 18F-fluoride activity (A, red arrow). At 
baseline, the calcium score of this segment was 496 AU (B) and subsequently 
increased to 944 AU at 12 months. In this participant, the proximal left circumflex 
artery was selected as the PET-negative reference lesion (C, blue arrow). At baseline, 
the calcium score in this segment was 496 AU and subsequently increased to 616 AU  
at 12 months.   
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4.3.5 STATISTICAL ANALYSIS 
Categorical variables are reported as number (%) and continuous variables as mean ± 
standard deviation for parametric or median [interquartile range] for non-parametric 
data. Continuous unpaired variables were compared using Student’s T-test or the Mann 
Whitney U test where appropriate and paired variables compared using Student’s t-
test or the Wilcoxon matched-pairs signed-ranks test, dependent on normality. 
Categorical variables were compared using Chi Square tests. Logarithmic 
transformation (Ln[x+1]) was used to achieve normality of continuous variables. Two-
tailed Pearson’s correlation analysis was performed to investigate the relationship 
between continuous variables where normally distributed. Non-parametric continuous 
variables were compared using Spearman’s rank correlation. To investigate the 
relationship between 18F-fluoride activity and progression of coronary calcification at 
the patient level, linear regression was used with log transformation of the dependent 
variable. To investigate at the per-segment level, a linear mixed model was used with 
the participant as a random effect to adjust for repeated measurements within 
individuals. Using calcium mass at 12 months as the dependent variable, analysis of 
variance (ANOVA) was then used to compare two mixed models; model one using 
calcium mass at baseline, and model two using baseline calcium and segmental TBR 
as independent variables. Statistical analysis was undertaken using IBM SPSS 
Statistics 23 and R version 3.5.0 (R Foundation for Statistical Computing, Vienna, 
Austria). Statistical significance was considered as a two-sided p value <0.05.  
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4.4 RESULTS 
4.4.1 BASELINE CHARACTERISTICS 
A total of 185 participants underwent combined PET-CT angiography and CT calcium 
scoring at baseline and follow-up (mean age 65±8, 80% male; Figure 4.2). For the 
purposes of this analysis, we excluded participants who underwent coronary 
revascularisation during the course of the trial with implantation of a coronary stent 
within a previously unstented coronary segment (n=2). Coronary revascularisation 
decisions were made by the attending clinician independent of the research study team 
or knowledge of the PET-CT scan findings.  Of the participants who underwent 
percutaneous coronary intervention, both had evidence of increased 18F-fluoride 
activity. One participant underwent stenting to the left anterior descending artery and 
left circumflex artery, and the other underwent stenting to the left anterior descending 
artery. All three lesions showed obstructive stenosis on baseline san (70-99% stenosis) 
and two of three had high-risk plaque features (positive remodelling and spotty 
calcification). In the remaining eligible participants (n=183), there was a high 
prevalence of cardiovascular risk factors, of which 69% (n=126) had a history of acute 
coronary syndrome, 81% (n=148) of participants had previous percutaneous coronary 
intervention and the majority 96% (n=175) were on statin therapy (Table 4.2). 
Of the 183 participants included in this analysis, 63% (n=116) patients had evidence 
of increased 18F-fluoride uptake in at least one vessel (PET-positive). The PET-positive 
cohort was predominantly male (89%, n=103 versus 64%, n=43; p<0.001), with a 
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higher prevalence of prior coronary artery bypass graft surgery (28%, n=33 versus 6%, 
n=4; p<0.001).  
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Figure 4.2 Consort diagram. 
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Table 4.2. Baseline characteristics. 










Male gender 146 (80) 103 (89) 43 (64) <0.001 
Age, years 66[59-71] 67[61-73] 65[57-70] 0.02 
BMI (kg/m2) 29.5 29.3 29.9 0.35 
Medical History 
Current Smoker 24 (13) 12 (10) 12 (18) 0.14 
History of acute coronary syndrome 126 (69) 80 (69) 46 (69) 0.97 
Percutaneous Coronary Intervention 148 (81) 93 (80) 56 (84) 0.48 
Coronary Artery Bypass Grafting 37 (20) 33 (28) 4 (6) <0.001 
Hypertension 101 (55) 65 (56) 36 (54) 0.76 
Hypercholesterolaemia 177 (97) 112 (97) 65 (97) 1.0 
Diabetes Mellitus 32 (17) 22 (19) 10 (15) 0.58 
Prior Stroke/Transient Ischemic Attack 4 (2) 3 (3) 1 (1) 1.0 
Medications 
Aspirin 183 (100) 116 (100) 67 (100)  
Statin 175 (96) 110 (95) 65 (97) 0.71 
Beta-Blocker 124 (68) 78 (67) 46 (69) 0.84 
Angiotensin Converting Enzyme 
Inhibitor/Angiotensin II Receptor 
Blocker 
138 (75) 86 (74) 52 (78) 0.60 
Biochemistry 
Haemoglobin, g/dL 14.0±1.2 14.0±1.2 14.0±1.3 0.87 
Creatinine, µmmol/L 80 ± 13 80±12 80 ± 13 0.89 
Total Cholesterol, mg/dL 162±39 162±39 159±31 0.33 
High density lipoprotein, mg/dL 46±12 46±12 43±12 0.46 
Low density lipoprotein, mg/dL 85±31 89±31 81±27 0.14 
Triglycerides, mg/dL 151±89 1.7±1.2 1.7±0.8 0.79 
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4.4.2 BASELINE 18F-FLUORIDE ACTIVITY AND PER-PARTICIPANT 
CALCIUM BURDEN  
Participants with increased coronary 18F-fluoride uptake had higher baseline calcium 
scores (524 [242 to 1091] versus 136 [55 to 361] AU; p<0.001), higher calcium mass 
(99 [46 to 212] versus 24 [11 to 69] mg; p<0.0001), and higher calcium volume (491 
[247 to 984] versus 131 [64 to 343] mm3; p<0.0001) compared to those without 
increased 18F-fluoride uptake (Table 4.3).  The proportion of PET-positive participants 
rose with increasing baseline calcium score (Figure 4.3). Thirty-eight participants had 
a total calcium score >1000 Agatston units at baseline and, of these, thirty-five (92%) 
had evidence of increased 18F-fluoride uptake in at least one vessel.   
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Figure 4.3. The proportion of 18F-fluoride positive and negative participants with increasing 
baseline total calcium score.  
Increased overall disease burden is associated with an increased frequency of 18F-
fluoride activity.   
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Table 4.3. Progression of calcification in participants with evidence of increased 18F-







(N=67) P value 
BASELINE  
Total Agatston Score (AU) 378 [107-823]  524 [242-
1091] 
136 [55-361] p<0.001 
Calcium Volume (mm3) 352 [131-771]  491 [247-984] 131 [64-343] p<0.001 
Calcium Mass (mg) 70 [23-153] 99 [46-212] 24 [11-69] p<0.001 
FOLLOW-UP   
Total Agatston Score (AU) 476 [173-1045] 660 [292-
1216] 
165 [61-461] p<0.001 
Calcium Volume (mm3) 417 [167-887] 611 [313-
1041] 
149 [68-407] p<0.001 
Calcium Mass (mg) 89 [32-195] 129 [58-241] 32 [11-81] p<0.001 
PROGRESSION 
Change in Calcium Score 
(AU) 
70 [22-143] 97 [39-166] 35 [7-93] p<0.001  
Change in Calcium Volume 
(mm3) 
60 [16-121] 82 [29-149] 33 [3-82] p<0.001 
Change in Calcium Mass 
(mg) 
14 [4-35] 22 [7-42] 6 [1-20] p<0.001 
PET – positron emission tomography. PET positive and PET negative denote the presence or 
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4.4.3 18F-FLUORIDE UPTAKE AND PLAQUE CHARACTERISTICS 
Sixty (52%) of the PET-positive participants and 37 (55%) of the PET-negative 
participants had at least one high-risk plaque feature on CT coronary angiography. 
There was no difference in the median number of high-risk plaque features per patient 
in PET-positive (1.0 [0.0-2.3]) compared with PET-negative (1.0 [0.0-3.0]) 
participants (Table 4.4). Nine participants were excluded from quantitative plaque 
analysis due to suboptimal image quality. On quantitative plaque analysis in the 
remaining 174 participants, total plaque volume, non-calcified plaque volume and 
calcified plaque volume were higher in PET-positive participants at baseline and at 
one-year follow-up (Table 4.5).   
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Table 4.4. CT-defined plaque characteristics in PET-positive and PET-negative participants 






Number of positively remodelled plaques 
0 112 (61%) 70 (60%) 42 (63%) 
1 41 (22%) 25 (22%) 16 (24%) 
2 23 (13%) 14 (12%) 9 (13%) 
3 5 (2.7%) 5 (4.3%) 0 (0%) 
4 1 (0.5%) 1 (0.9%) 0 (0%) 
5+ 1 (0.5%) 1 (0.9%) 0 (0%) 
Number of low attenuation plaques 
0 164 (90%) 104 (90%) 60 (90%) 
1 17 (9.3%) 10 (8.6%) 7 (10%) 
2 2 (1.1%) 2 (1.7%) 0 (0%) 
Number of plaques with 
the napkin ring sign 
4 (2.2%) 3 (2.6%) 1 (1.5%) 
Number of plaques with spotty calcification 
0 116 (63%) 79 (68%) 37 (55%) 
1 34 (19%) 21 (18%) 13 (19%) 
2 16 (8.7%) 8 (6.9%) 8 (12%) 
3 12 (6.6%) 4 (3.4%) 8 (12%) 
4 4 (2.2%) 4 (3.4%) 0 (0%) 
5+ 1 (0.5%) 0 (0%) 1 (!.5%) 
Number of plaques with punctate calcification 
0 179 (98%) 114 (98%) 65 (97%) 
1 2 (1.1%) 0 (0%) 2 (3.0%) 
2 2 (1.1%) 2 (1.7%) 0 (0%) 




1.00 [0.00-2.25] 1.00 [0.00-3.00] 
Data presented as n (%) and median [IQR]. HRP; high-risk plaque. 
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Calcified Plaque Volume (mm3) 89 [34-224] 154 [62-
285] 
37 [7-78] <0.0001 
Low Density Non-Calcified Plaque 
Volume (mm3) 
87 [43-168] 91 [54-154] 78 [35-169] 0.485 
Remodelling Index 1.5 [1.4-1.7] 1.5 [1.4-1.8] 1.4 [1.3-1.6] 0.020 
FOLLOW-UP   




















43 [13-79] <0.0001 
Low Density Non-Calcified Plaque 
Volume (mm3) 
91 [48-157] 84 [49-153] 104 [41-
161] 
0.829 
Remodelling Index 1.5 [1.3-1.7] 1.5 [1.3-1.7] 1.4 [1.3-1.6] 0.438 
PROGRESSION 














Change in Calcified Plaque 
Volume (mm3) 
4 [-13-37] 14 [-12-47] 1 [-15-17] 0.02 
Change in Low Density Non-
Calcified Plaque Volume (mm3) 
2[-20-28] 1 [-23-26] 3 [-16-32] 0.558 
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4.4.4 18F-FLUORIDE UPTAKE AND PROGRESSION OF CALCIFICATION ON 
A PER-PATIENT LEVEL 
The median increase in calcium score, calcium mass and calcium volume were higher 
in PET-positive compared to PET-negative participants (p<0.001 for all; Table 4.3). 
Change in total calcified plaque volume on CT coronary angiography was also higher 
in PET-positive participants. There was no difference in change in non-calcified 
plaque, low-density plaque or total plaque volume (Table 4.5). Per-patient TBRmax 
correlated with change in calcium score (Spearman’s r = 0.37), calcium mass (r = 
0.46) and calcium volume (r = 0.38; p<0.001 for all; Table 4.6).  There was a weak 
positive correlation between baseline TBRmax and change in total calcified plaque 
volume (Spearman’s Rho 0.165; p=0.029; Table 4.6). 
After adjusting for age, sex and baseline calcium score, baseline 18F-fluoride activity 
was not an independent predictor of calcium score at 12 months when investigated at 
the patient level (p=0.50).   
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Table 4.6. Correlation between baseline maximum Tissue-to-Background Ratios (TBRmax) 
and progression of calcification. 
 







Calcium burden on non-contrast CT 
Change in total 
calcium burden 
(AU/year) 
183 0.371 <0.001 
Change in total 
calcium volume 
(mm3/year) 
183 0.379 <0.001 
Change in total 
calcium mass 
(mg/year) 
183 0.456 <0.001 
Quantitative plaque characteristics on CT coronary angiography 
Change in total 
plaque volume 
(mm3/year) 





174 -0.001 0.990 









174 0.165 0.029 
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4.4.5 PER-SEGMENT 18F-FLUORIDE ACTIVITY AND PROGRESSION OF 
CALCIFICATION 
Calcification in individual coronary segments with evidence of 18F-fluoride uptake 
was compared to a proximal reference segment with atherosclerotic plaque but without 
increased 18F-fluoride uptake within the same individual (Figure 4.4). Six participants 
in whom the only PET-positive lesion or only PET-negative lesion was stented were 
excluded from analysis. Amongst the remaining PET-positive participants (n=110), 
lesions with 18F-fluoride uptake had a higher calcium score, calcium mass and volume 
at baseline than PET-negative reference lesions in the same individuals (p<0.001 for 
all; Table 4.7).  There was no difference in baseline average calcium density or change 
in average calcium density between PET-positive and PET-negative lesions (Table 
4.8).  
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Figure 4.4. 18F-Fluoride activity predicts progression of coronary arterial calcification.  
18F-Fluoride activity predicts progression of coronary arterial calcification. In an 18F-
fluoride PET positive lesion (A-E), contrast-enhanced CT coronary angiography (A) 
and fused PET-CT (B) demonstrate 18F-fluoride uptake in the left main stem (LMS) at 
baseline overlying a mixed plaque shown on coronal view (A) and cross-section (C). 
Repeat CT coronary angiography at one year demonstrates progression of calcification 
in this segment with a higher calcium score (D) and dense calcium visible on cross 
section (E). (Calcium score 75AU at baseline, TBRmax 1.7, calcium score 110AU at 
one year). In the same patient, a calcified plaque in a proximal obtuse marginal branch 
without evidence of increased 18F-fluoride activity is shown on coronal (F, G) and 
cross-section views (H). This plaque does not demonstrate progression in calcium 
score at one year (I, J). (Calcium score 186AU at baseline, TBRmax 1.0, calcium score 
172AU at one year). 
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Table 4.7. Progression of calcification at a segmental level in coronary arterial segments 

















95 [30-209] 46 [16-113] <0.001 
Calcium Volume (mm3) 519 [276-
1014] 
106 [37-185] 47 [21-95] <0.001 
Calcium Mass (mg) 101 [51-222] 19 [6-40] 9 [4-21] <0.001 
FOLLOW-UP   




148 [61-289] 49 [20-115] <0.001 
Calcium Volume (mm3) 651 [330-
1094] 
129 [62-226] 44 [21-103] <0.001 
Calcium Mass (mg) 131 [62-242] 28 [11-55] 9 [4-23] <0.001 
PROGRESSION 
Change in Calcium Score 
(AU) 
104 [45-170] 39 [20-70] 2 [-7-11] <0.001 
Change in Calcium 
Volume (mm3) 
86 [35-154] 30 [14-53] 1 [-8-8] <0.001 
Change in Calcium Mass 
(mg) 
23 [10-44] 7 [4-14] 0.62 [-0.8-2.1] <0.001 
PET – positron emission tomography. PET positive and PET negative denote the presence or 
absence of 18F-fluoride uptake 
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FOLLOW-UP   















In PET-positive segments, there was an increase in calcium score (from 95 [30 to 209] 
to 148 [61 to 289] AU), calcium mass (from 19 [6 to 40] to 28 [11 to 55] mg) and 
calcium volume (from 106 [37 to 185] to 129 [62 to 226] mm3; p<0.001 for all). In 
PET-negative reference segments, there was no change in calcium score (from 46 [16 
to 113] to 49 [20 to 115] AU; p=0.329) and calcium volume (from 46 to 44 mm3, 
p=0.666), although there was a small increase in calcium mass (from 9.1 to 9.2 mg; 
p=0.017; Figure 4.5). Similarly, changes in calcification were greater in PET-positive 
plaques compared to PET-negative plaques for the calcium score (39 [20 to 70] versus 
2 [-7 to 11] AU), calcium mass (7 [4 to 14] versus 0.6 [-0.8 to 2.1] mg) and calcium 
volume (30 [14 to 53] versus 1 [-8 to 8] mm3; p<0.001 for all). When segmental 
calcium mass and calcium score were measured as a ratio of follow-up to baseline, the 
calcium mass and calcium score ratio were each higher in PET-positive segments 
(Figure 4.6). 
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Figure 4.5. The relationship between baseline 18F-fluoride activity and coronary 
calcification at one year. 
Panels A-C display the change in calcium score (A), mass (B) and volume (C) in 18F-
fluoride positive versus negative lesions over twelve months. Median and interquartile 
range displayed.  
 
Figure 4.6. Ratio of calcification at follow-up to baseline.  
Ratio of  follow-up total calcium mass (A) and Agatston score (B) to baseline in 
individual PET-positive and PET-negative segments in participants with at least one 
PET-positive lesion.  
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When the relationship between 18F-fluoride activity and progression of calcification 
was investigated at the segmental level, baseline TBRmax was an independent 
predictor of 12-month calcium mass when adjusting for baseline calcium mass (beta 
0.67 Standard Error 0.06), Agatston score (beta 0.60 SE 0.09) or volume (beta 0.52 SE 
0.07) and the repeated within individual measurements (p<0.001 for all). 
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4.5 DISCUSSION 
In this pre-specified sub-study of a randomized controlled trial, we have demonstrated 
that increased 18F-fluoride uptake is associated with more rapid progression of 
coronary atherosclerotic calcification. This finding was consistent across a range of 
measures of calcification and whether this was considered on a per-patient or per-
segment basis. However, when considering total calcification burden at the patient 
level, baseline calcium score remained a powerful predictor of calcification 
progression. These findings nonetheless support 18F-fluoride PET as a marker of 
increased disease activity and active mineralization within coronary atherosclerotic 
plaques.  
Calcification plays a complex role in the development and progression of 
atherosclerosis. Hydroxyapatite deposition is heralded by intense inflammation, cell 
death and necrosis which precipitate the formation of calcifying matrix vesicles and 
leads to the earliest microscopic deposits of calcium which are not visible on 
conventional anatomical imaging modalities. (17, 20, 172) As well as reflecting the 
pro-inflammatory environment, microcalcification may also be directly implicated in 
plaque rupture as a consequence of destabilisation of the plaque’s fibrous cap. (178) 
As microcalcific deposits coalesce to form larger macroscopic structures, plaque 
stability improves - a feature reflected by the observation that heavily calcified plaques 
are less prone to rupture or precipitate acute coronary events. (2, 179) Thus, while 
advanced macrocalcification may be considered a marker of plaque stability and inert 
disease, the earlier stages of calcium deposition are associated with increased 
inflammation and plaque vulnerability. (20, 180) 
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The precise natural history of calcification activity remains poorly understood. Indeed, 
the process of calcification does not progress in a linear manner and, while the earliest 
microcalcific deposits are associated with intense inflammation (17), it is likely that 
active calcification may accelerate during the process of plaque healing. This 
observation is concordant with prior randomized trials that have observed a pro-
calcific effect of statins due to phenotypic transformation of low attenuation material 
to calcified plaque. (178)  While computed tomography can provide quantitative 
measures of total plaque burden, it does not provide insight into the underlying 
biological disease process or disease activity, hence the rationale for utilizing targeted 
radiotracers. 
18F-Fluoride preferentially binds developing microcalcification (178), with uptake 
therefore potentially reflecting the earlier and more unstable stages of atherosclerotic 
mineralisation. Here, we have confirmed that increased 18F-fluoride uptake provides 
an assessment of calcification activity within the coronary arteries, with uptake 
predicting progression in macroscopic calcium measured in individual plaques on CT, 
similar to previous results in the aortic valve and mitral valve annulus. (61, 181) 
Indeed, while calcium scores remained static in lesions without uptake, there was 
progression of calcification in plaques with increased 18F-fluoride uptake, with an 
approximately 50% increase in median calcium score and calcium mass in as little as 
12 months. Furthermore, the median change in calcium score in individual lesions with 
18F-fluoride uptake was almost twenty times greater than the change in calcium score 
in those without uptake. In individual coronary lesions, this finding remained even 
following adjustment for baseline calcium mass. 
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While the temporal nature of 18F-fluoride activity remains unknown, it is possible that 
18F-fluoride uptake may increase as the atheromatous plaque begins to stabilise. 
Previous reports have highlighted that, while coronary 18F-fluoride uptake can be 
localised to culprit plaques in the majority of patients following acute myocardial 
infarction, quantitative PET activity, as measured by tissue-to-background ratio, is 
higher in patients with stable coronary artery disease compared to immediately 
following acute myocardial infarction. (55)  In a recent post-hoc analysis of nearly 300 
patients with established coronary artery disease, increased 18F-fluoride activity was 
an independent predictor of fatal and non-fatal myocardial infarction. Quantification 
of coronary microcalcification activity, a novel marker of 18F-fluoride uptake, 
demonstrated powerful prediction of future adverse events leading to a 7-fold 
increased risk of fatal or nonfatal myocardial infarction in participants with elevated 
coronary microcalcification activity. (182)  
In the present study, we have for the first time linked coronary 18F-fluoride activity to 
progression in coronary atherosclerotic calcification. The main hypothesis for this 
study was to investigate the relationship between 18F-fluoride activity and calcification 
progression. However, we also investigated the relationship between PET activity and 
other morphological features of atherosclerosis, including low attenuation plaque, non-
calcified plaque and total plaque volume. We have demonstrated that total plaque 
volume and non-calcified plaque volume are higher in patients with increased 18F-
fluoride activity. The presence of increased 18F-fluoride activity was also associated 
with a greater change in total calcified plaque volume.  
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The study highlights the high frequency of increased 18F-fluoride activity in patients 
with established multivessel coronary artery disease, with two-thirds of patients having 
evidence of increased activity in at least one vessel. The prevalence of increased 18F-
fluoride uptake is similar to previous reports in clinically stable patients. (54, 55) 
Previous studies have reported that over one third of patients with calcium scores 
greater than 1000 do not have evidence of increased 18F-fluoride activity. (54) In this 
study, we have shown that the majority of patients (92%) with calcium scores greater 
than 1000 had evidence of increased 18F-fluoride uptake in at least one vessel, 
suggesting ongoing calcification activity. Indeed, an increasing disease burden was 
associated with an increase in the proportion of patients with evidence of increased 
PET activity in at least one vessel. This may reflect the underlying study population 
whom were largely high risk, with the majority (70%) having prior acute coronary 
syndrome and over 80% having previous coronary revascularisation.  
We recognise that there are some limitations to our study. PET-CT imaging was 
performed in a single centre with experience in coronary PET-CT, and we need to 
explore the generalisability of our findings across multiple centres with different 
scanners. The high prevalence of previous percutaneous coronary intervention and 
stenting precluded calcium scoring assessment from at least one arterial segment in 
many patients. We mitigated for this by excluding those participants who underwent 
revascularisation in a previously untreated arterial segment prior to the follow-up scan, 
ensuring the calcium burden on the follow-up scan was not underestimated. Although 
scan-rescan reproducibility of CT calcium mass and volume within individual plaques 
has not been reported, repeatability and variability of CT calcium scoring protocols 
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has been demonstrated to be less than 20%. (147) Furthermore, our scans were all 
performed on a single imaging system with the same scanning protocol and 
reconstruction protocol, thereby minimising interscan variability. Lastly, our 
population represents a high-risk patient group with advanced disease and the majority 
having had a previous acute coronary event. Hence, these results may not be applicable 
to all patients with known or suspected coronary disease and future studies in different 
risk groups would be welcomed. While recent data have highlighted the predictive 
value of 18F-fluoride activity in cardiovascular risk stratification, ultimately, 
prospective studies investigating the relationship between coronary 18F-fluoride 
uptake and cardiovascular events will determine the prognostic utility of this novel 




In conclusion, increased coronary 18F-fluoride uptake is associated with more rapid 
progression of coronary calcification at one year in patients with clinically stable 
multivessel coronary artery disease. In individual diseased segments, this association 
is independent of baseline calcium score, but at the patient level this finding is not 
independent of baseline calcium burden.  18F-Fluoride uptake provides new insights 
into disease activity and progression of coronary atherosclerosis.   
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Chapter 5 Optimisation of Reconstruction and 




Although coronary PET has shown initial promise in the detection of high-risk 
atherosclerosis, there remains a need to optimize imaging techniques to improve 
quantification and overcome challenges faced by motion. We investigated the impact 
of different reconstruction and quantification methods in 18F-Sodium Fluoride (18F-
fluoride) PET in patients presenting with acute coronary syndrome (ACS). Further, we 
applied a cardiac motion-correction method in the same group of patients and 
investigated whether this led to improvements in PET quantification.  
Methods 
Twenty-two patients underwent 18F-fluoride PET within 22 days of ACS. Optimal 
reconstruction parameters were determined in a subgroup of 6 patients. Subsequently, 
motion-correction by diffeomorphic mass-preserving anatomy-guided registration 
within vessels automatically defined by computed tomography angiography was 
performed on ECG-gated data of all patients forming motion-frozen images from all 
cardiac gates. Tracer uptake was quantified in culprit and reference lesions by 
computing signal-to-noise ratio (SNR) in diastolic, summed and motion-corrected 
images. 
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Results  
PET reconstruction using 24 subsets, 4 iterations, point-spread-function modelling, 
time of flight and 5-mm post-filtering provided the highest median SNR (31.5) 
compared to 4 iterations 0-mm (22.5), 8 iterations 0-mm (21.1) and 8 iterations 5-mm 
(25.6; p<0.05 for all). In all subjects, motion-correction improved SNR of culprit 
lesions (n=33) (24.5 [19.9-31.5]) when compared to diastolic (15.7 [12.4-18.1]; 
p<0.001) and summed data (22.1 [18.9-29.2]; p=<0.001). Further, motion-correction 
led to a greater SNR difference between culprit and reference lesions (10.9 [6.3-12.6]) 
compared to diastolic (6.2 [3.6-10.3] p=0.001) and summed data (7.1 [4.8-11.6] 
p=0.001). 
Conclusions 
The number of iterations and extent of post-filtering in 18F-fluoride PET reconstruction 
has marked effects on quantification and should be considered when using coronary 
PET. Cardiac motion-correction improves discrimination between culprit and 
reference lesions. 
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5.2 INTRODUCTION 
Positron emission tomography (PET) using 18F Sodium Fluoride (18F-fluoride) has 
emerged as a promising non-invasive imaging modality to potentially identify high-
risk and ruptured coronary atherosclerotic plaques. (55, 183-185) However, imaging 
of the coronary arteries faces many challenges. First, the small calibre of coronary 
vessels combined with their tortuous course means that optimizing spatial resolution 
is of great importance. Second, the impact of motion from cardiac contraction, 
respiration and patient movement can degrade visual quality and PET quantification, 
highlighting the need for sophisticated methods to overcome these limitations.  
To compensate for the effects of motion, prior coronary PET-CT studies have analysed 
data from the end-diastolic phase of the cardiac cycle (with 4-bin gating), utilizing 
only one quarter of PET counts and effectively discarding the remainder. While a 
useful initial strategy, this method leads to markedly increased noise and potentially 
additional difficulty in distinguishing active plaques from noise-related artefact. 
Indeed, in an initial study, the difference in target-to-background ratio between 
positive and negative plaques was small (approx. 33%), which may be a result of both 
noise and signal blurring due to motion. (55) 
Recently, we have demonstrated that a novel cardiac motion-correction method, using 
a diffeomorphic mass-preserving anatomy-guided registration technique, improves 
PET quantification when applied to original image data from a single imaging site. 
(149) However, there is a need to optimize and standardize imaging and quantification 
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methods between centres to minimize variation and enable comparison in multicentre 
studies.   
In this analysis, we evaluated a series of 18F-fluoride coronary measurements with 
respect to the optimal reconstruction and motion-correction techniques. We aimed to 
investigate the influence of reconstruction protocols on image quality (judged both 
visually and quantitatively) in a subgroup of patients who presented with acute 
coronary syndrome. Secondly, we utilized the optimal reconstruction in a larger group 
of patients with acute coronary syndrome and evaluated the subsequent improvement 
in signal quantification gained by the application of our novel motion-correction 
method, now integrated within image analysis software to help streamline this process.   
  
                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 122 
5.3 METHODS 
5.3.1 STUDY POPULATION  
Patients with a diagnosis of ACS and who underwent invasive coronary angiography 
were recruited from Cedars-Sinai Medical Center between December 2015-June 2016 
(n=22). All patients underwent a comprehensive baseline clinical assessment, 
including evaluation of their cardiovascular risk factor profile. The study was approved 
by the Institutional Review Board and all patients provided written informed consent. 
5.3.2 IMAGING PROTOCOLS AND PET RECONSTRUCTION 
All patients were administered a target dose of 250 MBq of 18F-fluoride and rested in 
a quiet environment. After 60 minutes, image acquisition began on a hybrid PET-CT 
scanner (GE Discovery 710). Following the acquisition of a non-contrast CT 
attenuation correction scan, PET acquisition was performed in list mode for 30 
minutes. Finally, coronary computed tomography angiography (CTA) was performed 
at end-expiration immediately following PET acquisition.  
ECG-gated PET images were reconstructed using 4 and 10 cardiac bins. A standard 
ordered subset expectation maximization (OSEM) algorithm was used with time of 
flight and resolution recovery. Four different reconstruction algorithms were applied 
in a subgroup of 6 patients; 4 iterations with 0-mm post-filtering, 4 iterations with 5-
mm post-filtering, 8 iterations with 0-mm post-filtering and 8 iterations with 5-mm 
post-filtering. For each subject, 24 subsets and a 256x256 matrix size with a 20x20 cm 
field of view were used in each reconstruction algorithm.  
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Following determination of the reconstruction parameters that provided the highest 
image quality and signal-to-noise ratio (SNR), the impact of time of flight and 
resolution recovery was then evaluated. PET images were then reconstructed for the 
remaining patients using the optimal parameters of those evaluated.  
5.3.3 MOTION CORRECTION 
We applied a novel motion-correction method that aimed to compensate for coronary 
artery motion by aligning all gates to the end-diastolic position. First, anatomical data 
was extracted from coronary CTA by applying a vessel tracking method implemented 
in dedicated software (Autoplaque 2.0, Cedars-Sinai Medical Center).  Second, a 
diffeomorphic mass-preserving image registration algorithm (demons) was used to 
align 10 gates of PET data with the position of the end-diastolic gate. (149, 186) This 
algorithm allowed non-linear transformations with a regularization function, 
facilitating smoother transitions between regions and gates than the originally 
proposed level-set method. (150) The algorithm was fully automated and implemented 
in dedicated image analysis software developed at Cedars-Sinai (FusionQuant 1.0) 
using ITK image processing library. (187)  After motion-correction, the 10 gates were 
summed back together to build a motion-free image containing counts from the entire 
duration of PET acquisition.   
5.3.4 IMAGE ANALYSIS 
Image analysis was performed using dedicated software (FusionQuant 1.0 Cedars-
Sinai Medical Center, Los Angeles). Images from the four different reconstructions 
for each patient were presented to an experienced observer (MKD) in a blinded fashion 
                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 124 
and a visual quality score was assigned to each reconstruction (score 1-4, 1 
representing the highest image quality and 4 the most difficult to interpret).  For each 
scan, fused PET-CTA images were co-registered, and the same registration was 
applied to diastolic, summed and motion-corrected images.  
For quantitative PET analysis, activity was measured by delimiting 3-dimensional 
spherical volumes of interest on coronary artery plaques. Lesions were considered 
PET-positive if there was visual focal tracer uptake in a plaque which followed the 
course of the vessel over more than one slice and was visible on more than one of four 
gates including the end-diastolic gate.  Reference lesions without visual PET-uptake 
(i.e. PET-negative) were measured in coronary vessels at the same segment or 
proximal to the PET-positive lesions.  Quantitative plaque volume was measured for 
all PET-positive and reference PET-negative lesions, which were present in epicardial 
vessels with a calibre >2mm and had not been stented prior to imaging, excluding 
those with poor image quality. This was performed using semi-quantitative software 
(AutoPlaque version 2.0, Cedars Sinai Medical Center). 
Background blood-pool activity was measured by delimiting 3cm2 regions of interest 
in the right atrium on three consecutive slices from the level of the lowest pulmonary 
vein insertion. Image noise was defined as the mean standard deviation of blood-pool 
activity. SNR was defined as the plaque maximal SUV inside the spherical region 
centred around the plaque (SUVmax) divided by noise. Tissue-to-Background Ratio 
(TBR) was defined as the SUVmax divided by the mean background blood-pool 
activity. For each image, PET registration and regions of interest were saved using the 
original image, and the same regions of interest were measured in the diastolic, 
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summed and motion corrected images. Semi-automated software (Autoplaque version 
2.0, Cedars-Sinai Medical Center) was used to quantify total plaque volume of 
coronary arterial plaques for PET-positive and PET-negative reference lesions after 
excluding those with stents and poor image quality (n=28).  
5.3.5 STATISTICAL ANALYSIS 
Continuous data is expressed as mean (standard deviation) or median [interquartile 
range] as appropriate. Data was tested for normality using Shapiro-Wilk test. 
Parametric data were compared using student’s T-test and non-parametric data 
compared using Wilcoxon Rank-Sum test as appropriate. A two-sided p value <0.05 
was considered statistically significant. Statistical analyses were performed using 
GraphPad Prism (version 7, GraphPad software Inc) and SPSS (version 22, IBM, 
USA) software. 
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5.4 RESULTS 
5.4.1 BASELINE CHARACTERISTICS 
Twenty-two patients were recruited 22 days within diagnosis of acute coronary 
syndrome (Table 5.1). All patients underwent PET-CT following invasive 
angiography with a mean duration of 8.7±4.8 days between angiography and PET-CT. 
Culprit lesions were identified on invasive angiography in 17 of the 22 patients. In one 
patient, the culprit vessel was a prior bypass graft and this patient was excluded from 
further motion-correction analysis. Of the remaining 21 patients, 10 (48%) had multi-
vessel disease on invasive angiography with at least one additional major epicardial 
vessel demonstrating >50% stenosis. Nineteen patients underwent percutaneous 
revascularization and two underwent coronary artery bypass grafting. Seven patients 
(33%) underwent revascularization of more than one vessel.  Seventeen (81%) patients 
had at least one PET-positive lesion. Of these patients, 16 demonstrated focal tracer 
uptake in a culprit vessel which was treated at the time of invasive angiography. The 
remaining patient had a PET-positive lesion in the mid right coronary artery, in which 
chronic total occlusion was demonstrated on invasive angiography.  There was no 
significant difference in total plaque volume between PET-positive and PET-negative 
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Table 5.1. Baseline characteristics. 
Variable Value SD/Percent 
Age in years, SD 62.4 11.2 
Men (n), (%) 20 91 
BMI (Kg,m2), SD 27.6 5.7 
Heart rate (beats per minute), SD 64.0 10.9 
Systolic blood pressure (mmHg), SD 128.4 17.1 
Diastolic blood pressure (mmHg), SD 72.1 11.2 
Cardiovascular History (n), %    
   Previous Myocardial Infarction 5 23 
   CVA/TIA 0 0 
   Previous PCI 5 23 
   Previous CABG 1 5 
Risk Factors (n),  %     
   Smoking 10 45 
   Diabetes 5 23 
   Hypertension 16 73 
   Hypercholesterolemia 14 64 
Serum Biochemistry (mg/dl), SD    
   Cholesterol 152.4 34.0 
   HDL 42.4 13.8 
   LDL 87.3 27.2 
   Triglyceride 136.3 82.6 
   Creatinine 1.1 1.0 
Medications (n), %     
   Aspirin, % 19 86 
   Clopidogrel, % 12 55 
   Statin, % 18 82 
   Beta Blocker, % 15 68 
   ACEI/ARB, % 9 41 
   Calcium Channel Blockers, % 4 18 
   Oral Nitrates 4 18 
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, 
body mass index; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCI, percutaneous coronary 
intervention; TIA, transient ischaemic attack 
 
 
                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 128 
5.4.2 RECONSTRUCTION SUBGROUP 
A subgroup of six patients was selected to assess the optimal reconstruction parameters 
needed to improve the balance between PET quantification and noise. When 
evaluating visual quality, use of 8 iterations and 0-mm post-filtering led to consistently 
poorer image quality (score of 4 in 6/6 patients) with difficulty in image interpretation 
due to noise, whereas the highest visual image quality was consistently observed in 
the reconstruction using 4 iterations and 5-mm post-filtering with time of flight and 
resolution recovery (score of 1 in 6/6 patients) (Figure 5.1). The reconstruction using 
4 iterations and 0-mm post-filtering scored 2 in two cases and 3 in four of six cases 
and, similarly, the reconstruction using 8 iterations and 5-mm post-filtering scored 2 
in four cases and 3 in two of the six cases. 
After motion-correction, the median signal-to-noise ratio was higher in the 
reconstruction using 4 iterations 5-mm (31.5 [19.5-33.9]) versus 4 iterations 0-mm 
(22.5 [16.7-26.8]), 8 iterations 0-mm (21.1 [16.1-22.5]), and 8 iterations 5-mm (25.6 
[17.2-27.0]) (p<0.05 for all). Conversely, TBR was consistently higher in the 
reconstruction method using 8 iterations and 0-mm post-filtering in the diastolic (4.3 
[3.0-7.0]), summed (2.9 [2.5-3.4] and motion-corrected (3.1 [2.8-3.9]) data. In the 
motion-corrected images, this reconstruction method generated higher TBR values 
(3.1 [2.8-3.9]) compared to 4 iterations 5-mm (1.8 [1.6-1.9]), 4 iterations 0-mm (2.2 
[2.1-2.5]) and 8 iterations 5-mm (2.0 [1.9-2.2]) (p=0.005 for all; Figure 5.2). 
 
 




Figure 5.1. The impact of different PET reconstructions on visual image quality in diastolic 
and motion-corrected images in a patient with a positive culprit lesion in the left main 
coronary artery.  
The PET reconstruction using 4 iterations and 5-mm post-filtering was considered to 








Figure 5.2. Signal-to-Noise Ratio (SNR) and Tissue-to-Background Ratio (TBR) in 
diastolic, summed and motion-corrected images for each reconstruction. 
In the diastolic, summed and motion-corrected images, median SNR was highest when 
PET data was reconstructed using 4 iterations and 5mm post-filtering. Conversely, 
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5.4.3 TIME OF FLIGHT AND RESOLUTION RECOVERY  
Following selection of the reconstruction which provided superior SNR, the influence 
of time of flight and resolution recovery was assessed in the same subgroup (Figure 
5.3). In the diastolic data, there was a trend but no significant difference in SNR with 
and without time of flight and resolution recovery (17.7 [15.6-19.0] versus 11.6 [10.1-
14.5]; p=0.074). In the summed data, SNR improved with the use of time of flight and 
resolution recovery (15.4 [13.3-19.3] versus 26.8 [20.5-30.3]; p=0.007). Similarly, 
following motion-correction, SNR was greater when time of flight and resolution 
















Figure 5.3. The impact of Time of Flight (TOF) and Resolution Recovery (RR). 
The impact of Time of Flight (TOF) and Resolution Recovery (RR) on Signal to Noise 
Ratio (SNR) in diastolic, summed and motion-corrected images in a patient with a 
PET-positive plaque in the mid right coronary artery.  In the summed and motion-












Figure 5.4. The effect of Time of Flight (TOF) and Resolution Recovery (RR) on SNR. 
SNR improved following TOF and RR, summed (27 versus 15; p=0.007) and motion-
corrected (32 vs 17 versus 32; p=0.005) data.    
 
When assessing TBR in reconstructions with and without the use of time of flight and 
resolution recovery, there was no difference in the diastolic data with compared to 
without these features (2.02 [1.75-2.27] versus 2.04 [1.81-2.72]; p=0.878). However, 
following the application of motion-correction, TBR was higher in the motion-
corrected data with time of flight and resolution recovery (1.79 [1.60-1.75] versus 1.59 
[1.46-1.73]; p=0.005). 
5.4.4 MOTION CORRECTION  
A representative example of the extent of coronary artery motion in the right coronary 
artery is shown in Figure 5.5. The effects of motion-correction on visual image quality 
is shown in Figure 5.6. 
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Figure 5.5.  Motion correction of physiological mid RCA motion. 
In a 60-year-old female the systolic excursion of the tricuspid annular plane led to 
displacement of the PET signal during the cardiac cycle (zoomed area of interest in 
blue squares). The difference in the shift of PET from reference is shown on the end-
systolic (top-right) and late-diastolic (mid right) images. Green arrows represent the 
vectors of mid RCA motion. By co-registration of all PET data to the reference end-
diastolic gate the final motion corrected image is corrected for the 14mm mid RCA 
motion (bottom-right). 
 
Figure 5.6. Fused PET-CTA images before and after motion-correction. 
An example of a PET-positive lesion in the right coronary artery (arrows) using the 
diastolic (A), summed (B) and motion-corrected (C) PET data.  
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5.4.4.1 Signal to Noise Ratio.   
Motion-correction was performed in all cases using 10 cardiac gates and the optimized 
reconstruction parameters: time of flight and resolution recovery, 4 iterations, 24 
subsets, 5-mm post-filtering and 256x256 matrix size. Compared to the original 
diastolic gate (15.7 [12.4-18.1]), motion-correction led to a significant improvement 
in SNR for PET-positive lesions (n=33; 24.5 [19.9-31.5]; p<0.001). Further, motion-
correction also increased SNR when compared with the summed data (22.1 [18.9-29.2] 
versus 24.5 [19.9-31.5], p<0.001).  
When analysing PET-negative reference lesions, there was an increase in SNR 
following motion-correction when compared to the diastolic gate (n=23; diastolic 8.8  
[7.2-11.3] versus 13.0 [11.2-15.7] p<0.001), but no significant difference between the 
summed and MC data (summed 13.3 [10.6-16.7] versus 13.0 [11.2-15.7] p=0.648).  
Background noise was higher in the diastolic (0.12 [0.10-0.19]) compared to motion-
corrected (0.08 [0.06-0.09]; p<0.001) data. There was no significant difference in 
background noise between the summed (0.07 [0.06-0.10]) and motion-corrected data 
(0.08 [0.06-0.09]; p=0.59; Figure 5.7). Motion-correction led to an improvement in the 
absolute difference between PET-positive culprit and PET-negative reference lesions 
compared to the diastolic gate (10.9 [6.3-12.6] versus 6.2 [3.6-10.3], p<0.001) and 
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Figure 5.7. Image noise and signal-to-noise ratio (SNR) in diastolic, summed and motion-
corrected data. 
(A) The median noise improves from 0.12 in the diastolic data to 0.08 following 
motion correction (median; p<0.001) and (B) Signal-to-Noise Ratio (SNR) before and 
after motion-correction. Median SNR for the motion-corrected data was highest in the 
positive lesions (n=33), and similar to SNR of the summed data for negative lesions 
(n=23). 
 
5.4.4.2 Tissue to Background Ratio.   
Tissue-to-background ratios for PET-positive lesions were higher in the original 
diastolic (2.1 [1.8-2.4]) versus motion-corrected image (1.8 [1.6-2.1]); p<0.001) and 
higher in the motion-corrected than summed image (1.8 [1.6-2.1] versus 1.6 [1.4-1.9]; 
p<0.0001). For PET-negative lesions, TBR was also higher in the original diastolic 
(1.4 [1.1-1.7]) versus motion-corrected image (1.2 [0.9-1.4]; p=0.002) and lower in 
the summed (1.1 [0.9-1.2]) versus motion-corrected image (1.2 [0.9-1.4]; p=0.014]).   
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5.4.4.3 Standardized Uptake Value.  
For PET-positive lesions, SUVmax was higher in the diastolic image (1.9 [1.7-2.5]) 
versus motion-corrected (1.8 [1.4-2.1]; p<0.001). When compared to the summed, 
non-gated data, SUVmax was higher following motion-correction (1.6 [1.3-1.92] 
versus 1.8 [1.4-2.1]; p<0.001). For PET-negative lesions, SUVmax was higher in the 
diastolic image (1.40 [1.07-1.79]) versus the motion-corrected image (1.10 [0.89-
1.56]; p<0.001). There was no significant difference in SUVmax of negative lesions 
between the summed and motion-corrected data (1.06 [0.91-1.38] versus 1.10 [0.89-
1.56]; p=0.078). 
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5.5 DISCUSSION 
While potentially a promising technique to identify adverse plaque features, coronary 
PET faces many challenges which must be overcome for this imaging method to reach 
its full research and clinical potential.  An accurate and reproducible method for 
quantification is necessary to distinguish positive and negative lesions, as well as to 
allow use in monitoring disease progression and response to therapies.  In this study, 
we have evaluated the effect of a variety of reconstruction methods on quantitative 
coronary PET and have subsequently demonstrated improved discrimination between 
positive and negative lesions following the application of cardiac motion-correction. 
We have demonstrated that, while more iterations and no post-filtering results in 
higher SUVmax and TBR values, these images are excessively noisy and difficult to 
interpret.  Similarly, although end-diastolic images may demonstrate higher SUVmax 
and TBR as compared to summed or motion-corrected images, these images are of 
poorer visual quality with lower SNR values. Moreover, plaque lesions without visible 
radiotracer uptake often demonstrate higher SUVmax and TBR values in the end-
diastolic images, which likely represents the noisier character of these data rather than 
a true increase in PET signal. (188, 189) Thus, while TBR is used to provide useful 
information with regards to biological activity of atherosclerosis within the peripheral, 
carotid and coronary arteries, (58, 190-193) TBR and SUVmax may not be the most 
suitable parameters for assessing the optimal method of coronary PET reconstruction. 
Instead, SNR assessments capture both the signal intensity and the surrounding noise, 
improving the ability to discriminate between active and inactive disease, thereby 
potentially improving the overall specificity and reliability of the test. Indeed, while 
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we also observed a small increase in SNR for negative lesions following motion-
correction, the difference between positive and negative lesions in each patient also 
increased, suggesting improved discrimination between active and inactive plaques.  
Similar to previous reports, the majority (81%) of patients had evidence of increased 
18F-fluoride activity following an acute event, and sites of 18F-fluoride uptake 
corresponded to regions of severe disease on invasive angiography. (55) 
Our study highlights the marked influence of different reconstruction parameters on 
PET quantification of coronary uptake. A recent report highlighted that details of the 
reconstruction algorithm used were not documented in one third of published PET 
studies. (194) As this imaging modality continues to evolve and become more widely 
adopted, standardization of imaging protocols is of extreme importance in drawing 
meaningful conclusions from quantitative PET results. Even small changes in imaging 
protocols may markedly influence results. The choice of the reconstruction algorithm, 
particularly the number of iterations used as well as post-filtering have the most 
marked effect on quantification when compared to image analysis methods. Indeed, 
acquisition protocols have been shown to lead to variations in SUV up to a factor of 
three. (194) In a recent report, it was highlighted that increasing the number of 
iterations reduced bias in SUV measurements and OSEM with at least 120 
maximization equivalent iterations and no post-filtering was recommended. (194)  
However, the majority of studies have considered large-calibre stationary vessels such 
as the aorta and carotid arteries, which are less subject to motion than the coronary 
arteries. (195) In order to optimize the research and clinical potential of 18F-fluoride 
PET, there must be a balance between recovering ‘true’ lesion activity while 
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maintaining image quality for the clinician or researcher interpreting the study. Thus, 
reducing noise by applying smoothing is necessary to improve visual image quality 
when interpreting coronary PET. In our results, image noise was lowest and visual 
quality highest in the reconstruction using 4 iterations (4x24subsets=96 image 
updates) and 5-mm post-filtering.  
We have recently demonstrated that the application of level-set-based nonlinear PET 
registration improves PET image quality and quantification in a small cohort of 
patients with acute coronary syndrome. (149) This study adds to these initial findings 
by focusing on further optimization of image reconstruction and applying a new and 
improved motion correction approach which produces smoother deformation fields 
and better noise characteristics compared to our initial study. (150) The refined motion 
correction method is now integrated within image analysis software, facilitating 
automation of results within the research and clinical setting.  
We recognize that there are limitations to our study. Firstly, we did not apply 
corrections for partial volume effects in our patient population. The impact of partial 
volume effects on PET quantification in this study is uncertain without precise 
quantification of lesion size. It is likely that partial volume effects would decrease with 
higher resolution provided by increasing number of iterations, however, further 
increases beyond a maximum resolution would increase noise without improving 
spatial resolution. (75) Future studies should consider investigating the effects of 
partial volume correction on PET quantification. Secondly, we did not apply dual 
cardio-respiratory motion to our patient population. Although the effects of cardiac 
contraction exceed that of respiration with regards to displacement of the coronaries 
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(cardiac contraction displaces the coronary arteries 8-26mm during the cardiac cycle, 
while normal respiration leads to movement of the heart of approximately 6-13mm),  
(195) the development and integration of novel methods to allow dual cardio-
respiratory motion correction will likely lead to further improvements in signal-to-
noise ratio in future studies. This will require innovative dual cardio-respiratory gating 
and dual correction approaches which do not rely upon segmentation of the 
myocardium (due to low myocardial uptake of 18F-fluoride) and therefore overcome 
difficulties relating to the lack of anatomical landmarks to reference motion within the 
vicinity of the heart.  
In this study, we investigated the influence of time of flight and resolution recovery in 
combination and did not measure the incremental effects of each feature in isolation. 
Prior studies have, however, demonstrated that both parameters in combination 
provide optimal results when compared to each feature individually. (196, 197) 
Moreover, we evaluated performance on only one scanner platform under a fixed 
acquisition protocol and the optimal reconstruction settings will likely be different for 
other vendors, injected activities, and scan durations. Further, our study involved only 
rigid alignment between PET and CTA using a whole heart approach, which may lead 
to modest inaccuracies in precise PET-CTA fusion. The research software developed 
at our institution provides the ability to save rigid registration and regions of interest 
and load the same registration and measurements on multiple studies. This therefore 
provides an accurate method for quantification and direct comparison between 
multiple reconstructions, minimizing variation in plaque measurements. Fully 
automated registration between CTA and PET would further improve this process and 
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may enable patients to undergo initial clinical coronary CTA before proceeding to 
PET-CTA, thereby improving clinical workflow.  
While the number of patients in our study population is small, we have demonstrated 
significant differences between different reconstruction parameters and following the 
application of motion-correction.  Although this suggests an improvement in 
diagnostic capability, results from prospective clinical trials are required to explore the 
relationship between coronary 18F-fluoride PET activity and future risk of cardiac 
events, and define thresholds associated with increased risk. While this was not a focus 
of our study, a large multicentre trial is currently seeking to answer this question 
(NCT02278211). Finally, although our study focused on 18F-fluoride, this motion-
correction method would be applicable to other PET tracers exploring alternative 
pathophysiological processes within the coronary arterial system.  
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5.6 CONCLUSION 
In conclusion, the number of iterations and extent of post-filtering in 18F-fluoride PET 
reconstruction has marked effects on quantitation and should be considered when 
using coronary PET. Motion-correction, using a diffeomorphic mass-preserving 
registration algorithm driven by anatomical framework from coronary CTA improved 
signal to noise ratio in active culprit plaques, and improves discrimination between 
active and reference coronary lesions. 
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Chapter 6 Computed Tomography Aortic Valve 
Calcium Scoring for the Assessment of 
Aortic Stenosis Progression 
6.1 SUMMARY 
Background 
Computed tomography quantification of aortic valve calcification (CT-AVC) is useful 
in the assessment of aortic stenosis severity. Our objective was to assess its ability to 
track aortic stenosis progression compared with echocardiography.  
Methods 
Subjects were recruited in two cohorts; 1) a reproducibility cohort where patients 
underwent repeat CT-AVC or echocardiography within four weeks and 2) a disease 
progression cohort where patients underwent annual CT-AVC and/or 
echocardiography. Cohen’s d statistic was computed from the ratio of annualized 
progression and measurement repeatability and used to estimate group sizes required 
to detect annualized changes in CT-AVC and echocardiography.  
Results 
A total of 33 (age 71±8) and 81 participants (age 72±8) were recruited to the 
reproducibility and progression cohorts respectively. Ten CT scans (16%) were 
excluded from the progression cohort due to non-diagnostic image quality. Scan-
rescan reproducibility was excellent for CT-AVC (limits of agreement -12-10 %, 
intraclass correlation [ICC] 0.99), peak velocity (-7-17%; ICC 0.92) mean gradient (-
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25-27%, ICC 0.96) and dimensionless index (-11-15%; ICC 0.98). Repeat 
measurements of aortic valve area (AVA) were less reliable (-44-28%, ICC 0.85).  
CT-AVC progressed by 152 [65-375] AU/year. For echocardiography, the median 
annual change in peak velocity was 0.1 [0.0-0.3] ms-1/year, mean gradient 2 [0–4] 
mmHg/year and AVA -0.1 [-0.2-0.0] cm2/yr. Cohen’s d statistic was more than double 
for CT-AVC (d=3.12) than each echocardiographic measure (peak velocity d=0.71 ; 
mean gradient d=0.66; AVA d=0.59, dimensionless index d=1.41).  
Conclusion 
CT-AVC is reproducible and demonstrates larger increases over time normalized to 
measurement repeatability compared to echocardiographic measures.  
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6.2 INTRODUCTION 
Aortic stenosis represents a major cause of morbidity and mortality, the burden of 
which is set to increase.  Currently the only definitive treatment is surgical or 
transcatheter aortic valve replacement in patients with severe symptomatic stenosis. 
Aortic valve narrowing progresses inexorably but at a variable and unpredictable rate 
in individual patients. Frequent echocardiographic follow-up is therefore mandated to 
determine the optimal timing for intervention. (98)  
The clinical assessment of aortic stenosis severity is based upon two-dimensional 
echocardiography and Doppler, with measurement of the peak jet velocity, mean 
gradient and aortic valve area frequently used to guide severity assessment. (98) 
However, the measurement of disease progression by echocardiography is challenged 
by small changes in these markers of haemodynamic severity over time, combined 
with a relatively high degree of variability between measurements. (103, 198) A 
complementary imaging technique capable of providing improved reproducibility and 
sensitivity to change is therefore desirable.  This is of importance in the clinical setting 
for accurate tracking of disease progression, and also in the research arena, where 
imaging endpoints are increasingly being utilized to assess the effects of novel 
therapies on aortic stenosis progression.  
Quantification of aortic valve calcification by non-contrast computed tomography 
(CT-AVC) has demonstrated promise in accurately defining the valvular calcification 
burden, with sex-specific thresholds demonstrating good diagnostic accuracy 
compared to concordant echocardiography and providing incremental prognostic 
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information. (107, 199) In this study, our objective was to assess the ability of CT-
AVC to monitor aortic stenosis progression compared to echocardiographic 
assessments. We investigated scan-rescan reproducibility and annual progression of 
both CT-AVC and echocardiographic measurements in a large prospective cohort of 
patients with aortic stenosis.  
6.3 METHODS 
6.3.1 STUDY POPULATION 
Participants aged >50 years attending the outpatient department of the Edinburgh 
Heart Centre with aortic stenosis (peak aortic jet velocity >2 m/s) were recruited into 
two cohorts as part of a previously reported study (NCT01358513) and an ongoing 
clinical trial (NCT02132026). (60, 200, 201) In the reproducibility cohort, participants 
underwent repeat echocardiography or CT-AVC scanning within 4 weeks. In the 
disease progression cohort, participants underwent either repeat echocardiography, 
CT or both after at least one year. The study was approved by the Scottish Research 
Ethics Committee and performed in accordance with the Declaration of Helsinki. All 
patients provided written informed consent.  This research was undertaken without 
patient involvement.  Patients were not invited to comment on the study design and 
were not consulted to interpret the results or contribute to writing or editing of this 
document for readability or accuracy. 
                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 149 
6.3.2 BASELINE ASSESSMENT 
All participants underwent a comprehensive baseline clinical assessment. 
Echocardiography was performed by an experienced echocardiographer (AW) using a 
pre-specified protocol according to European Society of Echocardiography guidelines 
(202) on the same scanner of a British Society of Echocardiography accredited 
laboratory. Multiple acoustic windows were assessed with the S51 and D2cwc probes 
(Philips Medical Systems, the Netherlands). Aortic stenosis severity was assessed on 
the basis of the peak velocity, mean gradient, aortic valve area (AVA; calculated using 
the continuity equation) and dimensionless index (DI; defined as  left ventricular 
outflow tract [LVOT] peak velocity divided by aortic peak velocity) according to 
American Heart Association and American College of Cardiology guidelines. (203)  
To measure CT-AVC, an electrocardiogram (ECG)-gated non-contrast CT scan was 
performed during inspiration on a 128 multidetector scanner (Biograph mCT Siemens, 
40 mA/rot tube voltage 100 kV, tube current selected using automatic exposure 
control). (54, 60) In the absence of contraindications, participants were administered 
beta-blockade to achieve a resting heart rate ≤65 bpm. Images were reconstructed in 
the transverse plane with 3 mm slice width and 1.5 mm increment.  Valvular 
calcification was quantified by the Agatston method (31) using dedicated analysis 
software (Vitrea Advanced, Vital Images, Minnetonka, USA; Supplementary Figure 
1).  Care was taken to exclude calcium from extra-valvular structures such as the mitral 
valve annulus and coronary arteries.  When confluent calcium extended into the 
ascending aorta, the origin of the left coronary artery was set as the most rostral slice 
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beyond which further calcium was excluded.  (107, 204) The aortic valve calcium 
burden was expressed as CT-AVC in Agatston Units (AU).  
6.3.3 SCAN RE-SCAN REPRODUCIBILITY 
The reproducibility cohort consisted of two groups of participants with aortic stenosis 
who underwent either repeat CT-AVC scoring or echocardiographic assessment of 
their valve.  In one group, CT was performed at baseline and again within 4 weeks. 
Scan-rescan reproducibility was determined for CT-AVC measurements. In a second 
group, patients underwent two echocardiographic assessments during the same visit, 
using the same scanner on the same bed and in the same room by two accredited 
echocardiographers (AW, JA) blinded to each other’s assessment. Scan-rescan 
reproducibility was determined for haemodynamic measures of stenosis severity (peak 
velocity, mean gradient, AVA and DI). 
6.3.4 ASSESSMENT OF DISEASE PROGRESSION 
Participants in the disease progression cohort returned for repeat clinical assessment 
and echocardiography at 1 and 2 years as well as repeat CT at either 1 or 2-years. (61) 
The same scanner and imaging protocol was used for all CT scans and 
echocardiograms were performed by the same echocardiographer (AW) using the 
same scanner. To assess disease progression, annualized differences in each measure 
of stenosis severity were calculated.  In participants who underwent three 
echocardiograms (baseline, 1 and 2 years), a line of best fit was used to determine 
annualized progression. Finally, Cohen’s d statistic was calculated for CT-AVC and 
each echocardiographic assessment (peak velocity, mean gradient, AVA, DI) to 
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express the magnitude of progression normalized by the uncertainty in the 
measurement technique. This was calculated by dividing the annualized progression 
by the measurement repeatability, defined as (1/√2) of the standard deviation of the 
differences between measurements at scan and rescan.  (205) 
6.3.5 GROUP SIZE ANALYSIS 
Power analysis was performed to determine group sizes needed to detect changes in 
CT-AVC and echocardiographic parameters in a hypothetical clinical trial.  To 
determine the group size needed to detect changes after a therapeutic intervention in a 
single group, power analyses were based on paired t-tests.  The annualized progression 
and measurement repeatability for each modality were used to compute the effect size 
and subsequently group sizes required to detect i) disease progression using CT-AVC 
and each echocardiography measure and ii) sample sizes needed to detect treatment 
effects on disease progression using the different modalities.  Treatment effects of 30, 
20 and 10% of the annualized progression values measured in the progression group 
were considered. Group sizes were estimated for powers of 70, 80 and 90% and an 
error probability (α) of 0.05.  Analysis was carried out using G-power software. (206) 
6.3.6 STATISTICAL METHODS 
Continuous variables were expressed as either mean ± standard deviation or median 
[interquartile range] depending on normality. Parametric (unpaired Student’s t-test) 
and non-parametric (Mann-Whitney U) tests were used for independent variables as 
appropriate. Categorical data were presented as n (%) and compared when appropriate 
using a contingency table and Fisher’s or Chi-squared tests. Reproducibility was 
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assessed using Bland-Altman analysis and intra-class correlation (ICC). Correlation 
between continuous variables was assessed with linear regression analysis and either 
Pearson’s r or Spearman’s Rho subject to normality.  Annualized rates of progression 
were calculated using the difference between two time-points (CT-AVC) or regression 
analysis over three time-points (echocardiography).  Statistical significance was 
defined as two-sided p<0.05.   
6.4 RESULTS 
6.4.1 STUDY POPULATION 
Thirty-three participants comprised the reproducibility cohort (aged 71±8, 68% male). 
Eighteen participants underwent two echocardiograms (aged 70±8, 67% male, Table 
6.1) and fifteen underwent two CT scans (aged 73±7, 67% male, Table 1). A total of 
81 participants were enrolled in the disease progression cohort (aged 72±8%, 69% 
male, Table 6.1). Of these, 71 underwent repeat echocardiography and 61 underwent 
repeat CT-AVC.  Ten CT scans were excluded due to suboptimal image quality, 
leaving 51 included in the analysis. There was a high prevalence of cardiovascular risk 
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Table 6.1. Baseline characteristics 











Number  18 15 81 71 51 
      
Age (years) 70±8 73±7 72±8 72±8.2 73±7 
Male 12 (67) 10 (67) 55 (69) 50 (70) 34 (67) 
Body Mass Index 
(kg/m2) 
30±4 30±6 29±5 28±4 28±4 
Systolic Blood  
Pressure (mmHg) 
152±20 151±18 146±20 144±18 143±17 
Co-morbidity      
Diabetes Mellitus 4 (22) 4 (27) 15 (18) 13 (18) 9 (18) 
Hypertension 13 (72) 11 (73) 60 (74) 50 (70) 36 (70) 
Documented CAD 9 (50) 6 (40) 33 (41) 31 (44) 26 (51) 
Current smoker 8 (44) 6 (40) 9 (11) 8 (11) 5 (9) 
Serum Creatinine 
(mg/dL) 
0.89±0.23 0.70±0.11 1.01±0.31 1.00±0.30 0.98±0.28 
Medications      
ACE inhibitors 8 (44) 6 (40) 32 (40) 27 (38) 20 (39) 
AIIRB 4 (22) 3 (20) 11 (13) 9 (13) 7 (13) 
Beta Blockers 7 (39) 7 (47)  33 (41) 30 (43) 23 (45) 
Statins 14 (78) 9 (60) 54 (66) 46 (64) 34 (67) 
Baseline Echocardiographic Assessment 
AV jet velocity  
(m/s) 
3.5 [3.2-4.0] 3.3 [3.0-3.8] 3.4 [2.8-4.1] 3.3 [2.7-3.9] 3.0 [2.5-
3.6] 
AV mean gradient 
(mmHg) 
25 [21-31] 24 [22-30] 25 [16-36] 24 [14-32] 21 [13-25] 
AV area  
(cm2) 


























Mean±SD, median [IQR] and number (percentage). Abbreviations: ACE, angiotensin 
converting enzyme; AIIRB, angiotensin 2 receptor antagonists; AS, aortic stenosis; AV, aortic 
valve; CAD, coronary artery disease; AU, Agatston units; LV, left ventricle; LVH, left 
ventricular hypertrophy. 
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6.4.2 REPRODUCIBILITY COHORT 
Within the reproducibility cohort (n=33), 15 patients underwent two non-contrast CT 
scans within 3.9±3.3 weeks. Scan-rescan reproducibility for CT-AVC was excellent, 
without fixed or proportional bias (mean difference -1% [limits of agreement -12 to 
10%], ICC 0.99;Table 6.2, Figure 6.1). Measurement variability for CT-AVC was 49 
AU, or 4.2% when normalised to the median CT-AVC at baseline. Intra-observer 
(median CT-AVC 1178 AU, mean difference 1% [limits of agreement 9 to -11%], ICC 
0.99) and inter-observer (median CT-AVC 1207 AU, mean difference 0% [limits of 
agreement -5 to 6%], ICC 0.99) reproducibility were also excellent. Scan-rescan 
reproducibility was also assessed with two observers and demonstrated good 
reproducibility (ICC 1.00 (0.99-1.00) mean difference 2.57% (44 AU) and limits of 
agreement -27.5- 22.4%.(Figure 6.2). 
Eighteen patients underwent two echocardiograms during a single study visit. Scan-
rescan reproducibility was excellent for peak velocity (mean difference 5%; limits of 
agreement -7 to 17%; ICC 0.96; measurement repeatability 4.0%; ICC 0.96) and DI 
(mean difference -1.7%; limits of agreement -11.1-14.5%; ICC 0.98; measurement 
repeatability 3.3%). Reproducibility was also good for mean gradient (mean difference 
1%; limits of agreement -25-27%; ICC 0.97; measurement repeatability 12.0%; ICC 
0.97) but less reliable in the assessment of AVA (mean difference -8%; limits of 
agreement -44 to 28%;ICC 0.85, measurement repeatability 15.5%;Table 6.2). 
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Table 6.2 Reproducibility of CT-AVC and echocardiography assessments of aortic stenosis 
severity. 
 Bias, %  
(95% limits of 
agreement) 
Bias, units  
(SD of difference 







(95% limit of 
agreement) 














0 (-5 – 6) 11 (65) - 0.99 (0.99 – 
1.00) 
 Echocardiography, scan-rescan  




1 (-25 – 27) 0.28 (4.3) 3.0 (12.0%) 0.97 (0.91 – 
0.99) 




-2(-11-15) 0.01(0.02) 0.01(3.3%) 0.98(0.95-
0.99) 
Mean±SD, median [IQR].  Abbreviations: AV: aortic valve; AU: Agatston units 
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Figure 6.1. Scan-rescan reproducibility of CT-AVC and echocardiography assessments of 
aortic stenosis severity. 
Bland-Altman plots displaying the scan rescan reproducibility of aortic stenosis 
severity measurements on serial CT-AVC (3.9±3.3 weeks) and echocardiography (1±0 
days). VTI, velocity time integral. 
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Figure 6.2. Scan-rescan reproducibility of CT-AVC using a different observer for each scan.  
Scan-rescan reproducibility was also assessed with two different observers and 
demonstrated good reproducibility (ICC 1.00 (0.99-1.00) mean difference 2.57% (44 
AU) and limits of agreement -27.5- 22.4%. 
 
6.4.3 CT-AVC AND AORTIC STENOSIS SEVERITY 
At baseline, CT-AVC correlated with all echocardiographic measures (Table 6.3). The 
closest associations were observed with peak velocity (r=0.75 [95% CI 0.63 to 0.84], 
p<0.001) and mean gradient (r=0.75 [0.64 to 0.83], p<0.001) and the weakest with 
AVA (r=-0.46 [-0.61 to -0.25], p<0.001).  
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Table 6.3. Correlation between CT-AVC and echocardiographic measures of aortic stenosis 
severity.  
Pearson’s correlations between square-root transformed computed tomography 
calcium scores (CT-AVC) and echocardiographic indices.  R values (95% confidence 
intervals) are shown. 
 CT-AVC 
(AU) 











(0.63 to 0.84) 
P<0.001 
0.75 
(0.64 to 0.83) 
P<0.001 
-0.46 










(0.96 to 0.98) 
P<0.001 
-0.66 






(0.64 to 0.83) 
P<0.001 
0.97 










(-0.61 to 0.25) 
P<0.001 
-0.66 
(-0.76 to -0.53) 
P<0.001 
-0.71 
(-0.79 - -0.59) 
P<0.001 
 
Abbreviations: AVC, aortic valve calcium; CE, continuity equation. 
 
6.4.4 PATIENT FOLLOW-UP 
During the 2-year follow-up period, (736 [722–760] days), 61 participants (75%) 
underwent repeat CT (13 at 1 year and 48 at 2 years).  Images were non-interpretable 
in 10 participants (16%) due to motion artefact and were excluded, predominantly in 
those in whom beta-blockers were contra-indicated. Follow-up echocardiography was 
performed in 71 participants at 1 year and 62 at 2 years. No echocardiography scans 
were excluded from analysis.  
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6.4.5 AORTIC STENOSIS DISEASE PROGRESSION 
Across all patients, modest progression in each echocardiographic measure of severity 
was observed (D peak velocity 0.1 [0.0-0.3] ms-1/year; D mean gradient 2 [0–4] 
mmHg/year; D AVA -0.1 [-0.2-0.0), DDI 0.02 [-0.04 to -0.01]; Figure 6.3, Table 6.4). 
When patients were divided into mild, moderate and severe aortic stenosis, those in 
the moderate group demonstrated the clearest evidence of disease progression (n=30, 
D peak velocity 0.2 [0.1-0.3] ms-1/year; D mean gradient 3 [1–5] mmHg/year; Table 
6.4).  
Across the cohort as a whole, CT-AVC progressed by 152 [65-375] AU/year, with the 
most rapid rates of progression observed in participants with the most severe disease 
(D CT-AVC; mild AS 64 [48-134] AU/year, moderate AS 289 [106-443] AU/year, 
severe AS 342 [163-583] AU/year) (Figure 6.3, Table 6.4).  
The Cohen’s d-statistic (d) was calculated by dividing the overall annualized rate of 
change in each severity measure by the measurement repeatability (Table 6.4) By this 
method, CT-AVC displayed a greater progression to measurement repeatability ratio 
(CT-AVC: d = 3.12) when compared to each echocardiographic parameter (peak 
velocity: d = 0.71;  mean gradient: d = 0.66; AVA: d = 0.59; DI d=1.41). When patients 
with more advanced disease were considered, the differences between 
echocardiography and CT-AVC were greater. In participants with severe aortic 
stenosis, CT-AVC displayed a greater than six-fold higher value (d = 6.98) compared 
to echocardiographic measures (peak velocity d = 0.71; mean gradient d =1.0; AVA d 
=0.0; DI d=0.71).  In those with moderate and mild disease, the d-statistic for CT-AVC 
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remained higher when compared with echocardiographic measures of the same 
severity (Table 6.4). 
 
Figure 6.3. Aortic stenosis disease progression measured using CT-AVC and 
echocardiography. 
Annualized disease progression across each cohort using CT calcium scoring (A), peak 
aortic jet velocity (B), mean gradient (C) and aortic valve area (D). Relatively large 
annualized changes in the CT calcium score are observed compared to smaller changes 
and wide overlap in the measurements obtained by echocardiography. Dashed lines 
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Table 6.4. Disease progression on echocardiography and CT-AVC in patients with aortic 
stenosis. 







No. of patients 81 25 33 23 





























No. of patients 71 24 30 17 










D aortic jet velocity 
(%m/s/year) 
3.5 
[0.0 to 7.8] 
3.2 
[-0.7 to 6.3] 
5.0 
[2.3 to 10.2] 
3.2 
[-1.1 to 5.2] 
Cohen’s D statistic 0.71 0.71 1.43 0.71 









[0 to 5] 
D mean gradient 
(%mmHg/year) 
9.5 
[-0.5 to 17.0] 
7.5 
[-2.4 to 14.9] 
11.6 
[2.4 to 29.5] 
7.0 
[-1.7 to 13.7] 
Cohen’s D statistic 0.66 0.33 1.0 1.0 
D aortic-valve area 
(cm2/year) 
-0.1  
[-0.2 to 0.0] 
-0.1 
[-0.2 to -0.0] 
-0.1 
[-0.1 to -0.0] 
0.0 
[-0.1 to -0.0] 
D aortic-valve area 
(%cm2/year) 
-8.7 
[-14.4 to -2.9] 
-5.2 
[-13.3 to -0.6] 
-9.9 
[-15.6 to -4.8] 
-7.7 
[-15.0 to 0] 
Cohen’s D statistic 0.59 0.59 0.59 0.0 
D Dimensionless Index -0.02 [-0.04 to -
0.01] 
-0.02 [-0.04 to 
0.00] 
-0.02 [-0.04 to -
0.01] 
-0.01 [-0.02 to 
0.00] 
D Dimensionless Index 
(%/year) 
-5.7 [-11 to -2.0] -4.4 [10.0 to -
0.3] 
-6.7 [-13.6 to -
2.9] 
-5.7 [-10.3 to 
2.3] 
Cohen’s D statistic 1.41 1.41 1.41 0.71 
Baseline Computed Tomography 
No. of patients 72 23 30 19 
AV Calcium score 
(AU) 
1339 
[553 to 2422] 
489 
[281 to 693] 
1427 
[777 to 2215] 
3386 
[1770 to 6211] 
Follow-up Computed Tomography 
No. of patients 51 21 24 6 
D AV calcium score 









D AV calcium score 
(%AU / year) 
20.0 
[13.0 to 24.5] 
20.3 
[17.5 to 31.1] 
20.0 
[10.8 to 24.5] 
16.9 
[10.9-24.4] 
Cohen’s D statistic 3.12 1.30 5.90 6.98 
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Figure 6.4. Computed tomography calcium scoring and echocardiography to monitor 
disease progression in aortic stenosis.  
CT calcium scoring of the aortic valve and echocardiography in a patient at baseline 
(A-C) and one year (D-F). Baseline CT calcium scoring demonstrates CT-AVC of 
2372 AU (A), transthoracic echocardiography of the aortic valve shows calcified 
leaflets with a calcium score of 4 (B) and doppler echocardiography demonstrates a 
peak velocity of 3.77 m/s (C) at baseline. At one year, CT-AVC has increased to 2773 
(D), the aortic valve calcium score on echocardiography is graded as 4 (E) and the 
peak jet velocity has increased to 3.95 m/s (F).  
 
6.4.6 GROUP SIZE ANALYSIS 
Using the cohort-averaged progression and measurement repeatability values, the 
effect size for a matched-pairs t-test was computed for CT-AVC and each 
echocardiographic measure. The group size required to detect annualised disease 
progression for CT-AVC was smaller than for echocardiographic measures (CT-AVC: 
4, peak velocity: 33, mean gradient: 39, AVA: 48 [α = 0.05, power = 80%]).  Similarly 
the group size required to detect a treatment effect  of a new therapy (30, 20 and 10% 
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reduction in the annualized progression) was more than 10-fold smaller for CT-AVC 
than for echocardiographic measures (CT-AVC: 20, 43, 165 patients respectively; 
peak velocity: 351, 787, 3142 patients respectively; mean gradient: 403, 910, 3632 
patients respectively; AVA: 505, 1134, 4516 patients respectively [α = 0.05, power = 
80%]) (Figure 6.5). 
 
Figure 6.5. Sample sizes needed for studies of novel therapies in aortic stenosis using CT-
AVC to assess their effect on disease progression. 
The number of participants required in a study to detect a given treatment effect size 
at different levels of power are plotted.  For each modality an upper bound at 90% 
power and lower bound at 70% are plotted with α = 0.05 for all.  Nominal treatment 
effects up to 50% of the measured annualized progression for each modality are 
considered.     
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6.5 DISCUSSION 
In this study, we have investigated the utility of CT-AVC and echocardiography in 
assessing disease progression in patients with aortic stenosis. CT-AVC demonstrated 
excellent scan-rescan reproducibility.  Calculation of Cohen’s d-statistic demonstrated 
that CT-AVC had a large annualized change normalized to measurement repeatability 
compared to echocardiography, with a four-fold higher value for CT-AVC (d=3.12) 
compared to peak velocity (d=0.71). CT-AVC may therefore be a useful technique 
both in clinical practice for assessing aortic stenosis progression and as an endpoint in 
clinical trials assessing the efficacy of novel therapies.  
Given the central role of calcification in the progression of aortic stenosis, direct 
assessments of calcification hold major interest. (79) Quantification of aortic valve 
calcification has demonstrated considerable promise in a number of studies, discerning 
the presence of severe stenosis amongst patients with discordant echocardiography and 
providing powerful prognostic information. (106, 199, 207)  In this study, we have 
demonstrated excellent scan-rescan reproducibility of CT-AVC coupled with 
relatively large progression in values over time, demonstrating the feasibility and 
potential advantages of this modality for tracking aortic stenosis progression.  
Before an imaging technique can be applied to routine clinical practice, clinicians must 
be reassured that the technique is robust and reproducible. Measurement of CT-AVC 
is technically straightforward although can be complicated by motion artefact, 
particularly in patients with advanced disease, systolic dysfunction or conduction 
disease in whom administration of beta-blockade is not possible. In this study, this 
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resulted in exclusion of 16% of scans. This limitation of CT-AVC must be considered 
when deciding whether to use this test in the clinical or research settings and  certain 
patient characteristics including BMI, tachycardia or contraindications to beta 
blockade may be used to identify patients in whom CT-AVC may be unreliable.  
However, when CT-AVC is possible we have demonstrated that excellent 
reproducibility can be achieved with a consistent and standardized approach. While all 
echocardiography scans were of diagnostic quality in our study, we acknowledge that 
there is a selection bias in our patient population since participants were only recruited 
if they had clear assessments of aortic stenosis severity on clinical echocardiograms. 
In non-selective cohorts, it is estimated that 10-15% of patients have poor 
echocardiographic windows, similar to our observations for CT-AVC.  Further, 
variability in echocardiography was minimized by performing two echocardiograms 
under as consistent conditions as possible, thereby diminishing many sources of error 
encountered in clinical practice. This approach necessitated two different 
echocardiographers performing the scan to avoid recall bias.  
For echocardiography, while peak velocity and mean gradient both demonstrated good 
reproducibility, repeatability of AVA was poor, likely reflecting the multiple different 
measurements required for its calculation. Measurement of the left ventricular outflow 
tract (LVOT) diameter represents the major source of error in calculation of AVA.  By 
disregarding LVOT diameter and considering a simplified ratio of LVOT to aortic 
velocity, the dimensionless index (DI), this overcomes discrepancies in LVOT 
measurements and has proven effective in distinguishing aortic stenosis severity and 
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predicting adverse outcomes. (101, 208, 209) We have shown that this measure 
improves reproducibility when compared to AVA.   
In order to compare the utility of CT-AVC and echocardiography for tracking disease 
progression, both the magnitude of change and measurement repeatability must be 
considered. On this basis, we calculated the Cohen’s d-statistic for each modality. This 
indicated that CT-AVC appears superior to echocardiography for detecting small 
changes in disease severity over time.  Indeed, this marker was four times higher for 
CT-AVC compared to peak velocity. This may have important clinical implications 
when tracking disease progression and predicting when patients are likely to require 
valve intervention. Further research is required to assess how this approach may work 
in clinical practice, but CT-AVC is likely to be of particular value in patients whose 
heart rate can be optimised for imaging and who have poor echocardiographic 
windows or low flow states where mean gradient and peak velocity may underestimate 
disease severity.  
Our data also support a role for CT-AVC as an endpoint in research trials investigating 
the effects of novel therapies. Imaging end points are increasingly adopted for this 
purpose, and those with greater reproducibility and sensitivity to detect small changes 
in progression are likely to minimize cost and sample sizes required (SALTIRE 2 
NCT02132026). Indeed, our data suggest that >10-fold fewer patients would be 
required to detect 10, 20 and 30% treatment effects using CT-AVC (165, 43 and 20 
patients respectively) compared to peak velocity (3142, 787 and 351 patients 
respectively). While this suggests a considerable advantage in using CT-AVC, 
consideration should be placed on the frequency of non-diagnostic scans and clinical 
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characteristics for which CT-AVC may not be suitable. Indeed, the proportion of non-
interpretable CT scans must be taken into account when considering sample sizes and 
measurement repeatability. It is also important to consider that CT-AVC does not 
account for the effects of therapy on non-calcific valve thickening (i.e. fibrosis) and 
echocardiography remains the first line imaging technique to assess aortic stenosis. 
Further, another important consideration is the radiation dose associated with CT, 
although standard imaging techniques enable CT calcium scoring to be performed with 
low levels of radiation exposure (1-3 mSV). (35) 
Our study has several limitations. We acknowledge that our study numbers are small 
and in the reproducibility cohort different patients underwent repeat CT-AVC to those 
undergoing repeat echocardiography. While the characteristics of both patient groups 
were similar, we cannot rule out the possibility of confounding variables and recognise 
this as a limitation of our study. Our study findings should therefore be confirmed in 
larger studies with direct comparisons of reproducibility and disease progression for 
echo and CT-AVC within the same population. Further, we assessed annualised 
changes in disease severity in all patients who underwent follow-up beyond one year. 
This assumes linear disease progression and therefore does not take into account a 
more rapid rise in disease progression as severity increases, although this is consistent 
with other studies investigating disease progression in aortic stenosis. (110, 210)  
6.6  CONCLUSION 
CT-AVC is a robust and reproducible imaging technique that holds major promise as 
a method for tracking disease progression in aortic stenosis.  
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Chapter 7 Motion-Corrected Imaging of the Aortic 
Valve with 18F-fluoride PET-CT and 
PET-MR: A Feasibility Study. 
7.1 SUMMARY  
Introduction 
We investigated whether motion correction of gated 18F-fluoride PET-CT and PET-
MR of the aortic valve could improve PET quantitation and image quality. 
Methods 
A diffeomorphic, mass-preserving, anatomy-guided registration algorithm was used to 
align PET images from 4 cardiac gates, preserving all counts, and applied to PET-MR 
and PET-CT data of six patients with aortic stenosis. Measured Signal-to-Noise Ratios 
(SNRs) and Tissue-to-Background Ratios (TBRs) were compared with the standard 
method of utilizing only the diastolic gate.  
Results 
High-intensity 18F-fluoride uptake was observed in the aortic valve of all 6 patients. 
Following motion correction, SNR and TBR increased compared to the diastolic gate 
(SNR 51.61 vs 21.0; TBR 2.85 vs 2.22) and summed data (SNR 51.61 vs 34.10, 
p=0.028; TBR 2.85 vs 1.95, median, p=0.028 for all).  Furthermore, noise decreased 
from 0.105 (median, diastolic) to 0.042 (median, motion-corrected [p=0.028]).  
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Conclusion 
Motion-corrected 18F-fluoride PET-CT and PET-MR imaging markedly improves 
SNR, resulting in improved image quality.  
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7.2 INTRODUCTION 
Aortic stenosis is the commonest form of valve disease in the western world and is set 
to increase rapidly with an aging population.  (79, 80) Recently, interest has developed 
in the potential role of 18F-fluoride Positron Emission Tomography (PET) for the 
assessment of disease activity, the prediction of disease progression and as an end point 
in clinical trials investigating novel therapies. (61, 79) 
Combined PET Computed Tomography (PET-CT) and PET Magnetic Resonance 
(PET-MR) each possess unique attributes suited to the assessment of aortic stenosis. 
PET-CT provides detailed anatomical information with respect to valve morphology 
and calcification, whilst PET-MR informs about the hypertrophic response of the left 
ventricle, myocardial fibrosis and the transition to heart failure. (211)  
A major challenge faced in PET-CT and PET-MR imaging of the heart is the impact 
of cardiac, respiratory and gross patient movement on PET image quality. Prior 18F-
fluoride PET-CT studies have utilized data reconstructed from the diastolic gate (25% 
of the cardiac cycle) to avoid blurring from cardiac motion, but at the expense of 
increased image noise. (55, 120)We have developed a novel software cardiac motion 
correction method which allows the use of data from the full cardiac cycle. This 
enhances image quality and quantitation in the coronary arteries while reducing noise. 
(149) To our knowledge, this approach has not yet been applied to patients with 
valvular heart disease nor PET-MR imaging. In this dual centre study, we report the 
use of multimodality motion correction in hybrid PET-CT and PET-MR in a group of 
patients with aortic stenosis.   
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7.3 METHODS 
7.3.1 STUDY POPULATION 
7.3.1.1 PET-CT 
Patients with aortic stenosis were recruited prospectively from outpatient clinics at the 
Edinburgh Heart Centre as part of the ongoing SALTIRE 2 clinical trial 
(NCT02132026). The study was approved by the local research ethics committee in 
accordance with the declaration of Helsinki and all patients provided written informed 
consent.  
7.3.1.2 PET-MR 
A 60-year-old asymptomatic male was prospectively recruited as part of an ongoing 
research study. The study was approved by the IRB and the patient provided written 
informed consent for use of the data.  
7.3.2 IMAGE ACQUISITION AND ANALYSIS 
7.3.2.1 PET-MR 
The PET-MR protocol involved PET acquisition in list mode for 40-60 min, with 
concurrent MR acquisitions to assess the myocardium comprehensively (Biograph 
mMR scanner, Siemens). These included standard cine views to evaluate left 
ventricular function, contrast-enhanced MR angiography (MRA) acquired in diastole, 
late gadolinium enhancement for assessment of midwall fibrosis or infarction  (212, 
213) and a new interleaved T1-weighted sequence (‘CATCH’). (214) The pre-contrast 
CATCH sequence facilitates acquisition of a dark-blood T1-weighted image in one 
heartbeat followed by an anatomical bright-blood reference in the next; post-
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reconstruction, a hyper-intense signal has been shown to correspond to potential intra-
plaque haemorrhage. (214) 
For PET-MR imaging, 212 MBq of 18F-fluoride was injected and MR image 
acquisition began 20 min later.  PET acquisition began one hour post injection and was 
performed in list mode for over 60 min. Dixon-based MR images for water and fat 
were used for attenuation correction using the standard method provided on the 
scanner.  
7.3.2.2 PET-CT 
125 MBq of 18F-fluoride was administered intravenously and patients were 
subsequently rested in a quiet environment. After 60 min, image acquisition was 
performed using a hybrid PET-CT scanner (Biograph mCT; Siemens). Attenuation-
correction CT scans were performed before acquisition of PET data in list mode using 
a single 30-min bed position centred on the valve in 3-dimensional mode. Finally, 
prospectively ECG-gated contrast-enhanced CT angiography was performed in end-
expiration. Patients were given 25 mg of oral metoprolol if their resting heart rate was 
>65 beats/min. 
For both PET-MR and PET-CT, PET images were reconstructed using a standard 
iterative Ordered Subsets Expectation Maximization (OSEM) algorithm with High 
Definition resolution recovery (215), using 4 cardiac gates. 
7.3.3 CARDIAC MOTION CORRECTION 
Cardiac motion correction was performed using an anatomically guided automated 
registration algorithm, similar to our method previously described. (74, 149) First, a 
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three-dimensional sphere was drawn to define the aortic valve region.  A non-linear 
registration algorithm used was a diffeomorphic mass-preserving, anatomy-guided 
Demons method which optimises the global energy between PET frames; with built-
in optimisation for anatomical data. (150, 186, 216) The motion corrected gates were 
then summed to form a motion-free image  (74) containing all the PET counts. The 
motion correction procedure required approximately 10 min per patient. PET 
quantification was performed by delimiting 3-dimensional regions-of-interest on fused 
PET-MR angiography and PET-CT angiography using FusionQuant software (Cedars-
Sinai Medical Center, Los Angeles, CA). For each PET-CT subject, rigid registration 
was performed between the PET data and CTA on the transverse, sagittal and coronal 
planes using CTA data from the most optimal diastolic phase. For the PET-MR 
subject, MR angiography was acquired during a single diastolic phase and this image 
was similarly fused and manually registered with the PET data. Background blood 
pool activity was measured in the right atrium using mean standardised uptake values 
from 3-dimensional spherical volumes. Maximum uptake in the aortic valve was 
computed by creating a sphere-shaped volume of interest through the aortic valve after 
re-orientation of the image into the aortic valve plane. (120) Signal to noise ratio 
(defined as the maximum uptake in the aortic valve divided by the image noise; SNR) 
and Tissue-to-Background Ratio (defined as the maximum uptake in the aortic valve 
divided by the mean standardised uptake value of the blood pool; TBR) were computed 
in the motion-corrected image, summed image and in the original diastolic gate. PET 
image noise was calculated as the standard deviation of the blood pool measurement.  
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7.3.4 STATISTICAL ANALYSIS  
Statistical analyses were performed with SPSS (SPSS version 22, IBM corp). 
Continuous variables are expressed as mean ± standard deviation. The Shapiro-Wilk 
test was used to assess normality for continuous data. Non-parametric data are 
expressed as median and interquartile range. Two-sample t-test or Wilcoxon rank-sum 
test were applied to compare groups for continuous variables. A two-sided p<0.05 was 
taken as statistically significant. 
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7.4 RESULTS 
Increased 18F-fluoride uptake in the aortic valve was observed in all six patients (Table 
7.1 and Figure 7.1 and Figure 7.2). Following motion correction, there was an increase 
in SNR and TBR when compared to the diastolic gate (SNR 51.61[32.79-61.15] vs 
21.0 [16.37-25.25]; TBR 2.85[2.45-3.84] vs 2.22 [1.94-3.29], median [IQR], p=0.028 
for all) and summed data (SNR 51.61[32.79-61.15] vs 34.10[24.36-42.54]; TBR 
2.85[2.45-3.84] vs 1.95[1.75-2.66], median[IQR], p=0.028 for all) (Figure 7.3). 
Further, there was a reduction in noise in the motion corrected image when compared 
to both the summed data 0.042[0.037-0.076] vs 0.052[0.051-0.104]) and original 
diastolic gate (0.042[0.037-0.076] vs 0.105[0.096-0.160], median[IQR] p=0.028 for 
all)  (Figure 7.4). On the PET-MR scan, detailed CMR investigation of the left 
ventricle was possible including measurements of the left ventricle mass volumes (45 
g/m2) and ejection fraction (53%) as well as late gadolinium enhancement imaging. 
The CATCH sequence was also well tolerated by the patient but did not reveal 
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Table 7.1. Baseline characteristics. 
Baseline Characteristics 
Age in years, mean (SD) 74 (9) 
Men, n (%) 4 (67) 
Body Mass Index (kg/m2), mean (SD) 27 (5) 
Past Medical History 
CABG/PCI, n (%) 2 (33) 
Previous MI, n (%) 0 
Hypercholesterolemia, n (%) 4 (67) 
Hypertension, n (%) 2 (33) 
Renal Disease, n (%) 0 
Diabetes, n (%) 2 (33) 
Medications 
ACE inhibitors/AIIRB, n (%) 3 (50) 
Beta blockers, n (%) 3 (50) 
Statin, n (%) 4 (67) 
Echocardiography 
AV jet velocity (m/sec), mean (SD) 3.23 (0.37) 







                                      Advanced Imaging in Coronary Artery Disease and Aortic Valve Disease 
 178 
  
Figure 7.1. Fused 18F-fluoride PET and contrast-enhanced MRA of the aortic valve in a 60-
year-old male with aortic stenosis. 
Images display the original diastolic gate (A), summed image (B) and motion-
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Figure 7.2. Fused PET-CTA images in a 79-year-old female with aortic stenosis. 
Images display the original diastolic gate (A&B), summed image (C&D) and motion-
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Figure 7.3. Signal-to-noise ratios (A) and tissue-to-background ratios (B) in original gate, 
summed and motion corrected data.  
 
Figure 7.4. Difference in noise between motion corrected image, original diastolic gate and 
summed image.  
While noise was higher in subjects 1 and 3, likely due to an increased body weight, 
the same trend was observed. 
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7.5 DISCUSSION 
This feasibility study represents the first analysis of multimodality cardiac motion 
correction guided by anatomical data from 18F-fluoride PET-MR and PET-CT. It also 
represents the first demonstration of hybrid PET-MR imaging in aortic stenosis which 
allows simultaneous imaging of calcification activity in the aortic valve using 18F-
fluoride PET alongside the detailed myocardial assessments provided by MR.  
In the future, this sophisticated imaging method has great clinical potential in assessing 
native aortic valve disease alongside markers of myocardial decompensation including 
midwall late gadolinium enhancement  (212) and T1 mapping. (217, 218) However, a 
limitation of PET-MR is the inability to accurately assess prosthetic valve disease due 
to the influence of metal artefact on PET attenuation and MR image quality. With the 
increasing use of Transcatheter Aortic Valve Replacement (TAVR), PET-CT is likely 
to play an important role in the assessment of aortic valve bioprostheses. Indeed, the 
role of 18F-fluoride PET-CT in assessing the longevity of TAVR valves is currently 
under investigation (NCT02304276). Here, we describe how these imaging techniques 
may be optimized with motion-corrected imaging of the aortic valve to maximize the 
research and clinical potential of hybrid cardiac imaging.  
Our study is limited by data from only a small number of patients. While this was 
sufficient to demonstrate the clear improvements in SNR and TBR values offered by 
motion correction techniques, larger studies are required for confirmation. 
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7.6 CONCLUSION 
Simultaneous motion-corrected PET imaging of the aortic valve is feasible with both 
hybrid 18F-fluoride PET-MR and PET-CT. Motion correction, using a diffeomorphic 
mass-preserving image registration algorithm improved quantitative SNR and TBR, 
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Chapter 8 Conclusions and Future Directions 
 
8.1 SUMMARY OF THESIS FINDINGS 
Despite innovative advances in investigation and management strategies, 
cardiovascular disease remains a leading cause of death worldwide. In order to 
improve outcomes, more individualised care with improved identification of those at 
greatest risk of disease progression and future events is crucial.  Technological 
advances in the non-invasive investigation of cardiovascular disease provide the 
opportunity to identify detailed features of disease burden, activity and progression 
and potentially those who may benefit from tailored therapies. Further, they provide a 
platform on which to investigate the effects of novel therapeutic interventions.   
The principal aim of this thesis was to investigate whether complementary non-
invasive imaging strategies could improve the assessment of disease burden, activity 
and progression in two leading forms of cardiovascular disease; coronary artery 
disease and aortic stenosis.   
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8.1.1 NON-INVASIVE FRACTIONAL FLOW RESERVE AND CORONARY 
PLAQUE BURDEN 
Non-invasive fractional flow reserve derived from computed tomography (FFRCT) 
can provide a surrogate measure of the haemodynamic effects of coronary stenosis.  
To investigate the effects of diffuse non-obstructive atherosclerosis, the relationship 
between whole vessel FFRCT (V-FFRCT) and quantitative plaque features on 
coronary CTA was assessed in 155 participants undergoing coronary CTA. 
Total, calcified and non-calcified plaque volume, as well as low-density plaque 
volume were each greater in vessels with an abnormal V-FFRCT. Quantitative plaque 
measures predicted an abnormal V-FFRCT, independent of the degree of arterial 
stenosis. This suggests non-invasive fractional flow reserve may provide a marker of 
diffuse non-obstructive atherosclerosis. 
8.1.2 CORONARY 18F-FLUORIDE UPTAKE AND PROGRESSION OF 
CORONARY ARTERY CALCIFICATION 
Combined PET-CT imaging of the coronary arteries has been demonstrated to identify 
microcalcification beyond the resolution of computed tomography, providing 
important insights into calcification activity within the vasculature. In this sub-study 
of the Dual Antiplatelet to Reduce Myocardial Injury (DIAMOND) trial, I investigated 
whether 18F-fluoride activity at baseline could predict the progression of coronary 
calcium score at one year.  
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Participants with increased 18F-fluoride activity demonstrated greater progression of 
coronary calcification at one year compared to those without evidence of increased 
18F-fluoride activity. When individual coronary plaques were examined, those with 
increased 18F-fluoride uptake exhibited progressive calcium deposition at one year, 
whilst plaques without 18F-fluoride activity had no increase in calcium score at one 
year. At the individual segment level, baseline 18F-fluoride activity predicted change 
in calcification at one year. However, at the patient level, these associations were not 
independent of age, sex and baseline calcium score.  These findings confirm the role 
of 18F-fluoride as a marker of disease activity in coronary atherosclerosis.  
8.1.3 OPTIMISATION OF RECONSTRUCTION AND QUANTIFICATION OF 
CORONARY PET-CT 
The application of positron emission tomography to the coronary arteries remains 
challenging as a consequence of cardiorespiratory motion and limits of spatial and 
temporal resolution. This leads to signal blurring which may impair the ability to 
distinguish ‘active’ from ‘inactive’ lesions.  In a study of patients with acute coronary 
syndrome, I evaluated quantitative coronary PET by applying different reconstruction 
algorithms to PET data. A novel motion correction method was applied to correct for 
cardiac motion. 
The signal-to-noise ratio was affected by small changes in reconstruction. The 
application of a novel cardiac motion correction method in which the entire PET 
dataset was utilised led to a reduction in noise and an improvement in discrimination 
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between positive culprit and negative reference lesions when compared to the 
technique utilised in previous studies.  
8.1.4 COMPUTED TOMOGRAPHY AORTIC VALVE CALCIUM SCORING FOR 
THE ASSESSMENT OF AORTIC STENOSIS PROGRESSION 
Aortic stenosis remains an important cause of morbidity and mortality worldwide and, 
in an ageing population, its burden is set to increase. Two-dimensional 
echocardiography is currently the gold standard imaging modality to define and track 
changes in disease severity over time. Computed tomography has recently emerged as 
a useful modality to quantify valvular calcification burden in aortic stenosis.  
In a study of patients with aortic stenosis, quantification of aortic valve calcification 
burden by computed tomography (CT-AVC) was reproducible and able to detect 
smaller changes over time when compared to haemodynamic markers of aortic 
stenosis severity measured on echocardiography. Measurement variability between 
scans was lower for CT-AVC compared to echocardiography, suggesting that this 
modality may be of value in clinical trials investigating the effects of novel therapies 
on disease progression, and in monitoring disease progression in the clinical setting. 
Important limitations of CT-AVC remain, however, and further work is required to 
improve feasibility of this modality in patients with a raised body-mass index or in 
whom rate control is contra-indicated.  
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8.1.5 MOTION-CORRECTED IMAGING OF THE AORTIC VALVE WITH 18F-
FLUORIDE PET-CT AND PET-MR: A FEASIBILITY STUDY 
Similar to imaging of the coronary arteries, utilising PET for imaging of the aortic 
valve is subject to challenges secondary to cardiorespiratory motion.  In a cohort of 
seven patients with aortic stenosis undergoing hybrid imaging with 18F-fluoride PET, 
I investigated the application of a novel cardiac motion-correction technique. 18F-
Fluoride PET-CT was performed in six participants and one participant underwent 18F-
fluoride PET-MR. The application of a novel cardiac motion correction technique led 
to a reduction in noise and an increase in the measured PET activity in the aortic valve 
of all patients, demonstrating the feasibility of this motion correction technique in 
aortic valve imaging and, for the first time, in PET-MR imaging.  
8.2 FUTURE DIRECTIONS 
The findings of this thesis lay important groundwork for future studies investigating 
novel advanced imaging techniques in coronary heart disease and aortic valve disease.  
With an expanding catalogue of novel therapies targeting multiple different aspects of 
the atherosclerotic disease process, early indicators of therapeutic efficacy and safety 
are of critical importance prior to the initiation of phase III outcome studies. Non-
invasive imaging modalities have already played a valuable role in our understanding 
of drug effects and with the advent of hybrid imaging offer comprehensive multi-
parametric assessments of drug efficacy. These approaches are likely to play an 
expanding role in the testing and development of novel therapies targeted against 
atherosclerosis and aortic stenosis. 
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8.2.1 PREDICTING RECURRENT CORONARY EVENTS USING 18F-
FLUORIDE (PREFFIR) 
Despite optimal medical therapy, one in five patients will suffer a recurrent cardiac 
event following myocardial infarction. (219) Predicting subsequent events is 
challenging and these events may arise from vessels with only mild disease at the time 
of the index event. Events arise in non-culprit vessels which had previously mild 
disease just as frequently as recurring in the original culprit vessel. (219) 
Hybrid imaging provides useful insight into biological disease activity and we have 
shown that 18F-fluoride PET-CT can detect plaques which demonstrate more rapid 
progression of calcification.  However, the relationship between 18F-fluoride uptake 
and coronary heart disease outcomes is yet unknown. Whilst attractive in the research 
setting for monitoring disease activity and progression, the clinical utility of PET-CT 
will be guided by its prognostic impact. In a recent post-hoc analysis of observational 
studies which included patients with established stable and unstable coronary artery 
disease, increased 18F-fluoride activity was associated with an increased risk of 
subsequent myocardial infarction. Using a novel measure to quantify 18F-fluoride 
activity throughout the coronary vasculature, coronary microcalcification activity 
(CMA), this study showed that participants with an elevated CMA were seven times 
more likely to suffer fatal or non-fatal myocardial infarction. 18F-fluoride activity, 
measured by TBR or CMA, was a powerful predictor of future myocardial infarction 
independent of age, comorbidities, number of coronary stents, the presence of 
multivessel disease and calcium score. (220) While promising, these initial findings 
should be confirmed in larger prospective studies.  
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The Prediction of Recurrent events with 18F-fluoride to Predict Ruptured and High 
Risk Plaques in Patients with Myocardial Infarction (PREFFIR NCT02278211) aims 
to determine whether 18F-Fluoride activity can predict recurrent events in patients with 
multivessel coronary disease following myocardial infarction. This prospective 
International study will recruit over 700 participants with follow-up over five years 
and will include repeat CTCA to measure plaque progression at two years.   
8.2.2 INVESTIGATING THE ROLE OF ANTI-CALCIFIC THERAPY IN AORTIC 
STENOSIS (SALTIRE 2) 
CT-AVC has been shown to be a reproducible imaging modality with the capability of 
detecting small changes in aortic valve calcification burden over time. This attribute is 
attractive for research trials seeking to investigate the effect of novel therapies for 
aortic stenosis, in which fewer patients and shorter follow-up periods are likely to be 
required to demonstrate a positive effect of therapies on disease progression. Similarly, 
18F-Fluoride PET may provide early indications of disease activity. Indeed, a number 
of studies have employed CT-AVC and 18F-Fluoride PET as endpoints in the 
investigation of novel treatments for aortic stenosis.  (136) The Study Investigating the 
effect of Drugs used to Treat Osteoporosis on the Progression of Calcific Osteoporosis 
(SALTIRE 2 NCT 02132026) is a randomised double-blind clinical trial of 
bisphosphonate and RANK-L inhibition in which participants are randomised to 
alendronic acid, denosumab or matched placebo. The study involves clinical and 
imaging follow up over a two-year period with the primary end point being change in 
CT-AVC at two years. 18F-Fluoride PET-CT is also employed by the study design and 
change in disease activity as measured by 18F-fluoride PET at one year is an 
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exploratory endpoint. Recruitment and clinical follow-up of 150 participants is now 
complete and results of this study will be publicly available this year.  
8.2.3 NOVEL PET TRACERS 
While coronary PET has demonstrated the successful translation of radiotracers with 
recognised safety profiles and widespread use in oncological imaging, the feasibility 
of coronary imaging now sets the stage for the application of novel PET tracers. A 
number of tracers targeted to a variety of different features of atherosclerosis are 
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Table 8.1 Applications of novel PET tracers in cardiovascular disease 
Target Process Radiotracer Action Applications 
Microcalcification 18F-fluoride Binds to hydroxyapatite 
Coronary and carotid 
atherosclerosis, 
aortic aneurysm, 
aortic stenosis.  (55, 
58, 61, 221) 
Inflammation 
18F-FDG Uptake by metabolically active cells  
Carotid and coronary 
atherosclerosis, 




Binds to somatostatin 
receptor subtype 2 






incorporated into cell 
membrane 




11CK-11195 Binds to translocator protein 18-kDa 
Carotid 
atherosclerosis (227) 
Thrombus 18F-GP1 Binds to GPIIb/IIIa receptors on activated platelets 
Acute arterial 
thrombosis including 
aortic aneurysm and 
carotid disease (228) 
Hypoxia 18F-FMISO 
Reduction to amine 
derivative in hypoxic 
environment 




18F-fluciclatide Binds to avß3 and avß5 integrin 
Aortic 
atherosclerosis (231) 






Binds to phosphatidylserine 





infarction. (233, 234) 
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Refining PET and overcoming challenges faced by motion will also be of benefit in 
the application of novel PET tracers to coronary imaging. 18F-Glycoprotein I (18F-
GP1) is one promising novel tracer and binds with high affinity to the glycoprotein 
IIb/IIa receptor on activated platelets, representing a key target for direct imaging of 
thrombosis. First in-human studies have demonstrated the ability of this tracer to 
localise to acute arterial thrombosis and venous thromboembolism with high tissue-to-
background ratios and a favourable safety and pharmacodynamic profile. (228, 235) 
The In-vivo Thrombus Imaging with 18F-GP1, a Novel Platelet PET Radiotracer 
(iThrombus NCT03943966) will investigate whether this radiotracer can identify 
arterial and venous thrombosis in a spectrum of cardiovascular conditions including 
myocardial infarction, aortic valve replacement and acute stroke and transient 
ischaemic attack.  
8.2.4 COMBINED POSITRON EMISSION TOMOGRAPHY AND MAGNETIC 
RESONANCE IMAGING 
Following the demonstration of feasibility of a novel cardiac motion-correction 
applied to PET-MR, this may be further utilised in the investigation of both aortic 
stenosis and coronary artery disease.  Further refinement of PET with combined 
respiratory gating and advanced techniques for correction of respiratory motion as well 
as gross patient motion will further enhance this technique. (236, 237) With the added 
advantages of superior soft tissue resolution and ability to provide detailed information 
about the myocardial response to aortic stenosis (238), this imaging modality will be 
particularly useful in research studies investigating the role of novel therapies in aortic 
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stenosis. (136) A further advantage of hybrid PET-MR imaging is the lower radiation 
dose associated with this modality, potentially enabling imaging at many different time 
points or the use of multiple PET tracers while incurring lower radiation doses than 
PET-CT.  
8.3 CLINICAL PERSPECTIVE 
In this thesis, it has been demonstrated that advanced non-invasive imaging 
technologies can provide novel and complementary measures of disease burden and 
disease progression in coronary heart disease and aortic valve disease.  
It has been demonstrated that quantification of plaque burden and composition can 
relate to non-invasive measures of fractional flow reserve in coronary atherosclerosis. 
It has also been demonstrated that measures of disease activity by positron emission 
tomography can provide an indication of progressive calcification in coronary 
atherosclerosis. In the study of aortic stenosis, aortic valve calcification quantified by 
computed tomography can provide a reproducible and sensitive measure of disease 
progression. Finally, application of advanced cardiac motion-correction techniques 
provides the ability to refine imaging of both the coronary arteries and aortic valve, 
improving image quality and thereby aiding future research and clinical applications 
of hybrid imaging.  
Advanced non-invasive imaging techniques can provide a safe, efficient means of 
monitoring response to therapies – highlighting any positive effect in trials which may 
be designed with fewer patients and shorter follow-up durations than clinical outcome 
trials. Further, as well as providing early indicators of drug efficacy, imaging-based 
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end points can provide early indicators of safety of novel therapies. This can in turn 
provide evidence to inform the planning of larger clinical outcomes-based trials.  
Further research is now needed to utilise these methods to improve risk stratification 
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